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I Draft NOTICE TO APPLICANTS 
FOREWORD 
This Notice to Applicants has been prepared by the European Commisson, in 
consultation with the competent authorities of the Member States (Committee for 
Veterinary Medicinal Products and its Operations Working.Party). 
This Notice has no legal force and does not necessarily represent the final views of the 
Commission. In case of doubt, therefore, reference should be made to the appropriate 
Community Regulations and Directives. It is important, . when readiQg this text, to 
appreciate that the legal requirements of the Directives and the Regulation must be met 
and that this Notice presents the preliminary views of the Member States on how those 
requirements may be met. 
This current draft is being issued for a period of consultation and comments are therefore 
invited by 1 June 1995. During this period, further improvements to the text may be 
possible due to: 
a) the establishment of the new Committee for Veterinary Medicinal 
Products, within the European Agency for the Evaluation of Medicinal 
Products, and its experience with the new procedures; 
b) some practical experience in the Member States with the operation of 
the mutual recognition procedures; 
c) experience of companies in operating these procedures. 
I 
The requirements for the content of the application dossier are set out in Directive 
811852/EEC as amended. The 1993 edition of Volume VB presents the structure and · 
content of the dossier for application for marketing authorisation and Volume VI does so 
for applications for the establishment of maximum residue limits of veterinary medicinal 
products in foodstuffs of arvmal origin. This guidance remains currently valid. 
CHAPTER I 
. GENERAL INTRODUCTION 
1. OBJECTIVES 
The primary purpose of any rules governing medicinal products is to safeguard the public 
health. However, this objective must be achieved by means which do not hinder the 
development of the pharmaceutical industry or trade in medicinal products within the 
Community. Thus, the pharmaceutical legislation of the European Community has 
consistently pursued the twin objectives: the protection of public health and the free 
movement of medicinal products. 
2. MARKETING AVTBORISA TION 
A veterinary medicinal product may only be placed on the market of a Member State if a 
marketing authorisation has been issued by the competent authority of that Member State 
(national authorisation) or an authorisation has been granted in accordance with Regulation 
(EEC No. 2309/93 (Community authorisation)). 
For veterinary medicinal products intended for food-producing animals containing a 
pharmacologically active substance not already authorised in the Member State for the 
concerned species, the safety of residues must have been evaluated in accordance with 
Regulation (EEC) Nr. 2377/90, taking into account Volume VI of the Rules governing 
Medicinal Products in the European Union. 
For applications made after the 1.1.1995, the person responsible for placing the medicinal 
product on the market must be established within the Community .. For medicinal products 
already on the market, this requirement will be applied at the time of the 5 year renewal. 
2.1 National authorisations 
The competent authorities of the Member States are responsible for the granting of. 
marketing authorisations for medicinal products which are placed on the market in that 
Member State. Important exceptions to this provision occur : 
- medicinal products developed by means of o.ne of the biotechnological processes 
referred to in Regulation (EEC) No. 2309/93, Annex, Part A, which may only be 
authorised by the Community~ 
veterinary medicinal products, including those not derived from biotechnology, 
intended primarily for use as performance enhancers in order to promote the growth of 
treated animals or to increase yields from treated animals (Regulation (EEC) No. 
2309/93, Annex, Part A)~ 
- medicinal products referred to in Regulation (EEC) No. 2309/93, Annex, Part B, which 
may, at the request of the person responsible for placing it on the market, be authorised 
by the Community. 
In order to obtain a national marketing authorisation, an application· must be submitted to 
the competent authority of the Member State. In cases where national authorisations are 
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requested in more than one Member State, an application must be submitted in each 
Member State (see Chapter VII for .-,umber of dossiers and languages accepted). For 
national applications, whether part of a mutual recognition procedure or not, the language 
requirements of the Member State always apply. 
For marketing authorisations in more than one Member State, the person responsible for 
placing the product on the market may 
- make an application in one of the Member States and once the marketing authorisation 
has been granted, make applications in other Member States concerned, requesting 
them to mutually recognise the marketing authorisation already granted (see Chapter II 
for further details). 
- make (parallel) applications in each of the Member States concerned and request a 
national authorisation in each (after 1.1.1998, Member States are required to mutually 
recognise the first marketing authorization decision). 
2.2 Mutual recognition 
Mutual recognition procedures may arise in four instances: 
i) in accordance with Article 17.1 of Directive 81/851/EEC as amended: where 'in order to 
obtain the recognition according to the procedures laid down in this Chapter in one or more 
of the Member States of an authorization issued by a Member State in accordance with 
Article 4 (of Directive 81/851/EEC), the holder of the authorization shall submit an 
application to the competent authorities of the Member State or Member States concerned'; 
ii) in accordance with Article 8.2 of Directive 81/851/EEC as amended: 'where a Member 
State notes that an application for authorization submitted after 1 January 1995 is already 
under active examination in another Member State in respect of that veterinary medicinal 
product, the Member State concerned may decide to suspend the detailed examination of 
the application on order to await the assessment report prepared by the other Member State 
in accordance with Article Sb'. 
iii) in accordance with Article 19 of Directive 81/851/EEC as amended 'if several 
applications submitted in accordance with Article 5 and Sa of Directive 81/851/EEC have 
been made for marketing authorization for a particular veterinary medicinal product, and 
Member States have adopted divergent decisions concerning the authorization of that 
veterinary medicinal product, or its suspension or withdrawal from the market, a Member 
State, or the Commission, or the person responsible for placing the aforementioned product 
on the market may refer the matter to the Committee for application of the procedure laid 
down in Article 21 (ofDirective 81/851/EEC)'; 
iv) in accordance with Article 20 ofDirective 81/851/EEC as amended: 'the Member States 
or the Commi;sion or the applicant or the holder of the marketing authorization may, in 
specific cases where the interests of the Community are involved, refer the matter to the 
Committee for the application of the procedure laid down in Article 21'. 
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2.3 Community authorisations 
The Community is responsible for the granting of marketing authorisations for medicinal 
products 
- developed by means of one of the biotechnological processes referred to in Regulation 
(EEC) No. 2309/93, Annex, Part A, which may only be authorised by the-Community; 
- veterinary medicinal products, including those not derived from biotechnology, 
intended primarily for use as performance enhancers in order to promote the growth of 
treated animals or to increase yields from treated animals (Regulation (EEC) No. 
2309/93, Annex, Part A); 
- medicinal products referred to in Regulation (EEC) No. 2309/93, Annex, Part B, which 
may, at the request of the person responsible for placing it on the market, be authorised 
by the Community. 
In order to obtain a Community authorisation, an application must be submitted to the 
European Agency for the Evaluation of Medicinal Products (EMEA) (see Chapter VII for 
number of dossiers required). , 
The scientific evaluation of the application is carried out within the scientific committees of 
the Agency, and a scientific opinion is prepared. The opinion is sent to the European 
Commission which drafts a decision. Having consulted with the relevant Standing 
Committee, normally the Commission adopts the Decision and grants a marketing 
authorisation1 (see Chapter IV for further details). 
3. ACCESS TO THE MARKET 
The free movement of medicinal products within the Community has been greatly enhanced 
by the adoption of the new system of marketing authorisation. 
Thus access to the Community market may be achieved in a number of ways : 
- .15 applications in 15 Member States (with the benefit of mutual recognition: 15/15 = 1 
single market) 
- . a single application using the centralised procedure = 1 single market 
15/15 = 1 single market 1 single market 
In cases where there is not a qualified majority in favour of the draft Commission Decision, the matter is referred 
to Council. 
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The operational aspects of the mutual recognition procedures are given in Chapters II and 
III, whilst for the centralised procedure, this is set out in Chapter IV. 
In the legislative texts for the new systems of marketing authorization, there are a range of 
options for a regulatory strategy. Thus, a company may choose to use a mutual recognition 
route or a centralised route to access the single market (within the framework set out by 
the texts) or continue to submit parallel national applications (after 1.1.1998, Member 
States are required to mutually recognise the first marketing authorisation decision). 
From an administrative point of view, however, a consistent regulatory strategy is 
important both for the applicant and for the competent authority. For example, using the 
mutual recognition procedure with Member State X as reference (originating) Member 
State for an application for a marketing authorization, followed by Member State Y for an 
abridged application (e.g. extension), and perhaps Member State Z for an other abridged 
application (e.g. a new indication), may not be the most efficient procedure and may pose 
problems for the management of the marketing authorization. 
Therefore, it would be appropriate that the reference Member State for the first marketing 
authorization be used as the reference Member State for subsequent abridged applications 
for that medicinal product. The reference Member State for variations is, of course, the 
Member State which prepared the assessment report upon which mutual recognition was 
based or the Member State chosen in this respect by the marketing authorisation holder. 
Equally for applications using Part B of the Annex ofRegulation (EEC) No. 2309/93, the 
optionality provided for in the legislation should not be interpreted as a mechanism to 
partition the market. Thus for abridged applications (e.g. informed consent and extensions) 
the option to use either the centralised route or mutual recognition route is available. 
Where such abridged applications use the mutual recognition procedure, both the Member 
States and the Commission must take up their responsibilities regarding the maintenance of 
a harmonised market, including as necessary, availing of references in accordance with 
Article 20 ofDirective 81/851/EEC as amended in cases ofCommunity interest. 
4. TRANSITION ARRANGEMENTS FOR COMMUNITY PROCEDURES 
4.1 Fate of pending multi-state applications 
A multi-state procedure was triggered when, in accordance with Article 17.1 of Directive 
81 /851/EEC as amended and in order to make it easier to obtain a marketing authorization 
in at least two Member States taking into due consideration an authorization issued in one 
Member State in accordance with Article 4 of Directive 81/851/EE, the holder of an 
authorization submits an application to the competent authorities of the Member States 
concerned together with the information and documents referred to in Articles 5, Sa and 5b 
ofDirective 81/851/EEC. 
Submissions made before the 31.12.94 (i.e. those for which the telex starting the 120 day 
period had been sent by the Commission before that date), which invoked Article 17.1 of 
Directive 81/851/EEC are considered as multi-state applications. On 1 January 1995, an 
inventory of such submissions was compiled. 
For procedures which have not been completed, these remain for the new Committee to 
complete. These procedures will be completed in accordance with Directive 81/851/EEC 
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i.e. an opinion (where necessary) in accordance with Article 22 of Directive 81/851/EEC 
which is not legally binding and upon which Member States notify action taken within 60 
days. 
Neither these applications nor their variations fall within the scope of the mutual 
recognition procedures unless a new application or a referral (Articles 19, 20 or 42h of 
Directive 81/851/EEC as amended) is made. 
4.2 Conversion of concertation to centralised proceclure 
Article 2 of Directive 93/41/EEC provides that applications for marketing authorization 
which have been refe"ed to the Committee for Proprietary Medicinal Products before 1 
January 1995 in accordance with Article 2 of Directive 87122/EEC and in respect of 
which the Committee has not given an opinion by 1 January 1995 shall be considered in 
accordance with Regulation {EEC) No 2309/93. 
In these cases the legislative texts provide for the conversion of former concertation 
procedures, for which an opinion had not been adopted by 1 January 1995, into centralised 
applications. In order to ensure a smooth transition, a number of practical issues were 
considered. A series of pragmatic options were developed 
i) timetable: the time scale for the opinion in both the concertation and centralised 
procedure is 210 days (120 plus 90 in exceptional cases for the concertation procedure). 
The date of receipt of a valid application starts this period. · 
Normally, the Committee adopted the timetable proposed by the rapporteur for the review 
of the application at a CVMP meeting. In order to adopt the timetable, submissions must 
have been made (and validated) in the concerned Member States before the meeting in 
question. Applications not validated and accepted within the concertation procedure will 
therefore have to be treated in accordance with Regulation (EEC) No 2309/93. 
ii) rapporteur: in the concertation procedure, the applicant will have selected the Member 
State acting as rapporteur and a co-rapporteur may have been identified. -Depending on the 
stage of a~vancement of the procedure, that rapporteur will have prepared an assessment 
report and may even have prepared a draft opinion on behalf of the Committee. 
In order to ensure a smooth transition from the concertation procedure to the centralised 
procedure, it is the · intention that the future Committee would confirm that the 
rapporteurship would be continued by a member of the Commi~tee belonging to the 
competent authority of the Member State which was previously rapporteur. 
iii) assessment: as the composition and mandate of the committee changed (1.1.95), and in 
order to retain the assessment wo~k of the previous rapporteurs, the rapporteur's 
assessment report, consolidated list of questions, assessment of responses etc. which had 
already been prepared would be taken up by the new Committee. In order to facilitate this 
pragmatic approach, the working methodology of the Committees during 1994 moved 
towards that of the future system (e.g. appointment of a co-rapporteur, preparation of a 
committee assessment report, labelling, package insert, etc.). 
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4.3 Conversion of concertation to mutual recognition procedure 
In the case of applications made in accordance with List A or B of Directive 87 /22/EEC, 
for which the committee has already issued before 1 January 1995 an opinion, Member 
States will have already granted (or be in the process of granting) a national authorisation. 
However, these applications have benefited from a Community procedure and a mechanism 
to maintain the harmonisation achieved has been foreseen in Article 23b of Directive 
81/851/EEC as amended: 
'Anicles 23 and 23a shall apply by analogy to veterinary medicinal products 
authorised by Member States following an opinion of the Committee given in 
accordance with Anicle 4 of Directive 87122/EEC before 1 January 1995'. 
Article 23 of Directive 81/851/EEC as amended provides for arrangements (for mutual 
recognition) of variations to such marketing authorizations by the person responsible for 
placing the veterinary medicinal products on the market. For these veterinary medicinal 
products which had been the subject of an opinion in the concertation procedure, the 
summary of product characteristics (SPC) was generally adopted. In cases where the SPC 
was not harmonised, it is important for marketing authorization holders to appreciate that 
any disharmony in the SPC could be a basis for arbitration when a request for a variation is 
submitted as the arbitration procedure of Article 21 and decision-making mechanism of 
Article 22 of Directive 81/851/EEC as amended applies to these veterinary medidnal 
products. 
Article 23a of Directive 81/851/EEC as amended sets out the procedure for situations 
where a Member State considers that, for one of these medicinal products, a variation of 
the terms of a marketing authorization, its suspension or withdrawal is necessary for the 
protection of animal or public health or the environment. 
The arrangements for variations to such products have been set out in Commission 
Regulation XX/95 (see Chapter II for details). 
4.4 New applications for List A products 
A question has arisen regarding medicinal products within the scope of List A of Directive 
87 /22/EEC. Some of the concertation procedures for List A products have included all 
Member States (existing before 1.1.95); for the others, as well as for those products which 
may not have been authorised in the new Member States before 1.1.95, the company may 
wish to make an application in previously unconcerned Member States. 
Similarly, companies may wish to make abridged applications (Article 5.10 a, i or ii or iii) 
for these veterinary medicinal products, and/or wish to make new applications for 
extensions for these products. 
Given that the Annex in Part A of Regulation (EEC) No 2309/93 is the same (or larger) in 
scope as the Annex List A ofDirective 87/22/EEC, the question has arisen as to whether 
such new applications must use the centralised procedure. Following discussions with the 
Member States, a pragmatic approach has been considered, in order to avoid disruption in 
the marketplace. 
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Since such abridged applications make reference to the full dossier (already submitted in the 
Member States), the appropriate procedure could be the national one, co-ordinated through 
the principle of mutual recognition. Likewise, for new applications (either in Member 
States not previously concerned, or m new Member States) these could be treated as 
national applications co-ordinated through mutual recognition which would maintain the 
objective of a harmonised market. 
For the purposes of mutual recognition, the Member State which acted as rapporteur for 
the concertation procedure would be the reference Member State for these applications. 
5. APPLICATION FOR A MARKETING AUmORIZA TION . 
The legal basis for making an application for marketing authorisation is set out in Directive 
81/851/EEC as amended. 
The legal basis used for an application may be cumulative (i.e. Article 5.10 i) and iii))~ In 
such cases the legal basis is a 'hybrid'. Further, the application dossier may be supplemented 
with additional tests and trials. . · 
A brief description of the legal bases for making a marketing application is set out below. It 
is important, however, that the legal basis is not confused with the content of the 
application dossier, which is given in sections 8 to 10 of this Chapter. 
5.1. Full applications 
An application for marketing authorization must be accompanied by the particulars and 
documents set out in Article 5 of Directive 81/851/EEC. In cases where the. exemptions in 
Article 5.10 (a) do not apply and therefore the results of 
- physico-chemical, biological or microbiological tests, 
- . pharmacological and toxicological tests, 
- clinical trials 
are included in the dossier, the application is referred to as a 'full' application. 
5.2. Abridged applications 
The requirements which must be fulfilled in order to receive a marketing authorization are 
set out in Article 5 of Directive 81/851/EEC and include the provision of results of 
physico-chemical, biological or microbiological tests, pharmacological and toxicological 
· tests and clinical trials. However, in the following situations, the results of pharmacological 
and toxicological tests. or clinical trials do not have to be provided, thus allowing for an 
abridged application to be made. 
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Applications may be abridged in the following cases: 
a) with an application for an essentially similar2 veterinary medicinal product for 
which consent has been given by a marketing authorization holder to refer to its 
dossier (so called 'informed consent'); 
b) where the constituent or constituents of the veterinary medicinal product have a 
well established medicinal use, with recognised efficacy and an acceptable level 
of safety, demonstrated by detailed references to published literature presented 
in accordance with second paragraph of Article 1 of Directive 811852/EEC (so 
called 'bibliographical'); 
c) a veterinary medicinal product which is essentially similar to a veterinary 
medicinal product which has been authorised in the Community for 6 years 
(may be extended to 10 years by a single decision of a Member State for all the 
products marketed on its territory) and is marketed in the Member State 
concerned; or 10 years for a veterinary medicinal product authorised by the 
Community in accordance with the provisions of Regulation (EEC) No. 
2309/93. 
5.2.1. Informed Consent from the marketing authorization holder 
In accordance with Article 5.10 i) ofDirective 81/851/EEC, the applicant is not required to 
provide the results of pharmacological and toxicological tests or clinical trials when the 
medicinal product is essentially similar and the marketing authorization holder has 
consented to the pharmacological, toxicological or clinical references contained in the 
dossier of the original product being used for the purpose of examining the application. 
5.2.2 Bibliographical applications 
During the period of exclusivity ( 6 or 10 years), an applicant wishing to use Article 5 .1 0 
(a)(ii) of Directive 81/851/EEC must fully satisfy all the requirements of Directive 
81/851/EEC as amended. 
Directive 81/852/EEC Article 1 states that "where pursuant to point 10(a) or (b) of the 3rd 
paragraph of Article 5 of Directive 81/851/EEC, references to published data are 
submitted, the provisions of this Directive [i.e. Directive 81/852/EEC] shall apply in like 
manner." 
In such cases, the full article or reference should be supplied, with necessary translations. 
Moreover, the Expert Reports must clearly state the grounds for using published references 
under the conditions set out in Directive 81/852/EEC. This would include the completion 
of all of the tabular formats provided in the Notice to Applicants, where relevant. The 
impurity/related substances profile and the decomposition products arising during storage 
must be clearly indicated in order to allow assessment of appropriate efficacy and safety. 
2 The definition of "essentially similar" is taken to be: 
"the same qualilative and quantilative composition in terms of active principles, tmd 
the pharmaceutical fonn is the same, tmd 
where necessary, appropriate bioavailability studies have been carried out" 
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In the event that detailed reference to published literature is not available to cover all the 
requirements, the applicant may supplement the missing data with appropriate additional 
studies. 
5.2.3. Product essentiallv similar to a product authorised for 6 or 10 vears 
Essentially similar veterinary medicinal products are multi-source products interchangeable 
with a medicinal product which has been authorised in the Community for 6/10 years, and 
is marketed in the Member State concerned. 
When a second applicant submits a dossier for ·a veterinary medicinal product which is 
essentially similar to a product which has been authorised for 6/10 years, bioequivalence 
should be substantiated (the need for appropriate bioavailability studies should be addressed 
in the dossier and Expert Report, cf. guideline on bioavailability and bioequivalence in 
Volume VII). The impurity/related substances profile and the decomposition products. 
arising during storage must be clearly indicated in order to allow assessment of appropriate 
efficacy and safety. The excipients used should be justified by the manufacturer, well · 
known, safe and suitable for the dosage form and compatible with the same efficacy and 
safety. 
Under Directive 81/851/EEC as amended by Directive 87 /20/EEC, the period of 
exclusivity, from the date of authorization in any of the Member States in the Community 
on the basis of a full dossier, is as follows: 
- 10 years for veterinary medicinal products submitted through the centralised procedure 
ofRegulation (EEC) No .. 2309/93 
10 years for veterinary medicinal products which h~ve been authorised following an 
opinion of the CPMP in accordance with Article 4 of Directive 87/22/EEC 
( concertation procedure) 
- 10 years (by single decision) for other veterinary medicinal products in Austria, 
Belgium, Germany, France~ Italy, the Netherlands, Sweden and United Kingdom 
6 years in Ireland and Luxembourg 
- 6 years in Denmark, Finland, Greece, Spain and Portugal; however this period will not 
be applied beyond the date of expiry of a patent protecting the original product. 
Evidence of the date of authorization for more than 6/10 years and the confirmation that 
the veterinary medicinal product is marketed in the Member States concerned should be 
provided in the application for marketing authorization. It should be noted that these 
periods do not prejudice the patent rights of the manufacturer of the original product. Any 
application for a marketing authorization submitted before the expiry of the periods 
referred to must be a full application. 
After 6 or 10 years' knowledge and experience with a veterinary medicinal product, it 
would be inappropriate for ethical and scientific reasons to require a second applicant to 
repeat all tests, studies and trials, which are already known to the authorities. Appropriate 
data on the quality of the active substance and the dosage form mu~t always be provided (in 
Part IT of the dossier). However some guidance on the appropriate additional studies 
required is indicated in the following illustrative examples: 
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Abridged applications Additional data usually required 
Different salt/ester/complex/derivative Evidence that there is no change in 
(with the same therapeutic moiety) pharmacokinetics of the moiety, 
(after CVMP has confirmed that new pharmacodynamics and/or in toxicity 
MRLs are not required). which could change the safety/efficacy 
profile. 
Otherwise to be considered as a new 
chemical entity 
Different therapeutic use, in same target Part IV, Chapter II, clinical data 
species, with same dosing regime 
Therapeutic use in new species Full Part IV + residue depletion studies 
Different route/form of administration; 
- new route of administration Full Part IV + residue depletion studies 
- new oral form for immediate release Bioavailability 
-
new dosage form for modified release Bioavailability + residue depletion studies 
+ target animal tolerance studies, if 
necessary may suffice 
Modification of dosing schedule and/or Bioavailability + residue depletion studies 
strength of unit doses may suffice. 
An abridged application for fixed combination products of known constituents may be 
appropriate where the constituents are known for 6/10 years and the requirements of the 
guideline on Fixed Combinations in Volume VII are met. 
By extension, the concept of essentially similar also applies to different oral forms (e.g. 
tablets and capsules) with the same active substances for immediate release. 
5.3 Extensions by existing marketing authorisation holders (so called 'extensions') 
Extensions can only be used by the existing marketing authorisation holder. 
Certain changes to a marketing authorization have to be considered to fundamentally alter 
the terms of this authorization and therefore cannot be considered as a variation. For these 
changes, set out in annex 2 of the regulations on variations and listed below, an application 
for a new marketing authorization must be made. 
Appropriate data on the quality of the active ingredient and the dosage form must always 
be provided (in Part II of the dossier). In addition, necessary support of the safety and 
efficacy of the medicinal product must also be submitted. 
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1. Changes to the active substance(s): 
i) addition of one or more active substance(s) including antigenic components for 
vaccines; 
ii) deletion of one or more active substance(s) including antigenic components for 
vaccines; 
iii) quantitative changes in the active substance(s); 
iv) replacement of the active substance(s) by a different salt/ester complex/derivative 
' (with the same therapeutic moiety), 
v) replacement by a different isomer, a different mixture. of isomers, of a mixture by an 
isolated isomer (e.g. racemate by a single enantiomer); 
vi) replacement of a biological substance or product of biotechnology with one of a 
different molecular structure, modification of the vector used to produce the 
antigen/source material, including a master cell bank from a different source. 
vii) a new ligand or coupling mechanism for a radiopharmaceutical 
l. Changes to the therapeutic indications3 
i) addition of an indication in a different therapeutic area, either treatment, diagnosis or 
prophylaxis 
ii) change of the indication to a different therapeutic area, either treatment, diagnosis or 
prophylaxis; 
3. Changes to strength, pharmaceutical form and route of administration 
i) change of bioavailability 
ii) change of pharmacokinetics e.g. change in the rate of release 
iii) addition of a new strength 
iii) change or addition of a new pharmaceutical form 
iv) addition of a new route of administration 
4. Other changes specific to veterinary medicinal products to be administered to 
food producing animals 
i) addition or change of target species 
ii)shortening of the withdrawal period 
A marketing authorization as a result of a new application in accordance with annex 2 of 
the Regulations on variations, may be assimilated to an existing authorization (including 
where relevant, the existing authorization number) in accordance with the procedures 
operated by the competent authority. 
3 For parenteral administration, it is nec:essary to distinguish bdween intraarterial, inlravenous, intramuscular, subcutaneous, and other 
routes. 
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6 APPLICATION FOR A VARIATION 
In accordance with Directive 81/851/EEC, a marketing authorization for a veterinary 
medicinal product is granted for a period of five years, renewable upon application at least 
three months before expiry. Throughout the life of a veterinary medicinal product, the 
holder of the authorization is responsible for the product which circulates in the 
marketplace and is also required to take into account technical and scientific progress, and 
to make any amendments that may be required to enable the product to be manufactured 
and checked by means of generally accepted scientific methods. Such amendments must be 
approved by the competent authority prior to their introduction. 
Marketing authorization holders may, in addition, wish to alter/improve the veterinary 
medicinal product or to introduce an additional safeguard during the period of five years. 
Such changes or 'variations' may involve administrative and/or more substantial changes, 
and speedy and efficient procedures for the approval of such changes, without jeopardising 
animal or public, have been set out in the Regulations on variations. 
6.1 Regulations on variations 
With the implementation of the new system of authorisation, the need was identified to 
categorise variations and to set out common procedures which, on the one hand facilitate 
the task of both industry and authorities and on the other hand, guarantee that changes to 
the veterinary medicinal product do not give rise to public or animal health concerns or 
concerns for the environment. 
Express provisions have therefore been set out in two Commission regulations 
- Regulation (EEC) No XX/95 ofthe Commission ofx.x.1995 concerning the 
examination of variations to the terms of a marketing authorization granted by a 
competent authority of a Member State in a mutual recognition procedure; 
- Regulation (EEC) No XX/95 of the Commission ofx.x.1995 concerning the 
examination of variations to the terms of a marketing authorization granted in 
accordance with Council Regulation (EEC) No. 2309/93. 
The operational procedures for these regulations are set out in Chapter II for marketing 
authorizations granted by a competent authority of a Member State in amutual recognition 
procedure and in Chapter IV for marketing authorization granted in accordance with 
Council Regulation (EEC) No. 2309/93. 
6.2 Urgent Safety Restrictions 
The Regulations do not impede the marketing authorization holder from taking provisional 
urgent safety restrictions in the event of risk to animal or public health or the environment. 
In such cases, the marketing authorization holder shall forthwith inform the appropriate 
competent authority/ Agency. If the competent authority/ Agency has not raised any 
objections within 24 hours, the urgent safety restrictions may be introduced and the 
corresponding application for approval ofthe variation shall be submitted without delay. 
Urgent safety restriction is defined as an interim change to product information by the 
marketing authorisation holder restricting the indication(s), and/or dosage, and/or target 
species of the product; or adding a contra-indication, and/or warning due to new 
information having a bearing on the safe use of the product. 
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6.3 Labelling changes 
Changes to an aspect of the labelling or package inserts of veterinary medicinal products 
connected with the summary of product characteristics follow the procedure foreseen for 
variations - Type I or ll as appropriate. 
6.4 Manufacturing changes 
The manufacture~ both total or partial, of a veterinary medicinal product is subject to a 
manufacturing authorisation. In order to obtain a manufacturing authorization, the applicant 
must provide particulars in support of the application: 
a) specify the veterinary medicinal products and pharmaceutical forms which are to 
be manufactured or imported and also the ·place where they are to be 
manufactured and/or controlled; 
b) have at his disposal, for th~ manufacture or import of the above, suitable and 
sufficient premises, technical equipment and control facilities complying with 
the legal requiremttnts; 
c) have at his disposal the services of at least one qualified person within the 
meaning of Article 29 of Directive 811851/EEC as amended. 
The time taken for the procedure for granting the manufacturing authorisation does not 
exceed 90 days from the day on which the competent authority receives the (valid) 
application. 
·For changes requested by the manufacturer to any of the particulars in a) or b) above, the 
time taken for the procedure relating to the request shalt not exceed 30 days. In exceptional 
·cases this period may be extended to 90 days. 
Should there be a requirement for further information from the applicant,. the time limits 
shall be suspended until the additional data required has been supplied. 
7. APPLICATION FOR RENEWAL 
According to Council Directive 81/851/EEC, Article 15, a: marketing authorization shall be 
valid for five years and be renewable for five-year periods upon application by the holder at 
least three months before expiry. 
Not later than three months before the end of five years, the marketing authorization holder 
an application for renewal of the marketing authorization, .including all currently approved · 
presentations. 
Before the procedure of renewal of a marketing authorization starts, the holder is advised 
to liaise with the competent authority/ Agency concerning relevant, documentation and 
timetable. 
Only in special cases will it be acceptable to proceed with a variation for a product within a 
short time of the renewal application. 
See Chapter II for renewals of marketing authorization granted following an opinion of the 
CVMP in accordance with Article 4 ofDirective 87/22/EEC (concertation procedures). 
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8. PRESENTATION OF mE APPLICATION 
The application dossier, which should be submitted in either a Community or national 
procedure, consists of administrative infonnation and the necessary demonstration of 
quality, safety and efficacy of the product. 
For non-immunological products, this is presented in four Parts: 
Part I - Summary of the dossier 
Part II - Chemicallphannaceuticallbiological documentation 
Part III - Safety and residues documentation, including the environment 
Part IV - Pre-clinical and clinical documentation. 
For immunological products, this is presented in five Parts: 
Part I - Summary of the dossier 
Part II - ChemicaVphannaceutical/biological documentation, including the 
GMO infonnation where relevant 
Part III - Safety documentation 
Part IV - Efficacy documentation 
Part V - General conclusions 
8.1 Part 1 
Part I is divided into 3 sub-sections: 
• Part lA consists of the administrative data, samples, manufacturing and marketing 
authorizations applied for or obtained elsewhere. A hannonised fonnat for Part lA has 
been agreed by the competent authorities of the Member States and is reproduced in 
Chapter VII. 
• Part IB consists of the proposed Summary of Product Characteristics (SPC), in 
accordance with Article 5a of Directive 81/851/EEC, as well aas the package insert, 
labelling, packaging and mock-ups. The guideline on the presentation of the SPC is 
reproduced in Chapter VII. 
• Part IC consists of the Expert Reports and Annexes 
Parts lA and IB must be in the language(s) of the Member State concerned or in all 
Community languages for centralised applications. 
8.2 Invented name (Brand name) 
Member States grant a marketing authorization to a single authorization holder who is 
responsible for placing the veterinary medicinal product on the market. The marketing 
authorization includes when available the INN (International Non-Proprietary Name) and 
when branded, a single invented name (brand name). In cases where companies wish to use 
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a second brand name, then a second authorization (perhaps using Article 5.10 a) i) must be 
submitted. · 
This principle will be applied similarly in the case of Community authorizations granted 
following applications through the centralised procedure. 
It is important therefore, that applicants identify a brand name which would be valid 
throughout the Community when proposing to use the centralised procedure·. 
For applications through the mutual recognition procedures, it is recommended that the 
same brand name for a given medicinal product should be used in all Member States. If a 
different brand name is to be used, it should be quoted in a covering letter from the 
applicant to the competent authority giving the justification for the different nalne. 
8.3 Technical documentation 
Parts II, Ill, and IV of the application dossier consist of the chemical, pharmaceutical and 
biological documentation; the safety documentation and the efficacy documentation 
respectively, in accordance with the requirements of Directive 81/852/EEC. 
8.4 GMO medicinal products 
An application for marketing authorisation must be accompanied by the particulars and 
documents referred to in Article 5 of Directive 81/851/EEC as amended and in the Annex 
to Directive ~11852/EEC. In the case of a veterinary medicinal product containing or 
consisting of genetically modified organisms, the application must also be accompanied by 
i) a copy of any written consent· or consents of the competent authorities to the 
deliberate release into the environment of the genetically modified organisms for research 
and development purposes where provided for by Part B of Directive 90/220/EEC, 
ii) the complete technical dossier supplying the information requested in Annexes II 
and III to Directive 90/220/EEC and the environmental risk assessment resulting from this 
information; the results of any investigations performed for the purposes of research or 
development. 
The presentation of particulars concerning the environmental risk assessment for veterinary 
medicinal products which contain, or consist of, genetically modified organisms should be 
included in Part IIH of the dossier, as a separate (detachable) section. 
From 1.1.95, applications for marketing authorizations should include in Part IIIR an 
indication of any potential risks presented by the veterinary medicinal product for the 
environment (see Chapter VI). 
9. EXPERT REPORTS IN THE APPLICATION DOSSIER 
9.1 General principles 
, Directive 81/851/EEC as amended requires that the particulars and documents submitted in 
the application dossier are drawn up and signed by experts, with the necessary· technical or 
professional qualifications. The chemical/pharmaceutical/biological, safety and efficacy 
parts of the dossier should each include an Expert Report. In the case of a veterinary 
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medicinal product for food-producing animals, the safety expert repport should discuss, in 
addition to safety for the target species, the safety for consumers. Moreover, a specific 
Expert Report on the depletion of residues studies and, where appropriate, on the analytical 
methods proposed and the adequacy of the proposed withdrawal period(s) is also 
necessary. The Expert Reports, their tabular formats and eventual written summaries are 
placed in Part IC of the dossier. 
It is important to emphasise that well prepared Expert Reports greatly facilitate the task of 
the competent authority in evaluating the dossier and contribute towards the speedy 
processing of applications. For these reasons particular care should be taken in the 
preparation of Expert Reports, following the guidance on the preparation of Expert 
Reports given in the 1993 edition ofVolume VB. 
Where relevant Community guidelines on the conduct of tests, studies and trials on a 
veterinary medicinal product exist, these should be taken into consideration when Expert 
Reports are prepared. Any deviation from guidelines should be discussed and justified. In 
particular, the experts should give a justification for the statements in the proposed SPC, 
taking into account the submitted data and the SPC guideline and also considering the need 
for bioavailability studies with reference to the guideline on bioavailability and 
bioequivalence in Volume VII. 
An Expert Report for each of Parts II, III, IV is required for all types of applications, i.e. 
full and abridged (including hybrid) applications. 
9.2 Expert Reports for abridged applications 
As appropriate, Expert Reports may be abbreviated for an abridged (or amendment) 
application. 
9.2.1 Consent from the marketing authorization holder 
For applications based upon Article 5.10 (a)(i) of Directive 81/851/EEC, the Expert 
Reports of the original marketing authorization holder may be used. 
9.2.2 Bibliographical applications 
For applications based upon Article 5.10 (a)(ii) of Directive 81/851/EEC, the Expert 
Reports should particularly focus on the following elements: 
a. the grounds for using published references and the relevance of the references 
selected 
b. an update of published literature relevant to the substance and the present 
application. The expert may annotate review articles published in "peer review" 
journals, which may be acceptable in this respect. 
c. a summary of impurities present in batches of the active substance (and, where 
relevant, decomposition products arising during storage) as proposed for use in 
the product to be marketed. 
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d the issue of bioavailability, and bioequivalence where appropriate, related to the 
proposed formula for marketing should be addressed taking into account the 
relevant pharmacokinetic parameters of the formulation used in the literature. 
e. comparison of pharmacokinetic parameters (Cmax, Tmax, AUC etc.) of the 
formulations used in the literature and the formulation proposed for marketing; 
f. for food-producing animals, relevance of the published data must be evaluated 
in comparison to the product formulations used (dosage, site of application, 
route of administration, etc) · 
g. an evaluation of the results of additional studies to provide for missing data in 
the file. These data should be discussed in the perspective of what is known 
from published literature. Additional studies should also be submitted in tabular 
formats provided in the Notice to Applicants; 
h. every claim in the Summary of Product Characteristics (SPC) not known from 
or inferred from the properties of the veterinary medicinal product and/or its 
therapeutic group should be discussed in the Expert Reports and substantiated 
by published literature and/or additional studies. 
9.2.3 Product essentially similar to a product authorised for 6 or 10 years 
For applications based upon Article 5.10 (a)(iii) of Directive 81/851/EEC, the Expert 
Reports should particularly focus on the following elements: 
a. the grounds for claiming essential similarity 
b. a summary of impurities present in batches of the active substance (and where 
relevant decomposition products arising during storage) as proposed for use in 
the product to be marketed 
c. an evaluation of the bioequivalence studies or a justification why studies were 
not performed with respect to the note. for guidance on 'Investigation of 
Bioavailability and Bioequivalence' (Volume VII) 
d. an update of published literature relevant to the substance and the present 
application. It· may be acceptable for articles in "peer review" journals to be 
annotated for this purpose 
e. every claim in the Summary of Product Characteristics (SPC) not known from 
or inferred from the properties of the veterinary medicinal product and/or its 
therapeutic group should be discussed in the Expert Report and substantiated by 
published literature and/or additional studies. 
9.2.4 Extensions 
For applications based on annex 2 of the regulations on variations, an application for a new 
marketing authorization must be made. 
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The Expert Report should particularly focus on the following elements: 
a. an evaluation of the results of the additional studies. The results should be 
discussed in the perspective of what is known from published literature and 
previous submissions. Additional studies should also be submitted as required 
by the 1993 edition of Volume VB. 
b. an update of published literature relevant to the substance and the present 
application. The expert may annotate articles published in "peer review" 
journals, which may be acceptable for this purpose. 
c. every claim in the Summary of Product Characteristics (SPC) not known from 
or inferred from the properties of the medicinal product and/or its therapeutic 
group should be discussed in the Expert Report and substantiated by published 
literature and/or additional studies. 
10. WRITTEN SUMMARY 
A written summary may be of use, particularly for large application files. Applicants are 
therefore encouraged to include (systematically) a written summary in the following 
applications: 
+ new active substances; 
+ abridged applications where the demonstration of well established veterinary 
use, with recognised efficacy and an acceptable level of safety, relies on 
detailed references to published scientific literature; 
+ other abridged applications where, in the opinion of the applicant, the volume 
and complexity of the documentation would be such that a written summary 
would be helpful. 
The written summary should be factual, complete (i.e. covering all studies) and concise. It 
should contain cross-references to the documentation in the relevant part of the dossier as 
well as including tables, graphs, etc. 
It is important to avoid duplication and repetition between the Expert Report and the 
written summary. Equally, experience has shown that a good tabular presentation with a 
short written summary is an effective method of communication. Therefore, where tabular 
formats suffice, it is not necessary to duplicate the message in writing. 
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11. MAXIMUM RESIDUE LIMITS CMRLSl FOR NEW PHARMACOLOGICALLY 
ACTIVE SUBSTANCES 
Directive 81/851/EEC provides that no veterinary medicinal product intended for 
administration to food-producing animals whose flesh or products are intended for human 
consumption may be authorised unless: 
• the active substance or substances capable of pharmacological action contained in the 
veterinary medicinal product were authorised for use in other veterinary medicinal 
products in· the Member States concerned on 1.1.1992; 
• the active substance or substances capable of pharmacological action is or are 
mentioned in Annex I, II or m to Regulation (EEC) Nr. 2377/90. 
Currently, there are two ways of proceeding in order to obtain an MRL for a new 
pharmacologically active substance: 
a) to include the MRL file in the application for marketing authorisation for a 
veterinary medicinal product; in this case, the MRL documentation must be presented in 
separate volumes, which physically can stand alone and which can be handled separately 
from the remainder of the dossier; 
b) to present the MRL file separately in advance. 
In both instances, the file shall be presented as set out in Volume VI of The Rules 
governing Medicinal Products in the European Union. 
It should be noted that, as from 1 January 1997, Article 4.2 of Directive 81/851/EEC 
provides that the Member States shall not permit foodstuffs for human consumption to be 
taken from test animals unless MRLs have been established by the Community in 
accordance with .the provisions of Regulation (EEC) Nr. 2307/90 and an appropriate 
withdrawal period has been established to ensure that this maximum limit will not be 
exceeded in foodstuffs. The MRL file shall then always be presented in advahce. 
In accordance with Regulation (EEC) Nr. 2309/93, veterinary medicinal products intended 
for food-producing animals containing a new active substance which was not a1,1thorised in 
any Member State for use in food producing animals on 1 January 1995 benefit of List B 
status, i.e. optional use of the centralised procedure. 
The establishment ofMRLs being a Community procedure, the MRL file shall be submitted 
to the EMEA, also if the decentralised procedure . is chosen by the applicant for the 
veterinary medicinal product concerned. The file shall fulfill the provisions set out in 
Volume VI. 
When the application is made, one copy of the file is to be forwarded'to the Agency for the 
validation period. At its next meeting, the CVMP will appoint or confirm the rapporteur 
and the co-rapporteur, who should then receive one copy each. At this stage the CVMP 
also determines if any of its members should receive an extra copy. 
'Thirty-four (34) copies of Expert Reports (Residue & Safety) should be prepared. They 
are to be distributed as follows:· four copies are to be forwarded to the EMEA at the time 
the full dossier is submitted. Once the dossier has been validated by the EMEA, one copy 
should be sent to each member of the CVMP. 
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CHAPTER II 
MUTUAL RECOGNITION 
1 LEGAL BASIS AND PURPOSE 
As of 1 January 1995, a pharmaceutical company wishing to nuuket " veterinary 
medicinal product in more than one Member State can avail of mutual recognitio11. This 
can be achieved by asking the second or subsequent Member State to mutually recognise, 
within 90 days, the nuuketing authorisation granted by the reference Member State. 
Equally, Member States may benefit from the assessment of another Member State by 
mutual recognition even in cases where the company has not requested mutual recognition 
with its applicatio11. Again a period of 90 days applies. 
Thus rapid access to a single nuuket, with the necessary safeguards for the protection of . 
public health, can be obtained using the principle of mutual recognition, either at the 
request of the pharmaceutical company or the Member States. 
From 1 January 1998, Member States must mutually recognise a nuuketing authorisation 
granted by another Member State, also within 90 days. 
The legal texts setting out the mutual recognition procedures are in Directives 81/851/EEC 
and 811852/EEC as amended. 
The objective of these Community procedures is to facilitate access to a single market by 
relying upon the principle of mutual recognition. Thus with the~ exception of those veterinary 
medicinal products which are subject to the centrali$ed Community authorisation procedure 
established by Council Regulation (EEC) No. 2309/93 · of 22 July 1993 laying down 
Community procedures for the authorisation and supervision of medicinal products for human 
and veterinary use and establishing a European · Agency for the Evaluation of Medicinal 
Products, an authorisation to place a medicinal product on the~ market in one Member State 
ought in principle to be recognised by the competent authoriti1es of the other Member States 
(unless there are serious grounds for supposing that the authorisation of the medicinal product 
concerned may present a risk to human or animal health or the e~nvironment)1 . 
The procedure may be initiated either by the person respons:ible for placing the medicinal 
product on the market or by a Member State. . 
In addition to a speedy procedure, mutual recognition has been reinforced by two important 
new elements: 
* 
* 
a Member State should be able to suspend the examination of an application for 
authorisation to place a veterinary medicinal product on the market which is currently 
under examination in another Member State with a view to recognising the decision 
reached by the latter Member State. · 
in the event of a disagreement between Member States about the quality, the safety or the 
efficacy of the veterinary medicinal product, a scientific evaluation of the matter should 
be undertaken by the Committee attached to the European Agency for the Evaluation of 
1 The capres1ion wrilk to human or animal health or the enVironmenlw refers to the quality, aafety and efficacy of the veterinary medicinal 
. product. 
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Medicinal Products, leading to a single decision in the area of disagreement, binding on 
the Member States. 
2. SCOPE 
2.1 Applications eligible for the mutual recognition procedure. 
The mutual recognition procedure may be used for full applications and abridged applications. 
Once the procedure has been used, all variations to these veterinary medicinal products must 
use the mutual recognition procedure (cf Commission Regulation XX/95). In addition, 
variations to previous concertation products authorized by Member States following an 
opinion of the Committee given before 1 January 1995 are required to use the procedure set 
out in the Commission Regulation XX/95 (these applications "convert" to the mutual 
recognition procedure, see Commission Communication of 19.3. 94 0 .J. Nr. C82). 
2.2 Repeat use 
The mutual recognition procedure may be used more than once for a subsequent application 
made to another Member State in relation to the same veterinary medicinal product. In such 
cases, the application would comprise a dossier and a proposal for a SPC identical to that 
which had been authorised by earlier Member States. However, such subsequent applications 
may give rise to grounds for supposing risk(s) to human or animal health or the environment 
different from those which may have been considered in an earlier procedure. Should a risk for 
human or animal health or the environment lead to arbitration, all Member States where the 
veterinary medicinal product is authorised or an application is pending, would be concerned. 
For this reason it is recommended that, wherever feasible, persons responsible for 
placing the veterinary medicinal product on the market seek to involve all Member 
States (where it is already on the market or where it is envisaged that the product will 
eventually be marketed) in the first usage of the mutual recognition procedure and thus 
avoid potential repeated arbitrations on human or animal health or environment issues. 
2.3 Exclusions 
The procedure is not appropriate for applications submitted through the centralised (Part B) 
procedure, or for applications in respect of products developed by one of the biotechnological 
processes listed in Part A of the Annex to Council Regulation (EEC) No. 2309/93, except in 
the case of applications which were made in accordance with List A or List B of Directive 
87/22/EEC as amended, for which the CVMP had before 1 January 1995 issued an opinion. 
The procedure is not appropriate for variations to veterinary medicinal products which had not 
already been considered through the mutual recognition procedures or had not been authorised 
by Member States following an opinion of the Committee given before 31 December 1994 in 
accordance with Article 4 ofDirective 87/22/EEC. 
The procedure is not appropriate for medicinal products which have not yet been authorised 
according to all relevant Community Directives and guidelines (e.g. immunological veterinary 
medicinal products which have not yet been authorised in accordance with the directives; up to 
March 1998). 
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According to Article 14.5 ofDirective 75/319/EEC as amended the procedure is not foreseen 
for homoeopathic veterinary medicinal products for human use authorized according to Article 
9.2 of Council Directive 92/74/EEC. 
2.4 Maximum Residue Limits for veterinary medicinal products 
In the case of a veterinary medicinal product intended for use in food producing animals, 
Regulation (EEC) No. 2377/90 must be taken into consideration. If the pharmacologically 
active substance concerned is not inserted in Annex I, II or ill of Regulation (EEC) No. 
23 77/90 as amended, the person responsible for placing the product on the market has to 
verify, as early as possible, whether the substance has been authorised before the 1.1.1992 by 
the Member State(s) concerned for use in the food producing animals concerned. 
If the substance has not been authorised before the 1.1.1992 for use in food producing animals 
in the Member State concerned, an application for the establishment of the Maximum Residue 
Limit (MRL) for the active substance should be made to the EMEA either before or at the 
same time as an application for marketing authorisation is made to the Member State( s) 
concerned. However, in order to avoid any unnecessary delay in the evaluation, the persons 
responsible for placing the product on the market are strongly advised to submit an application 
for the establishment of MRLs as soon as the relevant documentation is ready, before an 
application for marketing authorisation is submitted to the Member State(s) concerned. In this 
case the 90 day period for the concerned Member State(s) starts after the substance has been 
inserted into Annex I, II, or III ofRegulation (EEC) No. 2377/90. 
3. PROCEDURES LEADING TO MUTUAL RECOGNmON 
The procedure to be followed will depend upon whether it is a Member State or the person 
responsible for placing the medicinal product on the market which initiates it. 
3.1 Initiation by a Member State 
3.1.1 Suspension o(detailed examination 
Where a Member State is informed that an application for authorisation submitted after 1 
January 1995 is already under active examination in another Member State in respect of that 
veterinary medicinal product, the Member State concerned may decide to suspend the detailed 
examination of the application in order to await the assessment report prepared by the other 
Member State in accordance with Article 5b ofDirective 81/851/EEC as amended. 
In such cases, the Member State concerned shall inform the other Member State and the 
person responsible for placing the veterinary medicinal product on the market of its decision to 
suspend detailed examination of the application in question. As soon as it has completed the 
examination of the application and reached a decision, the other Member State shall forward a 
copy of its assessment report to the Member State concerned. 
Where a Member State receives a notification under point 13 of Article 5 of Directive 
81/851/EEC as amended for veterinary medicinal products that another Member State has 
authorized the product in question, that Member State may request the assessment report from 
the reference Member State which has authorised the veterinary medicinal product. 
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Within 90 days of the receipt of the assessment report, the Member State concerned shall 
normally recognise the decision of the other Member Stat~ and the summary of the product 
characteristics as approved by it (by granting a marketing authorisation with an identical 
summary of the product characteristics). 
Only in exceptional circumstances, where a Member State considers that there are grounds for 
supposing that the authorisation of the medicinal product concerned may present a risk to 
human or animal health or the environment, the Member State shall apply the procedures set 
out in Articles 18 to 22 ofDirective 81/8S1/EEC as amended (see Chapter ill). 
The introduction of the possibility for Member States to suspend their detailed examination in 
order to await the assessment report of another Member State, allows efficient utilisation of 
resources and the avoidance of duplication of effort. Member States may use this possibly 
during the transition period from 1 January 199S to 1 January 1998, and after the transition 
period for applications which are submitted in parallel to Member States for veterinary 
medicinal products for which a marketing authorisation has not yet been granted. 
3.1.2 Automatic mutual recognition 
With effect from 1 January 1998, where a Member State is informed in accordance with point 
13 of Directive 81/8S1/EEC as amended that another Member State has authorized a 
veterinary medicinal product which is the subject of an application for authorisation in the 
Member State concerned, that Member State shall forthwith request the authorities of the 
Member State which has granted the authorisation to forward to it the assessment report 
referred to in Article Sb ofDirective 81/8S1/EEC as amended. 
Within 90 days of the receipt of the assessment report, the Member State concerned shall 
normally recognise the decision of the first Member State and the summary of the product 
characteristics as approved by it (by granting a marketing authorisation with an identical 
summary of the product characteristics},· or, if it considers that there are grounds for 
supposing that the authorisation of the veterinary medicinal product concerned may present a 
risk to human or a.nimal health or the environment, it shall apply the procedures set out in 
Articles 18 to 22 ofDirective 81/8S1/EEC as amended. 
3.2 Initiation by the penon resoonsible for placing the veterinary medicinal product on the 
market 
The person responsible for placing the veterinary medicinal product on the market may request 
one or more Member States to mutually recognise an authorisation granted by a reference 
Member State. An application is submitted to the competent authorities of the Member State 
or Member States concerned, together with the information and particulars referred to in 
Articles S, Sa, Sb of Directive 81/8S1/EEC as amended. The person responsible for placing the 
veterinary medicinal product on the market must give an assurance that the dossier is identical 
to that accepted by the first Member State, or identify any additions or amendments it may 
contain. In . the latter case, he must give an assurance that the summary of the product 
characteristics proposed by him in accordance with Article Sa of Directive 81/8S1/EEC as 
amended is identical to that accepted by the reference Member State in accordance with 
Article Sb of Directive 81/8S1/EEC as amended. Moreover he shall certify that all the dossiers 
filed as part of the procedure are identical. 
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3.2.1 Discussion with the reference Member State 
Before submitting an application under the mutual recogrutlon procedure, the person 
responsible for placing the veterinary medicinal product on the market must inform the 
reference Member State that such an application is to be made. 
The person responsible for placing the veterinary medicinal product on the market is in any 
case advised to discuss, in advance, the proposed mutual recognition application with the 
reference Member State, especially if the authorisation was granted some time previously. 
Such discussion would include whether the dossier and Expert Reports should now be 
updated to ensure that all relevant information is supplied (according to current requirements, 
legislative and technical aspects). The reference Member State may require the person 
responsible for placing the veterinary medicinal product on the market to provide reassurance 
that the dossier submitted in other Member States is identical to that upon which it took its 
own decision. 
When a national application is first submitted in a Member State with a view to subsequently 
requesting mutual recognition of the authorisation in other Member States, it is advantageous 
if this is known to the reference Member State at the time so that advice and counsel can be 
given. This would also facilitate the availability of the assessment report within a very short 
period after the grant of the authorisation in a language understood in the concerned Member 
States. 
For completeness of information, the person responsible for placing the product on the market 
is advised to also inform other Member States of the application for mutual recognition, 
particularly where the veterinary medicinal product is already authorised. 
3.2.2 Updating the dossier and expert report (i(necessarv.} 
As indicated under 3.2.1, the application should be updated, if necessary, according to current 
requirements, both legal and technical (including CVMP guidelines). 
In addition, the dossier and Expert Reports should be updated to bring them into line with the 
changes agreed during the assessment with the reference Member State in an appropriately 
updated dossier. In particular, the Expert Reports should include a comment or justification 
for the proposed wording of the Summary of Product Characteristics. 
3.2.3 Assessment Report 
As stated previously, it is preferable for the person responsible for placing the veterinary 
medicinal product on the market to give the reference Member State advanced notice of the 
intention to use the marketing authorisation in the mutual recognition procedure. In any event, 
the person responsible for placing the medicinal product on the market must request the 
reference Member State in writing to supply an (up-dated) assessment report. This is to be 
furnished as soon as possible, and not later than 90 days after the receipt of the request. 
Normally the assessment report prepared during the initial assessment will be available, but the 
reference Member State may need the 90 days to update it. The report would include an 
appropriate assessment of variations and any additional information bearing upon safety or 
efficacy reported since the authorisation had been granted. The reference Member State will 
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notifY the person responsible for placing the veterinary medicinal product on the market when 
the report is/will be available. 
There is no obligation upon the Member State to make the assessment report available to the 
applicant. Where it is made available to the company, the other concerned Member States will 
· be informed. In any event, the assessment report remains a confidential document, and further 
publication or distribution to other parties, either in whole or in part, is subject to the written 
agreement of the competent authority. 
Arrangements for translation will be made by the reference Member State, but the costs of 
translation are borne by the person responsible for placing the veterinary medicinal product on 
the market. 
3.2.4 Before submitting the aoplication: 
The person responsible for placing the veterinary medicinal product on the market must ensure 
that: 
·(a) the application is updated to current requirements (i.e. in accordance with Directives 
and Committee guidelines issued after the original marketing authorisation was 
granted); 
(b) that the product will be regarded as a veterinary medicinal product in all concerned 
Member States (and that it will not be regarded, for example, as a dietary 
supplement, a medical device or pesticide); 
(c) the veterinary medicinal product has been reviewed in accordance with the 
requirements of the Directives; 
(d) the clinical indications sought have either been previously authorised (and as 
appropriate submission of clinical data is exempted by the provisions of the 
Directives) for a veterinary medicinal product containing the same active substance in 
the concerned Member States or, if not, that adequate clinical data is available to 
support the claimed indications in the Summary of Product Characteristics; 
(e) the requirements for "essential-similarity" for abridged applications under Article 
· 5(10)(a)(iii) ofDirective 81/851/EEC as amended, have been met, i.e. that there is a 
veterinary medicinal product authorized in the EC more than 6 or 10 years previously 
and such a product is marketed in the concerned Member States; 
(f) in the case of active substances which may have been authorised in some Member 
States and not in others or, with regard to veterinary products, in different relevant 
target species, additional documentation will have to be provided for those Member 
States which have not previously authorised the activ~ substance or its use in the 
target animals concerned; 
(g) variations to the original authorisation have been authorised by the reference Member 
State in advance of the initiation of the procedure; and, 
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.. 
(h) the final text ofthe approved Summary ofProduct Characteristics and that of the 
package insert for infonnation, in the national language of the reference Member 
State should be available, with appropriate translations. 
3.3 Making the application 
The person responsible for placing the veterinary medicinal product on the market must submit 
an application to the competent authorities of each of the Member States wherein a marketing 
authorisation is to be sought (i.e. the "concerned Member States"). 
The person responsible for placing the veterinary medicinal product on the market is required 
to give an assurance (usually in the covering letter accompanying the application) that; 
• the dossier is identical (including any approved variations) to that accepted by the 
reference Member State, or to identify any additions, 
• the SPC is identical, and 
• the dossier and SPC as submitted are identical in all concerned Member States. 
The dossier must include the EC Application Fonn Part I A. 
The appropriate national fees need to be paid (names and addresses for fees enquiries and 
details of how payments are to be made are set out in Chapter VII). 
In some Member States, there may be different addresses for submission of the dossier and for 
correspondence in connection with an application (see Chapter VII). 
It is not part of the responsibility of the competent authorities to arrange customs clearance of 
applications. It is the responsibility of the person responsible for placing the veterinary 
medicinal product on the market to deliver the application to the officially designated address, 
free of any charges to the addressee. 
Reference Member States will indicate (during the discussion mentioned in 3.2.1 above) what 
documentation they require when they are the reference Member State. A copy of the 
application should be available to be sent to the reference Member State on request. 
3.3.1 Number of copies required and languages. 
The numbers of copies of the dossier and required languages of the Member States to be used 
are set out in Chapter VII. Copies of the SPC, label and leaflet texts are always needed in the 
nationallanguage(s). 
Requirements of each Member State for samples of the active substance and finished dosage 
fonn are set out in Chapter VII. 
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3.4 Notification to the Committee 
At the time of making the application, the person responsible for placing the veterinary 
medicinal product on the market must also notifY the Committee. 
The following information should be included in the notification:-
• the names of the concerned Member States and the dates the application has been 
submitted in each Member State; 
• a copy of the authorisation granted by the reference Member State; 
• copies of any marketing authorisations already granted by other Member States; 
• status of any application(s) currently under consideration in any Member State; 
• name and address of the person responsible for placing the veterinary medicinal 
product on the market, i.e. the marketing authorisation holder in the reference 
Member State; 
• name and address of the person responsible for placing the veterinary medicinal 
product on the market in each of the concerned Member States; 
• the INN name of the active ingredient( s) in the veterinary medicinal product; 
• the ATCN et code; 
• the trade name(s) of the products in the concerned Member State(s); 
• the mutual recognition procedure number [details to be announced later] for 
administrative handling (marketing authorisation numbers are given by the Member 
States concerned). 
3.5 Action following the submission of the Application 
The application is checked in by the concerned Member States using the check-in procedure in 
Chapter VII. Any problems are notified immediately (by telefax or E-mail to the person 
responsible for placing the veterinary medicinal product on the market and the reference 
Member State). The concerned Member States will notifY within 10 days, by telefax or E-mail, 
the reference Member State and the person responsible for placing the veterinary medicinal 
product on the market that a valid application together with the reference Member State's 
assessment report has been received. 
After all of the concerned Member States have confirmed receipt of the valid (checked in) 
application and the reference Member State's assessment report, the reference Member State 
notifies all Member States and the person responsible for placing the veterinary medicinal 
product on the market of the start ofthe 90-day period referred to in Article 17.4 ofDirective 
81/851/EEC as amended. 
3.6 Recognition of the original authorisation 
Normally, in accordance with Article 17.4 of Directive 81/851/EEC as amended, each 
Member State concerned will recognise the marketing authorisation and the SPC granted by 
the reference Member State and grant the national authorisation within the 90 days period.' 
They will inform the reference Member State, the other concerned Member States, the 
Committee and the person responsible for placing the veterinary medicinal product on the 
market. 
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3.7 Mutual recognition of the SPC 
In accordance with article 18.2 of Directive 81/851/EEC, as amended by Directive 
93/40/EEC, "all Member States concerned shall use their best endeavours to reach agreement 
on the action to be taken in respect of the application" submitted for mutual recognition. 
Therefore in order to maximise the efficiency of this clarification and dialogue stage, Member 
States have agreed the following three-step procedure: 
Step 0: 
Before initiation of the Mutual Recognition Procedure the Reference Member State (RMS) is 
requested to achieve an 'acceptable' Summary of Product Characteristics (SPC) through 
discussion with the applicant, which would take into account all existing national SPCs. 
It is expected that through this updating process harmonisation can be achieved concerning 
"core" issues and also additional issues. 
Both the RMS and the applicant are expected to react in a flexible manner. 
Step 1 : 
During the Clarification and Discussion phase (90 days) : 
a) the Reference Member State, having liaised with the applicant, would be flexible; 
b) discussion would concentrate on 
target species 
indications 
dosage 
contra-indications 
shelf-life 
withdrawal periods 
user safety 
Concerned Member State(s) would forward, in writing and within 60 days, their 
concerns and alternative wordings for the sections which cause concern. 
c) the remainder of the SPC of the RMS would be mutually recognised. 
Step 2: 
When necessary, and in cases where the remainder of the SPC is requested to be harmonised 
by the RMS i.e. development of a common SPC, the competent authorities of those Member 
States requesting SPC changes will meet, and try to define the necessary changes. This would 
be achieved through special liaison, using phone, fax, e-mail etc. and other face-to-face 
opportunities (e.g. meeting rooms in EMEA). 
In the event that consensus on one or more sections was not possible, the text of the RMS 
would be used. 
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Such liaison would result in 'the' draft SPC. 
The draft SPC is then circulated to all competent authorities for comment within 10 days. 
'The' SPC (for the veterinary medicinal product which is the subject of the mutual recognition 
procedure) would be presented to the CVMP for. information. 
The CVMP could use this SPC as a draft for the development of a (substance specific) Core-
S PC. 
To avoid duplication of work, normally, the CVMP will ask those experts who where involved 
in the discussions of'the' SPC to continue their work as a drafting group until the "Core"-SPC 
is finalised. Other Member States are asked to support this Expert Group with the aim to 
achieve a generally acceptable European Core-SPC. 
The mechanism of implementation of a harmonised SPC for veterinary medicinal products 
other than that directly concerned would also be considered. 
It is pointed out that the SPC in question is only for the veterinary medicinal product dealt 
with in the Mutual Recognition Procedure. Other similar products, common to all or some 
Member States will not be addressed by this procedure, unless they differ only in details, e.g. 
same company, different strength. 
Harmonisation across several veterinary medicinal products concerning the same ·active 
substance or across other issues of their SPC's would be addressed separately. 
3.8 Maintenance of identicality of the dossier 
Having the benefit of mutual recognition ·of the marketing authorisation also carries through 
the life of the veterinary medicinal product. Thus variations to a veterinary medicinal product 
which has benefited from mutual recognition, also benefit from a rapid mutual recognition 
procedure. In this way, a dossier which has been harmonised continues to be consistent and 
identical in all Member States where the veterinary medicinal product is authorised. 
4. CLARIFICATION AND DIALOGUE 
4.1 Ooerating procedure 
Any concerned Member State which considers there may be a potential risk to human or 
animal health or the environment must notify the reference Member State, the other concerned 
Member States, the person responsible for placing the veterinary medicinal product on the 
market and the Committee. Detailed reasons must be given, together with the action 
considered necessary to correct any defect in the application. This should be done as soon as 
possible. Member States have agreed that, where concern regarding such a risk exists and in 
order to provide time for 'their best endeavours to reach agreement', such notification would 
take place within 60 days (by telefax, E-mail etc.) of the start of the 90 days referred to in 
Articles 8, 8a and 17 ofDirective 81/851/EEC as amended. 
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Start of the 90 days 
Potential risk raised by a concerned Member State 
Clarification of issues; consideration of SPC; 
point of view of applicant (orally or in writing); 
using phone, fax, teleconferences, infonnal meetings etc. 
---------- ----------Issues resolved & 
national marketing 
authorisation issued 
Issues remain & 
subjected to 
arbitration 
Day l 
Day60 
Day90 
Within this period, clarification of potential concerns and deficiencies would be carried out by 
dialogue (telephone/telefax!E-mail) between the reference Member State, the other concerned 
Member States and the applicant. 
The person responsible for placing the veterinary medicinal product on the market will be 
given an opportunity to make his point of view known orally or in writing. Where a risk has 
been raised by only one of the concerned Member States, the person responsible for placing 
the veterinary medicinal product on the market is advised to liaise directly with that Member 
State in order to agree action to be taken in respect of the application, whilst keeping the 
reference and other concerned Member State(s) informed. If more than one concerned 
Member State raises concerns regarding risk( s) to human or animal health or the environment, 
direct liaison with individual Member States may lead to actions which would not be 
acceptable to other concerned Member States. Thus, for these cases, the person responsible 
for placing the veterinary medicinal product on the market is advised to liaise with the 
reference Member State as to the optimal mechanism for liason e.g. phone, fax, 
teleconference, E-mail or informal meetings. Different models will be explored and in the light 
of practical experience the best practice will evolve. 
Normally the issues raised may be resolved and the marketing authorisation of the reference 
Member State can be recognised within the 90 day period set out in Articles 8, Sa and 17 of 
Directive 81/851/EEC as amended. 
Where no issues in relation to risks to human or animal health or the environment remain, the 
concerned Member States will recognise the authorisation within 90 days of receipt of the 
application and assessment report, grant a national marketing authorisation and notify the 
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person responsible for placing the veterinary medicinal product on the market, the other 
concerned Member States and the Committee. 
Note: 
An application for a marketing authorisation may be withdrawn by the applicant at any time 
during the mutual recognition procedure. Thus an application may be withdrawn during 
examination by a competent authority, or during the mutu81 recognition procedure, including 
the clarification and dialogue phase. However, once an application has been submitted for 
arbitration, the opinion of the Committee will be given unless the veterinary medicinal product 
no longer exists (i.e. all applications and marketing authorisations are withdrawn). 
4.2 Revision of the authorisation in the reference Member State. 
Where, in the course of the procedure outlined in Article 18 ofDirective 81/851/EEC as 
amended, changes have been agreed by the person responsible for placing the veterinary 
medicinal product on the market and the reference Member State to the authorisation of the 
reference Member State, these will be introduced using the appropriate procedure. 
5. VARIATIONS TO A MARKETING AUTHORISATION 
Throughout the life of a veterinary medicinal product, the holder of the authorisation is 
responsible for the product which circulates in the .marketplace and is also required to take 
into account technical and scientific progress, and to make any amendments that may be 
required to enable the veterinary medicinal product to be manufactured and checked by means 
of generally accepted scientific methods. 
Marketing authorisation holders may, in addition, wish to alter/improve the veterinary 
medicinal product or to introduce an additional safeguard during the period of five years. 
Such changes or 'variations' may involve administrative and/or more substantial changes, and 
the procedures for the approval of such changes, without jeopardising public or animal health, 
have been set out in Regulation (EEC) No. XX/95. 
The term variation is defined in Regulation (EEC) No. XX/95: "an amendment to the contents 
of the documents refe"ed to in Article 5 Sa and 7 of Directive 81/851/EEC such as they 
existed at the moment the decision on the marketing authorisation or after approval of any 
previous variations, except where a new application for a marketing authorisation must be, 
presented pursuant to Annex II of this Regulation". 
An application for a variation is submitted simultaneously to each of the competent authorities 
of the different Member States where the veterinary medicinal product is authorised, 
accompanied by the appropriate fee and documentation. Member States grant a marketing 
authorisation to one marketing authorisation holder. The marketing authorization holder may 
be located in that Member State or in another Member State. In cases where the same 
person/company holds the marketing authorisation in all Member States, the application for a 
variation will be submitted by that person/company. In cases where the marketing 
authorisation holder is not the same in all Member States, it is essential that the holders 
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synchronise the submission of the application for the variation. It is clear that a variation to a 
veterinary medicinal product which has been the subject of one of the mutual recognition 
procedures, must remain harmonised and that variations occur at the same time in all Member 
States where such a veterinary medicinal product is authorised. 
In the Regulation XX/95 on variations to marketing authorization granted by the competent 
authorities of the Member States, the expression marketing authorization holder(s) is used. 
The use of the plural in this context is intended to cover situations where the marketing 
authorization holder is different in the different Member States - it must not be interpreted as 
signifying multiple holders of a single marketing authorization. 
5.1 Urgent Safety Restriction 
An urgent safety restriction is defined in Article 2.2 ofRegulation (EEC) No. XX/95 as: "An 
interim change to product information by the marketing authorisation holder restricting the 
indication(s), and/or dosage, and/or target species of the medicinal product; or adding a 
contra-indication, and/or warning due to new information having a bearing on the safe use 
of the product". 
The person responsible for placing the veterinary medicinal product on the market must 
immediately inform the Agency, the Commission and the Member States of any new 
information which might influence the evaluation of the benefits and risks of the veterinary 
medicinal product. In cases where the marketing authorisation holder is not the same in all 
Member States, it is essential that the holders co-ordinate any urgent action of the veterinary 
medicinal product (in Article 1.2 of Regulation XX/95, the reference to holder(s) is expressly 
to cover this type of situation). 
In cases of urgency, where there is a risk to public or animal health or the environment, 
marketing authorisation holder(s) may make urgent safety restrictions in accordance with 
Regulation XX/95. These measures must be communicated without delay to the national 
competent authorities. If the national competent authorities have not raised any objections 
within 24 hours, the urgent safety restrictions may be introduced and the corresponding 
application for this variation (type II) shall be submitted without delay to the national 
competent authorities, for application of the procedures set out in Articles 6 and 7 of 
Regulation XX/95. 
5.2 Extension applications 
Changes which are fundamental and which as a consequence require new applications may be 
assimilated to an existing authorisation (including where relevant, the existing authorisation 
number) in accordance with the procedures operated by the competent authority of the 
Member States concerned. 
5.3 Type I variations 
A "minor variation" (type I) means a variation as defined in Article 2 and listed in Annex I to 
Regulation (EEC) No. XX/95, provided the conditions for such variation laid down in the 
Annex are met. 
The procedure and documentation required for a type I variation are set out in the regulation. 
As an illustrative guide, the following procedure would generally be followed. 
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a) Initial application acceptable: 
Application submitted simultaneously to the reference Member State and 
all other Member States where the veterinary medicinal product is 
authorised 
Concerned Member States notify receipt of application to the reference 
Member State 
.J. 
Reference Member State informs concerned Member States and the Day 1 
marketing authorisation holder of the starting date of the procedure .J. 
No objection raised by any concerned Member State => variation .J. 
deemed to be accepted (without need for written confirmation) 
Day30 
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b) Initial application not acceptable; marketing authorisation holder does not amend 
Application submitted simultaneously to the reference Member State and 
all other Member States where the veterinary medicinal product is 
authorised 
Concerned Member States notify receipt of application to the reference 
Member State 
After the last concerned Member State notification has been received, Day 1 
the reference Member State informs concerned Member States and the 
marketing authorisation holder of the starting date of the procedure 
.J.. 
Objective grounds for non-acceptance raised by a concerned Member 
State and communicated to reference Member State Day 20 
Notification with grounds (i.e. refusal) sent by reference Member State 
to marketing authorisation holder, with copy to concerned Member Day 30 
States 
Marketing authorisation holder has 30 days to amend the application 
taking into account the objective grounds 
~ 
If no response IS received, the application IS deemed to have been 
rejected 
Reference Member State notifies rejection to other concerned Member 
States 
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+/- 30 days 
+/- 60 days 
c )Initial application not acceptable; marketing authorisation holder does not amend 
Application submitted simultaneously to the reference Member State 
and all other Member States where the veterinary medicinal product is 
authorised 
... 
Concerned Member States notify receipt of valid application to the 
reference Member State 
... 
After the last concerned Member State notification has been received, 
reference Member State informs concerned Member States and the 
marketing authorisation holder of the starting date of the procedure 
Day 1 
... Day20 
·Objective grounds for non-acceptance raised by a concerned Member 
State and communicated to reference Member State 
... 
Notification with grounds (i.e. refusal) sent by reference Member Day 30 
State to marketing authorisation holder, with copy to concerned 
Member States 
... 
Marketing authorisation holder has 30 days to amend the application Clock stopped 
taking into account the objective grounds for up to 30 days 
... 
Amendment is submitted to reference Member State and all other 
concerned Member States 
... 
Concerned Member States notify their final position to the reference Day +/- 60 
Member State 
Concerned Member 
States ·. are 
unanimously .. 
favourable => 
variation deemed to 
be accepted 
Concerned Member 
States are 
unanimously 
unfavourable => 
variation is rejected, .. 
written rejection from 
reference Member 
State 
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5.4 Type D variations 
A "major variation" (type II) means a variation which cannot be deemed to be a type I 
variation within the meaning of Article 2 of the Regulation and which does not require a new 
application. 
a) Standard mutual recognition 
Application submitted simultaneously to the reference Member State 
and all other Member States where the veterinary medicinal product is 
authorised 
~ 
Concerned Member States notify receipt of the valid application to 
the reference Member State 
~ 
After the last concerned Member State notification has been received, 
Reference Member State informs concerned Member States and the 
marketing authorisation holder of the starting date of the procedure 
~ 
Day 1 
~ 
~ 
~ 
~ 
Clock stopped 
(+/- 60 days) 
~ 
~ 
~ 
A single request for supplementary information may be made by the 
reference Member State. Other concerned Member States are 
informed of this request. Clock is stopped for up to 60 days, this 
period may be extended on the initiative of the reference Member 
State or at the request ofthe marketing authorisation holder. 
~ D~W 
Reference Member State sends an assessment report and draft (+/- 60 days) 
decision to other concerned Member States ~ 
~ D~W 
Other concerned Member States accept the draft decision and inform 
the reference Member State accordingly 
~ ~ 
Variation (unanimously) approved:::) 
Reference Member State and marketing 
authorisation holder, in consultation with 
the other concerned Member States, agree 
the date of effect of the national decisions 
Variation (unanimously) refused:::) 
All concerned Member States send written 
refusal to marketing authorisation holder 
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b) Divergent views between the Member States 
Application submitted simultaneously to the reference Member State 
and all other Member States where the veterinary medicinal product is 
authorised 
-!-
Concerned Member States notify receipt of the valid application to 
the reference Member State 
-!-
After the last concerned Member State notification has been received, 
Reference Member State informs concerned Member States and the 
marketing authorisation holder of the starting date of the procedure 
-1-
A single request for supplementary information may be made by the 
reference Member , State. Other concerned Member States are 
informed of this request. Clock is stopped for Up to 60. days, this 
period may be extended on the initiative of the reference Member 
State or at the request of the marketing authorisation holder. 
-!-
Reference Member State sends an assessment report and draft 
decision to other concerned Member States 
-1-
Day I 
-1-
-1-
-1-
-1-
Clock stopped 
(+/- 60 days) 
-1-
-1-
-1-
Day60 
(+/- 60 days) 
-1-
-1-If other concerned Member States cannot mutually recognise the draft 
decision, the matter is referred for arbitration (see Chapter Ill, section Day 90 
7) 
6. RENEWAL OF THE MARI(ETING AUTHORISATION 
The renewal process should not be confused with the procedure for variations. They are 
independent procedures and operate for different purposes. The holder of the marketing 
authorisation is required to update the marketing authorisation throughout the life of the 
product, taking into account all new technical and scientific factors concerning,quality, safety 
and efficacy and these updates are ~one through variations . 
6.1 Scope 
The text hereunder des~ribes the agreed procedure for renewal of marketing authorisation 
granted by Member States following an opinion of the CVMP in accordance with Article 4 of 
Directive 87/22/EEC i.e. concertation procedure, before 31 December 1994 and which 
'convert' to the mutual recognition procedure. 
6.2 Period of validity of a marketing·authorisation 
According to Council Directive 81/851/EEC, a marketing authorization shall be valid for five 
years and be renewable for five-year periods upon application by the holder at least three 
months before expiry. 
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The date of authorisation by a Member State following a CVMP opinion on an application in 
accordance with Article 4 ofDirective 87/22/EEC is used to calculate the starting date for the 
renewal. 
6.3 Making the application for renewal 
Not later than three months before the end of the five years after the first authorisation 
following the CVMP opinion on the veterinary medicinal product, the marketing authorisation 
holder should submit an identical application for the renewal of the marketing authorisation. 
This should be submitted simultaneously in all Member States where the veterinary medicinal 
product is authorised and where the holder wishes to renew the marketing authorisation 
When renewals for other presentations of the same veterinary medicinal product fall within a 
period of+/- six months, the renewal for all presentations could be covered by a single 
renewal. 
In support of the application for renewal, the following documentation should be submitted, 
together with the appropriate fee: 
a) an updated Part lA, including current manufacturing authorisation; 
b) a chronological list of all the variations of any type approved since the grant of the 
marketing authorisation or last renewal, including the CVMP opinion number and 
dates; 
c) the required periodic safety updates including all the relevant pharmacovigilance data 
since the grant of the marketing authorisation; 
d) update of studies requested in the CVMP opinion (if not already submitted); 
e) brief update of quality according to the relevant guidelines; 
f) the current SPC and a proposal for a harmonised SPC, if considered appropriate, 
together with an updated package insert and labelling text, taking into account 
applicable directives and guidelines. 
6.4 Procedure 
The documentation submitted is evaluated by the Member State which had acted as rapporteur 
during the concertation procedure on behalf of all Member States: 
a) within 60 days following the receipt of the application, the reference Member State 
prepares a succinct assessment report and a draft decision (including the SPC) which 
is addressed to the other Member States concerned; 
b) during this time, the competent authority of the reference Member State may request 
(once) supplementary information to that already submitted; 
c) if, within 30 days following the receipt of the draft decision and the succinct assessment 
report, no objection has been raised, the other Member States concerned accept this 
draft decision, inform the reference Member State to this effect, and grant the 
renewal of the marketing authorisation; 
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d) in cases where mutual recognition of the draft decision by one or more Member States 
is not possible i.e. there are serious grounds for supposing that the authorisation of 
the veterinary medicinal product concerned may present a risk to aniaml or human 
health or the environment, or if the draft decision of the reference Member State is 
unfavourable on the same grounds, a scientific evaluation of the matter would be 
undertaken by the CVMP (see Chapter ill). 
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1. LEGAL BASIS 
CHAPTER III 
COMMUNITY REFERRAL 
An authorisation to place a veterinary medicinal product on the market in one Member State 
ought in principle to be recognised by the competent authorities of the other Member States 
unless there are serious grounds for supposing that the authorisation of the veterinary 
medicinal product concerned may present a risk to human or animal health or the environment. 
In the event of a disagreement between Member States about the quality, the safety or the 
efficacy of a veterinary medicinal product, a scientific evaluation of the matter should be 
undertaken by the Committees attached to the European Agency for the Evaluation of 
Medicinal Products, leading to a single decision on the area of disagreement, binding on the 
Member States concerned. This decision should be adopted by a rapid procedure ensuring 
close co-operation between the Commission and the Member States. 
2. SCOPE 
The instances where a disagreement could arise are set out in Directive 81/851/EEC as 
amended and include referrals under either Articles 8 (suspension of examination),8a 
(obligatory mutual recognition), 18 (risk to health), 19 (divergent decisions), 20 (Community 
interest) or 23 (variation),. 23a (protection of public health), 23b (previous concertation 
procedures) or 29h (pharmacovigilance). 
3. MEMBER STATE LIAISON ON POTENTIAL RISK<Sl TO HUMAN OR ANIMAL 
HEALTH OR THE ENVIRONMENT 
Save in the exceptional case provided for in Article 18(1) of Directive 81/851tEEC as 
amended, each Member State shall recognise the marketing authorisation granted by the first 
Member State within 90 days of receipt of the application and the assessment report. It shall 
inform the Member State which granted the initial authorisation, the other Member States 
concerned by the application, the Committee, and the person responsible for placing the 
veterinary medicinal product on the market. 
These articles set out the procedure to be followed where a Member State considers there are 
grounds for supposing that the . granting of · a marketing authorisation for the product 
concerned may present a potential "risk to human or animal health or the environment", which 
. is defined as referring to quality, safety and efficacy. The procedure may be initiated as a 
consequence of a disagreement during a mutual recognition process arising from the 
possibilities foreseen in Articles 8, Sa and 17 of Directive 81/851/EEC as amended. · 
3.1 Referral to the Committee 
If the concerns raised cannot be resolved within the 90 day period, the reference Member 
State, in co~sultation with the person responsible for placing the veterinary medicinal product 
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on the market, may refer the matter to the Committee for the application of the procedure of 
Article 21 ofDirective 81/851/EEC as amended (even before the end ofthe 90 days). 
In these circumstances, the concerned Member States shall provide the Committee with a 
detailed statement of the matters on which they have been unable to reach agreement and the 
reasons for their disagreement. The person responsible for placing the veterinary medicinal 
product on the market shall be provided with a copy of this information. 
As soon as the person responsible for placing the veterinary medicinal product on the market 
is notified of the reference to the relevant Committee, a copy of the application should 
accordingly be sent to the Committee at the EMEA. This copy may be consulted at any time 
by any Member of the Committee. The person responsible for placing the veterinary medicinal 
product on the market should also certify (usually in the covering letter accompanying the 
application) that; 
• the dossier is identical (including any approved variations) to that accepted by the 
reference Member State, or to identify any additions, 
• the SPC is identical, and 
• the dossier and SPC as submitted are identical in all concerned Member States. 
4. ARTICLE 19 REFERRALS 
Article 19 ofDirective 81/851/EEC as amended provides that where divergent decisions have 
been adopted concerning a veterinary medicinal product which has been the subject of several 
applications for marketing authorisation in the Member States in accordance with Articles 5 
and Sa of Directive 81/851/EEC as amended, the matter may be referred to the Committees 
for application of the procedure as laid down in Article 21 of Directive 81/851/EEC as 
amended. The reference may be made by either one or more of the concerned Member States, 
the Commission or the person responsible for placing the veterinary medicinal product on the 
market. In invoking Article 19, whoever makes the reference shall clearly state the reasons for 
invoking the procedure and identify the question(s) referred to the Committee for 
consideration. 
4.1 Objective and scope 
The free movement of veterinary medicinal products in the Community may be hindered by 
national decisions which, though based on the same dossier, are divergent. Article 19 provide 
a mechanism for the resolution of divergence. However, priority should be given to the 
elimination of divergences liable to have the greatest effect on the functioning of the single 
market. 
Article 19 as amended may be invoked when divergence regarding current authorisation status 
of a particular veterinary medicinal product is known to exist at national level within the EC 
when the decisions were made on identical dossiers and the relevant applications were 
submitted in accordance with Articles 5 and Sa ofDirective 81/851/EEC as amended. 
With regard to authorisations granted before 111/95, Article 52 of Directive 81/851/EEC as 
amended required the provisions of the Directive to be applied progressively to veterinary 
medicinal products placed on the market by virtue of previous provisions within 15 years of 
the date ofits notification, i.e. by October 1991. The only group of products where the review 
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period is not yet closed is veterinary immunologicals, where Directive 90/677/EEC as 
amended requires completion by 31 March 1998. 
Given that only a small percentage of applications have been harmonised through the 
Community multi-state or conc~rtation procedures, it is likely that there will be some 
divergence between existing national decisions. It would appear to be in keeping with the spirit 
of the legislation and in the interests of animal health and the continuity of supply of veterinary 
medicinal products to refer cases where significant divergences exist, e.g. 
• where one Member State authorises and another refuses the same veterinary medicinal 
product; 
• where the same veterinary medicinal product has been authorized in two or more Member 
States but the authorisations, particularly the indications, differ significantly. 
As the principle of mutual recognition is reinforced by the legislative amendments, the 
likelihood of divergence after 1/1/95 therefore diminishes:-
• from 1/1/95, applications under Article 8 of Directive 811851/EEC as amended would be 
mutually recognised or, in exceptional circumstances, would result in binding arbitration; 
• from 1/1/95, applications under Article 17.3 ofDirective 81/851/EEC as amended would 
be mutually recognised or, in exceptional circumstances, would result in binding 
arbitration; 
• fro~ 1/1/98, applications under Article Sa ofDirective 81/851/EEC as amended would be 
mutually recognised or, in exceptional circumstances, would result in binding arbitration. 
Nonetheless, divergence may still arise after 1/1/95 during the transition period, for example: 
• in the case of parallel applications for the same veterinary medicinal product, submitted in 
two or more Member States using pur~ly national procedures; 
• where a negative decision in one or more Member State(s) is followed by a positive 
decision. on a subsequent application in another Member State. 
Referral may also be appropriate where a veterinary medicinal product, with a current 
marketing authorisation in some or all Member States, is suspended or withdrawn on the basis 
of new data on quality, safety or efficacy in some but not all of the concerned Member States. 
Article 19 could be used in these circumstances. 
4.2 Procedure 
4.2.1 Discussion with the Member State 
In advance of making a referral under these Articles, it is recommended that informal 
discussions take place between the person responsible for placing the product on· the market 
and the concerned Member States. Subsequent developments or the availability of additional 
information may have led to the divergent decisions, and such informal discussions may 
obviate the need for a referral. 
' 
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4.2.2 Refe"al 
In invoking Article 19, the Member State, the person responsible for placing the product on 
the market, or the Commission shall clearly state the reasons for invoking the procedure and 
identify the question(s) referred to the Committee for consideration. Confirmation should be 
provided that the dossiers submitted as applications for marketing authorisation, or for 
consideration of suspension or withdrawal, are identical in the Member States concerned. 
Where appropriate, the other relevant parties, i.e. the other Member States, the Commission 
and the applicant shall also be informed. 
In those cases where the referral comes from a concerned Member State, the reasons must be 
accompanied by an appropriately updated assessment report, which must include all available 
information relating to the matter in question. 
In the case of referrals from a person responsible for placing the veterinary medicinal product 
on the market, the reasons must be accompanied by expert reports on quality, safety and 
efficacy which take account of current regulations and which have been updated to include 
data supporting the reasons for referral. 
4.2.3 Time-frame 
For referrals in accordance with Article 19, the Committee considers the matter and issues an 
opinion within 90 days of the date of referral. This period may be extended by a further 90 
days. In case of urgency, on a proposal from its Chairman, the Committee may agree to 
impose a shorter deadline. 
5. ARTICLE 20 REFERRALS 
5.1 Legal basis 
Article 20 of Directive 81/851/EEC as amended provides that where the interests of the 
Community are involved, the Member States, the Commission or an applicant or holder of the 
marketing authorisation may refer the matter to the Committee for application of the 
procedure as laid down in Article 21 ofDirective 81/851/EEC as amended, before reaching a 
decision upon a request for a marketing authorisation, or the suspension, withdrawal or 
variation of an existing marketing authorisation. 
5.2 Objective and scope 
Where the interests of the Community are involved, a procedure for arriving at a rapid opinion 
has been foreseen. The amendment introduced by Directive 93/40/EEC provides for referrals 
in cases relating to applications, suspensions or withdrawals, including variations of 
Community or national authorisations. In addition, referrals may be made by Member States, 
the Commission, or the marketing authorisation holder or applicant. 
It is important that this Article is not interpreted as setting up an alternative procedure for new 
applications - preference must always be given to either the centralised or mutual recognition 
procedures. Equally, a referral must be in the interests of the Community and therefore must 
be determined on a case by case basis. 
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Where the interests of the Community are involved, a referral could be made in relation to:-
• a request for marketing authorisation of a product which appears to be of the highest 
importance from the point of view of protection of human or animal health or the 
environment but which is not eligible for the centralised procedure (reference under 
Article 20 would not be appropriate in respect of products which are eligible for Part B); 
• a proposal for suspension or withdraw8.t of an authorisation, in the light of new data 
relating to quality, safety or efficacy; 
• a variation to the terms of the authorisation appearing necessary, especially in the light of 
any new pharmacovigilance information available. 
• a proposal for granting or refusing a variation to the terms of a marketing authorisation. 
5.3 Procedure 
The person responsible for invoking Article 20 (Member States, the person responsible for 
placing the product on the market, the Commission) shall clearly state the question which is 
referred to the Committee for consideration and ~hall inform the other concerned parties. 
The Member States and the person responsible for placing the product on the market shall 
forward to the Committee all available information relating to the matter in question. 
In those cases where the referral comes from a concerned Member State, the reasons must be 
accompanied by an updated assessment report which includes all available information relating 
to the matter in question. 
In the case of referrals from a marketing authorisation holder, the reasons must be 
accompanied by expert reports on quality, safety and efficacy which take account of current 
regulations and which have been updated to include data supporting the reasons for referral. In 
addition, the MA holder must ensure that all. the concerned Member States have the updated 
or additional information available to them. 
5.4 Time-frame 
Article 21 ofDirective 81/851/EEC requires the Committee to consider the matter and issue a 
reasoned opinion within 90 days of the date of referral. This period may be extended by a 
further 90 days. In case of urgepcy, on a proposal from its Chairman, the Committee may 
agree to impose a shorter deadline. 
6. VARIATIONS AND SUSPENSIONS BY AUmORITIES 
The amendments to Directive 81/851/EEC provide that where a Member State considers that 
variation of the terms of a marketing authorisation which has been authorised by mutual 
recognition (or subsequent arbitration), or its suspension or withdrawal, is necessary for the 
protection of human or animal health or the environment, it !!!.!!!! refer the matter to the 
Committee for application of the procedure as laid down in Article 21. Article 21 of Directive 
81/851/EEC as amended require the Committee to consider the matter and issue a reasoned 
opinion within 90 days of the date of referral. 
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Article 42h of Directive 81/851/EEC as amended provides that where as a result of the 
evaluation of adverse reaction reports a Member State considers that a marketing 
authorisation should be varied, suspended or withdrawn, it must inform the Agency and the 
person responsible for placing the veterinary medicinal product on the market. In case of 
urgency, the Member State concerned may suspend the marketing authorisation. If it does so, 
it must inform the Agency at the latest on the following working day. In cases where the 
Community interest are involved, this would be dealt with in accordance with Article 20 of 
Directive 81/851/EEC as amended. 
In exceptional cases where urgent action is essential to protect human or animal health or the 
environment, a Member State may, until a definitive decision is adopted, suspend the 
marketing and the use of the veterinary medicinal product concerned on its territory. The 
Member State must inform the Commission and the other Member States no later than the 
following working day of the reasons for its action. 
7. THE ARBITRATION PROCEDURE 
7.1 Appointment of a Rapporteur to consider risks to human or animal health or the 
environment. 
To assist in its review of the outstanding grounds for supposing that serious risks to human or 
animal health or the environment may remain, the Committee will appoint a rapporteur from 
one of its members. The choice of rapporteur will depend on the product and the nature of the 
human or animal health or the environmental objections raised. Whilst it may be convenient to 
choose a Committee member from the reference Member State, there may be cases where a 
different rapporteur may be more appropriate. The Agency will notify the person responsible 
for placing the veterinary medicinal product on the market of the identity of the rapporteur. 
Where necessary, additional experts may be appointed to assist the rapporteur and to advise 
on specific defined questions. 
7.2 Timetable for the arbitration 
The timings shown are indicative. The timetable will be reviewed by the Committee rapporteur 
in conjunction with the person responsible for placing the veterinary medicinal product on the 
market. 
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Ref~rral to tbe ~ommittee Timin&2 
Committee discussion on: Day I 
- question which has been referred (e.g. human or animal health or the environment 
objections raised by concerned Member States; divergent decisions; interests of the 
Community) 
-views of the reference Member State, concerned Member States, the person 
responsible for placing the veterinary medicinal product on the market, the Commission 
- appointment of Committee rapporteur 
- appointment of individual experts, if needed 
- request for comments upon the question referred (human or animal health or the 
environment) from the person responsible for placing the veterinary medicinal produCt 
on the market 
Committee stops the clock while the person responsible for placing the veterinary Day2 
medicinal product on the market produces comments in writing ( 60 days will normally 
be allowed for written comments, but the Committee may extend this period either on 
their own initiative or at the request of the person responsible for placing the veterinary 
medicinal product on the market) 
Person responsible for placing the veterinary medicinal product on the market submits Day3 
comments to all members of the Committee in writing 
Clock restarts when all documentation is received, timetable is distributed 
Rapporteur prepares a report with conclusions on the written comments of the person byDay45-
responsible for placing the veterinary medicinal product on the market upon the 
objections relating to human or animal health or the environment 
Comment from the Committee members on the conclusions of the assessment report to byDay60 
the rapporteur 
Rapporteur liaises with the person responsible for placing the veterinary medicinal 
product on the market to highlight remaining issues, if any, and to give guidance on the 
oral explanation in the Committee, if necessary 
· Oral explanation before Committee and Committee opinion on the points of arbitration Day90 
2 When reforence is made to the procedure described in this Article, the Comminee shall consider the matter concerned and issue a 
reasoned opinion Within 90 days of the date on which the matter was referred to it. 
However, m cases submitted to the Comminee·m accordance With Articles 19 and 20, th1s period may be extended by 90 days. 
In case of urgency, on a proposal from its Chairman, the Comminee may agree to 1mpose a shorter deadline. 
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7.3 Committee Assessment Report. 
The Committee rapporteur will prepare a Report of the Assessment on the written 
information. A copy of the report will be sent to the person responsible for placing the 
veterinary medicinal product on the market and the Committee members. The objective of this 
report is to provide an assessment on the issues relating to human or animal health or the 
environment which remained in relation to the product in the light of the explanation of the 
person responsible for placing the veterinary medicinal product on the market. 
7.4 Oral explanation 
Oral explanations are part of the formal process and not to be confused with other informal 
meetings between persons responsible for placing the veterinary medicinal product on the 
markets, rapporteurs, other Member States, etc. 
Practical arrangements for oral explanations will be organised by the Agency. 
In order to maximise the benefit of an oral explanation, it is important that persons responsible 
for placing the veterinary medicinal product on the market and preparing to attend a 
Committee meeting for the purpose of an oral explanation bear in mind that its aim is to allow 
clarification of outstanding issues. They should remember: 
a) that the oral proceedings ofthe Committee are multi-lingual. Persons attending should 
notify the Agency in good time of the language(s) in which they intend to express 
themselves so that, if necessary, arrangements for interpretation can be ensured. 
Although there is normally simultaneous interpretation in most Community languages, 
arguments of a very technical or scientific nature are usually better expressed in writing. 
b) to liaise with the rapporteur regarding the content of any written documents, slides and 
overheads to be used. 50 copies of any visual aid material, including paper copies of 
overhead projector slides/overheads, should also be brought to the meeting for 
distribution immediately beforehand. 
c) for practical purposes, to limit the delegation to a small number. Depending on the issues 
raised, it would normally be appropriate for between one and four persons per company 
to appear on behalf of the person responsible for placing the veterinary medicinal product 
on the market, with a maximum of eight. 
7.5 Committee Opinion 
After consideration ofthe written representation and oral explanation, the Committee reaches 
an opinion on the points upon which were referred to it. 
Where the opinion of the Committee is that: 
the application does not satisfy the criteria for authorisation, or 
the SPC should be amended , or 
the authorisation should be granted subject to conditions with regard to the safe and 
effective use of the veterinary medicinal product including pharmacovigilance, or 
the authorisation in the reference Member State and any other EC Member States in 
which the product is authorised should be suspended, varied or withdrawn, 
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the Agency will forthwith inform the person responsible for placing the veterinary medicinal 
product on the market. 
In the event of an opinion in favour of granting or maintaining an authorisation to place the 
veterinary medicinal product concerned on the market, the following documents shall be 
annexed to the opinion: 
a) a draft summary of the product characteristics, a5 referred to in Article Sa of Directive 
81/851/EEC as amended; · 
b) any conditions affecting the authorisation 
Within 30 days of adoption of the opinion, it is sent by the Agency to the Member States, the 
Commission and the person responsible for placing the veterinary medicinal product on the 
market. Within 15 days of receipt of the opinion. the person responsible for placing the 
veterinary medicinal product on the market may notify the Agency of the intention to appeal. 
In that case detailed written grounds for appeal shall be forwarded to the Agency within 60 
days of the opinion. The Committee shall consider whether its opinion should be revised. 
7.6 Appeal Process 
Within 60 days, the Committee will reach a decision whether its opinion should be revised. In 
order to do so, it may appoint one of its members to act as rapporteur (generally a different 
member than that which had already acted as rapporteur for this veterinary medicinal product). 
The rapporteur is responsible for making an assessment, within 30 days of receipt of the 
documentation, of the grounds for appeal. The assessment report would consist of a summary 
of the appeal, a discussion of each of the grounds for appeal and a conclusion in which is 
stated which of the issues can be considered as resolved and which will still remain. 
This assessment report with a proposal for revision of the original opinion, if necessary, 
annexed to it, is prepared. 
The Committee will consider the report together with the original opinion and issue its 
decision within 60 days of receipt of the grounds for appeal. The company concerned may be 
afforded the opportunity to make an oral explanation. · 
7.7 Binding decision 
Where the provisions of Article 13 have been followed, and the opinion of the Committee is 
forwarded to the Commission for the decision making process foreseen in Article 42k of 
Directive 81/851/EEC as amended, this leads to a Decision which is legally binding on all 
Member States. Thus, where a Member St'ate has previously authorised the veterinary 
medicinal product, it may be necessary to change the marketing authorisation, within 30 days, 
in keeping with the decision. ' 
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CHAPTER IV 
CENTRALISED PROCEDURE 
1. LEGAL BASIS AND PURPOSE 
EC Regulation No. 2309/93 introduced the centralised procedure, a procedure for which 
there is a single application, single evaluation and a single authorisation for a medicinal 
product leading to direct access to the single market of the Community. 
Regulation No. 2309/93 responded to the need to protect public health within the 
Community whilst at the same time allowing rapid access to the single market for important 
new medicinal products. The regulation built upon the experience of the concertation 
procedure which had been set up by Directive 87/22/EEC in order to ensure the smooth 
functioning· of the internal market in the pharmaceutical sector, and relied upon the 
fundamental principle that the authorisation of medicinal products should be based on 
objective scientific criteria of quality, the safety and the efficacy of the medicinal product 
concerned. · 
A marketing authorisation granted following the centralised procedure is valid 
lfor the entire Community market. A Community authorisation applies to all 
Member States which means the medicinal product may be put on the market in 
all Member States. Whilst a,pharmaceutical company is not required to sell a 
medicinal product in all parts of the te"itory of the Community, a marketing 
authorisation holder cannot preven( a medicinal product which has been 
authorized centrally from being sold throughout the Community. 
2. SCOPE 
Applications which fall within the scope of Regulation (EEC) No. 2309/93 are set out in 
the Annex to that regulation. Applications for medicinal products listed in Part A of the 
annex are required to use the centralised procedure, while applications for medicinal 
product listed in Part B of the annex may, at the request of the applicant, use the 
centralised procedure. 
At set out in Chapter I, it is important from an administrative ·point of view that a 
consistent regulatory strategy is maintained, both for the applicant and for the competent 
authority. Therefore, whilst not obligatory, it is nonetheless recommended that for 
applications using Part B of the Annex of Regulation (EEC) No. 2309/93, the optionality 
provided for in the legislation should not be interpreted as a mechanism to partition the 
market. Thus for abridged applications (e.g. informed consent and extensions) the option to 
use either the centralised route or mutual recognition route is available. Where such 
abridged applications use the mutual recognition procedure, both the Member States and 
the Commission must take up their responsibilities regarding the maintenance of a 
harmonised market, including as necessary, availing of references in accordance with article 
12 ofDirective 75/319/EEC as amended in cases of Community interest. 
I 
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In accordance with Articles 13.4 and 35.3 of Regulation (EEC) No. 2309/93, medicinal 
products for human use and veterinary medicinal products which have been authorised by 
the Community shall benefit from the ten year period of protection referred to in point 8 of 
the second paragraph of Article 4 of Directive 65/65/EEC and in point 10 of the third 
paragraph of Article 5 ofDirective 81/851/EEC respectively. 
2.1 Part A - medicinal oroducts derived from biotechnology 
Persons wishing to obtain a marketing authorisation for a medicinal product developed by 
means of one of the following biotechnological processes: 
i) recombinant DNA technology, 
ii) controlled expression of genes coding for biologically active proteins in prokaryotes 
and eukaryotes including transformed mammalian cells, 
iii)hybridoma and monoclonal antibody methods 
must submit the application to the European Agency for the Evaluation of Medicinal 
Products and the application will be processed in the centralised procedure. 
This requirement also applies to veterinary medicinal products, including those not derived 
from biotechnology, intended primarily for use as performance enhancers in order to 
promote the growth of treated animals or to increase yields from treated animals. 
Unlike in the concertation procedure (Directive 87/22/EEC) there is no provision for an 
application for a Part A medicinal product to only one Member State being exempted from 
the scope of the centralised procedure. 
2.2 Part B - innovatory medicinal products 
In addition, innovatory medicinal products with novel characteristics as defined in Part B of 
the Annex to Regulation No. 2309/93 may, at the request of the applicant, be accepted for 
consideration under the centralised procedure. In addition applications for medicinal 
products containing a new active substance may also use the centralised procedure. 
The following categories of medicinal products for human or veterinary use are eligible for 
Part B status:-
''Medicinal products developed by other biotechnological processes which, in the 
opinion of the Agency, constitute a significant innovation. 
Medicinal products administered by means of new delivery systems which, in 
the opinion of the Agency, constitute a significant innovation. 
Medicinal products presented for an entirely new indication which, in the 
opinion of the agency, is of significant therapeutic interest. 
Medicinal products based on radio-isotopes which, in the opinion of the 
Agency, are of significant therapeutic interest. 
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New medicinal products derived from human blood or human plasma. 
Medicinal products the manufacture of which employs processes which, in the 
opinion of the Agency, demonstrate a significant technical advance such as 
two-dimensional electrophoresis under micro-gravity. 
Medicinal products intended for administration to human beings, containing a 
new active substance which, on the date of entry into force of this Regulation, 
was not authorized by any Member State for use in a medicinal product 
intended for human use. 
Veterinary medicinal products intended for use in food-producing animals 
containing a new active. substance which, on the date of entry into force of this 
Regulation, was not authorized by any Member State for use in food-producing 
animals". 
(extract from Annex to Regulation No. 2309/93) 
2.3 Variations to the terms of a marketing authorisation 
Regulation No. XX/95 sets out the procedure for varying the terms of the marketing 
authorisation granted by the Community. 
The procedure for the examination of a variation is identical whether the product is Part A 
orB. 
2.4 Renewal of marketing authorisations 
According to Article 15.1 of Council Directive 81/851/EEC, a marketing authorisation for 
a veterinary medicinal product shall be valid for five years and be renewable for five-year 
periods upon application by the holder at least three months before expiry. 
For a veterinary medicinal product which has been authorized by the Community, the 
application for renewal of the marketing authorisation should be submitted to the Agency 
at least three months before the expiry of the marketing authorisation. 
3. PRE-SUBMISSION 
3.1 Advice to companies 
According to Article 51 G) of Regulation (EEC) N° 2309/93, it is the task of the Agency -
within its Committees "where necessary, to advise companies on the conduct of the various 
tests and trials necessary to demonstrate the quality, safety and efficacy of medicinal 
products". 
The new CVMP has been constituted early in 1995. The Committee will wish to consider 
the appropriate mechanism for complying with article 51 (j) of the Regulation. The 
following procedure is a provisional one designed mainly to deal with major issues. of 
scientific principle concerned with the development of a new veterinary medicinal product. 
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This pr0visional procedure, the scope and timing of advice to be given to companies will be 
revisec ... the light of experience 
3.1.1 Necessity for advice 
Normally, advice is prepared in the form of guidelines which are published by the European 
Commission in 'The Rules governing medicinal products in the European Union.' A series 
of guidelines has already been published in Volume VII. 
Advice of the Agency, within its Committees, on the conduct of tests and trials to 
demonstrate the quality, safety and efficacy of medicinal products may be requested for 
products eligible for authorisation by the centralised procedure. In the case of a medicinal 
product referred to in Part B of the Annex to Regulation 2309/93, its suitability for 
authorisation via the centralised procedure must be confirmed, in principle, before advice 
can be given. 
Advice will only be given in those circumstances where Pharmacopoeia monographs or 
guidelines, especially those adopted by the CVMP and CPMP and published, do not 
already address the point of concern or do not provide sufficient guidance. 
The ultimate decision as to what advice, if any, will be given rests with the Agency. 
3.1. 2 Scope of advice 
Applicant companies seeking advice under Article 51 G) must note that any advice given is 
not and will not be binding on the Agency with regard to the eventual application for 
marketing authorisation of the concerned product. 
Advice will be given in good faith but circumstances could change especially in the case of 
early advice or subsequent scientific developments. In some cases, e.g. as a result of 
scientific developments, an alternative approach to that advised may be appropriate. 
However where companies choose not to apply the advice, an explanation should be 
provided in the appropriate part of the dossier. 
The applicant should take into account that the scope of advice offered shall be general 
rather than specific (e.g. the already published guidelines on the conduct of various tests 
and trials may serve as examples for the general scope of advice). Questions should be 
limited to general problems of the tests or trials (e.g. it is not possible to give advice on the 
number of test animals or on statistical analysis). However, on occasions, detailed advice 
may be appropriate. 
3.1.3 Consultation procedure 
If a company considering making an application for marketing authorisation requires 
technical advice, it shall bring forward a written request to the secretariat of the Agency. 
The request must identify clearly (in a maximum of 4 pages) the questions/issues to be 
addressed and the reasons why advice is being requested from the Committee, particularly 
why existing publications or guidelines cannot be used. 
Each request will be considered by the Agency within its Committees as to the true 
necessity for such advice on a case by case basis and if appropriate the relevant 
Committee(s) may decide to refuse to give advice. 
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The procedure to be followed will be determined on a case by case basis depending on the 
nature of the request. Usually, the Committee concerned will appoint one of its members 
to co-ordinate advice to industry. 
If necessary, the co-ordinator and the company shall undertake appropriate consultations 
which may be oral or written but shall in any event be documented. 
After this, the following steps could apply : 
i) The company shall prepare a report summarising the discussions~ 
ii) The report shall be discussed by the co-ordinator and the company to reach 
agreement~ 
iii) The co-ordinator shall inform the Committee~ 
iv) The members of the Committee may provide written comments to the co-
ordinator~ 
v) The co-ordinator shall prepare a response incorporating advice to the company 
taking into account all. comments received~ 
vi) After any necessary discussion, the Committee shall recommend the advice to be 
given which shall be transmitted to the company by the Agency . 
. Furthermore the Committee shall consider whether or not the case would lead to 
a) the amendment of guidelines~ 
b) the preparation of new guidelines~ 
c) and/or the dissemination of information, for example, through a press release. 
Where considered appropriate, e.g. in cases of minor concern, the Committee may decide 
on a different approach to be followed. The procedure followed and the advice given shall 
be documented. 
3.2 Verification of Part B status: 
When an applicant considers that a medicinal product is a significant innovation or of 
significant therapeutic interest or a significant technical advance under one or more of the 
indents in Part B, and would therefore wish to avail of a Community procedure for access 
to the single market, contact should be established with the Agency. In the case of a new 
active substance which, on the date of entry into force of Regulation (EEC) Nr. 2309/93, 
was not authorized by any Member State for use in a medicinal product, the centralised · 
procedure may be used (see section 3.2.1 below). 
In the case of very innovative treatment, companies may ask the advice of the Agency. In 
such cases, the acceptance, in principle, of the application falling within the scope of Part B 
would be a prerequisite to the process of consultation. 
An application may be accepted as falling, in principle, within the scope of Part B, even 
before the application dossier is finalised. In such circumstances, the applicant should 
provide a document (2-3 pages) describing the properties of the product in which the 
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innovative character according to one of the above mentioned indents is especially 
elaborated. 
The Committee is responsible for formulating the opinion of the Agency on any question 
relating to the admissibility of an application. In the event that the application is accepted 
as falling within the scope of Part B, the applicant will be advised by the Agency. 
It is not essential that the application be submitted immediately. 
Definition of a new active substance 
A new chemical, biological or radiopharmaceutical active substance includes: 
i) a chemical, biological or radiopharmaceutical substance not previously authorized 
as a medicinal product in the European Community; 
ii) an isomer, mixture of isomers, a complex or derivative or salt of a chemical 
substance previously authorized as a medicinal product in the European Community 
but differing in properties with regard to safety and efficacy from that chemical 
substance previously authorized; 
iii) a biological substance previously authorized as a medicinal product in the European 
Community, but differing in molecular structure, nature of the source material or 
manufacturing process; 
iv) a radiopharmaceutical substance which is a new radionuclide, or a ligand not 
previously authorised as a medicinal product in the European Community, or the 
coupling mechanism to link the molecule and the radionuclide has not been 
previously authorised in the European Community. 
3.3 Inspection of the manufacturing site 
3. 3.1 Products manufactured in the European Economic Area 
The rapporteur's assessment report will give information with regard to the suitability of 
the proposed manufacturer( s ), including confirmation from the supervising Member States 
that the manufacturer of a veterinary medicinal product or the importer from a third 
country is able to manufacture the veterinary medicinal product concerned and/or carry out 
the necessary control tests in accordance with the particulars and documents supplied 
pursuant to Article 28 ofRegulation (EEC) No. 2309/93. The procedure for the exchange 
of information on manufacturing authorisations (established by the ad hoc group on 
harmonisation of inspections) is set out in "Compilation of Community procedures on 
administrative collaboration and harmonisation of inspections, 11115698/94, Nov. 1994"). 
3.3.2 Products manufactured outside the European Economic Area 
Where it is considered necessary to complete the examination of an application, the 
rapporteur may recommend to the Committee that the applicant submit to a specific 
inspection ofthe manufacturing site(s) ofthe veterinary medicinal product concerned. The 
inspection would be undertaken by inspectors from the Member States who possess the 
appropriate qualifications and experience and who may, if need be, be accompanied by a 
rapporteur or expert appointed by the Committee. 
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In the absence of a Mutual Recognition Agreement on inspection and good manufacturing 
practice, it is likely that a Community inspection would be systematic for applications 
through the centralised procedure. Thus, for veterinary medicinal products which are to be 
manufactured outside the EEA, the applicant should liaise with the Agency well in advance 
of the submission of an application in order to avoid delays due to arranging inspections or 
effecting required remedial measures. Where necessary, the scientific evaluation may be 
suspended pending receipt of the inspection report. 
3.4 Liaision with the Agency 
Applicants are reminded that the initial contact point in a centralised procedure is the 
Agency. The applicant is advised to notify the Agency of the intention to submit an 
application about 3 to 6 months in advance, in order that preparations and scheduling may 
be initiated and to ensure that the application will be complete and valid (see 'Dossier 
Check-in Procedure' in Chapter VII) according to current requirements. 
4. SUBMISSION OF mE APPLICATION 
4.1 Dossier for submission 
The application is submitted to the Agency at 
7 Westferry Circus, 
Canary Wharf, 
GB-London E14 4HB 
and should be marked for the attention ofNN. 
When the application is made, one copy is forwarded to the Agency for the two-weeks 
validation period. At its next meeting, the CVMP will appoint or confirm the rapporteur 
and the co-rapporteur, who should then receive two copies each. At this stage the CVMP 
also determines if any of its members should receive an extra copy. 
Thirty-four copies of Part I should be prepared. They are to be distributed as follows: four 
copies are to be forwarded to the EMEA at the time the full dossier is submitted. One 
copy should be forwarded to each member of the CVMP. 
In the case of a veterinary medicinal product containing or consisting of genetically 
modified organisms within the meaning of Article 2.1 and 2.2 of Directive 90/220/EEC, the 
application must also be accompanied by: 
i) a copy of any written consent or consents of the competent authorities to the 
deliberate release into the environment of the genetically modifi,ed organisms for 
research and development purposes where provided for by Part B of Directive 
90/220/EEC, 
ii) the complete technical dossier supplying the information requested in Annexes II 
and III to Directive 90/220/EEC and the environmental risk assessment resulting 
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from this information; the results of any investigations performed for the purposes 
of research or development. 
Applicants are reminded that Part m (drafts of the summary of product characteristics, 
package insert and labels) must be submitted in all the languages ofthe Community. 
The application fee should be included with the submission i.e. bank transfer. Applications 
will not be processed until the full fee has been paid. 
4.2 Check-in of the application 
The application is checked in by the secretariat of the Agency within 10 working days of 
receipt, using the check-in procedure. 
Receipt of a valid application is notified to the applicant by the secretariat. Any problems 
are notified immediately in writing (by telefax) directly to the applicant and in the event that 
the deficiency cannot be rectified within 1 month, the dossier will be returned to the 
applicant, and a proportion of the fee will be retained to cover administration charges. 
5. PROCEDURE FOR SCIENTIFIC EVALUATION 
5.1 Selection of rapporteur/co-rapporteur 
The Committee appoints one of its members to act as rapporteur for the co-ordination of 
the evaluation of an application, taking into consideration any proposal from the applicant 
for the choice of a rapporteur. Thus in the covering letter which accompanies the dossier, 
the applicant should set out their proposal for rapporteur, if any. 
The Committee will select the rapporteur from amongst its members in such a way as to 
ensure that there is appropriate co-ordination between the tasks of the Agency and the 
work of competent national authorities, including the consultative bodies concerned with 
the marketing authorisation. Selection of the rapporteur will be by consensus. If such a 
consensus cannot be reached, the selection will be the position ofthe majority of members. 
The Committee may appoint a second member to act as co-rapporteur. Appointment of a 
co-rapporteur will not be systematic. However, in cases where a wide-ranging scientific 
debate would be constructive, a co-rapporteur -could be appointed. The role of the co-
rapporteur would be determined by the Committee on a case by case basis. 
The Committee shall ensure that all its members undertake the role of rapporteur or co-
rapporteur. 
5.2 Selection ofthe evaluation team 
Member States, in accordance with article 51 of Regulation (EEC) No. 2309/93, have 
transmitted lists of experts with proven experience in the assessment of medicinal products. 
This list is updated as necessary. 
In forming the evaluation team, the rapporteur will nominate experts from this list, in 
consultation with the Committee (a procedure may be elaborated by the new Committees). 
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The members of the Committees and the experts responsible for evaluating medicinal 
products rely on the scientific assessment and resources available to the national competent 
authorities. However, the assessment report is prepared for and on behalf of the 
Community. 
5.3 Timetable for the evaluation . 
The timings shown are indicative. The timetable proposed by the rapporteur will be 
reviewed by the Agency in conjunction with the Committee and the ~pplicant. 
Note : The new Committees may wish to elaborate procedures for the preparation of the 
timetable and to give further advice on aspects relating to the scientific evaluation 
process. In addition, the Committees may, in the light of experience, wish to 
improve the procedure in this context. 
Scientific Evaluation Timing 
Committee receives the valid application, a rapporteur (taking into 
consideration any proposal from the applicant for the choice of a rapporteur) 
and as appropriate a co-rapporteur, is nominated along with the experts in the 
evaluation team; Day 1 
I 
The secretariat liaises with the applicant, informing them of the rapporteur (and 
co-rapporteu.r) and timetable which has been prepared. 
Rapporteur (and co-rapporteur, as appropriate) circulate their preliminary Day90 
assessment reports to the Committee 
Committee considers preliminary assessment report(s) and establishes those Day 120 
issues which the applicant is invited to clarify and the clock is stopped 
Applicant submits a written response to the Agency Day 120 
Clock restarts when a response to all parts of the dossier is received 
Rapporteur(/co-rapporteur) prepares a report with conclusions on the written Day 150 
response of the applicant and circulates to members and the applicant 
The need for an oral explanation with the Committee is discussed with the Day 180 
rapporteur, which is then is arranged by the secretariat if necessary (clock may 
approx. be stopped to allow the applicant to prepare the oral explanation) 
The Committee members conclude the evaluation and adopt the opinion Day 210 
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5.4 Discussion with the rapporteur 
Once the rapporteur has been appointed by the Committee, the name of the rapporteur and 
the timetable will be sent to the applicant by the Agency. Liaison between the rapporteur 
and the applicant should be initiated by the rapporteur. 
The rapporteur is responsible for liaison with the applicant should any clarification of the 
dossier be required. 
When the Committee has considered the preliminary assessment report(s) and established 
those issues which the applicant is invited to clarify, these texts will be made available to 
the applicant by the Agency. All preliminary reports or other documents in advance of this 
stage are considered internal papers of the Committee and cannot be taken as representing 
the position of the Committee. 
The time limit laid down in Article 28 of Regulation (EEC) No. 2309/93 shall be suspended 
until such time as the supplementary information requested has been provided. 
5.5 Supplementary information 
The applicant may prepare supplementary information to the preliminary assessment report 
on those issues raised for clarification/completion. The issues, including those quality issues 
raised in an inspection report, should be presented in the order of the sequence for the 
dossier with their responses. Where appropriate, a revised text of the proposed SPC, 
label(s) and package inserts should also be included in the supplementary information. 
The response should include: 
i) the name, trade name and composition of the veterinary medicinal product, 
ii) the name and address of the applicant 
iii) centralised procedure reference number (and amendment/variation if relevant). 
iv) the text of the proposed SPC and package insert, revised appropriately in the light of 
the list of issues raised by the Committee. 
Each answer should start on a new page with a repetition of the particular point/points 
from the list of issues. 
The applicant should send the supplementary information in accordance with the agreed 
timetable to the Agency, (see Chapter VII for the numbers of copies required). An oral 
explanation may be requested by the applicant at the same time as the supplementary 
information is submitted. 
In the likelihood of a prolonged delay in preparation of the supplementary information, the 
applicant should notify the Agency, giving an indication of the time needed to finalise the 
supplementary information. It is not considered that a delay of longer than six months 
should normally be needed. In such an event, liaison with the Agency is essential. 
The applicant is advised to liaise with the rapporteur regarding the strategy for the response 
and in particular, the adaptation of the draft SPC. The applicant may consult with and/or 
62 
I 
I 
meet the rapporteur before the Committee meeting to be briefed on outstanding points and 
strategy for the opinion/oral explanation. If an oral explanation was originally requested, 
the actual need for one is reviewed in discussion between the rapporteur and applicant. 
5.6 The oral explanation 
In addition to written supplementary itiformation on issues raised for clarification, the . 
applicant may also avail of an oral explanation with the Committee. The time limit set out 
in article for the 28of the Regulation (EEC) No. 2309/93 shall be suspended for the time 
allowed to the applicant to prepare an oral explanation. 
In order to maximise the benefit of an oral explanation, it is important that applicants 
preparing for and attending oral explanations bear in mind that they are held to allow 
· clarification of outstanding issues. Thus the applicant should remember: 
i) That the oral proceedings of the Committee are multi-lingual. Persons attending 
such oral explanations should notify the Committee secretariat in good time of the 
language(s) in which they propose to express themselves so that, if necessary, 
arrangements for interpretation can be ensured. Although simultaneous 
interpretation into most Community languages is normally available, arguments of a 
technical or scientific nature are better expressed in writing. 
ii) Applicants should liaise with the rapporteur regarding the content of written 
documents/slides/overheads which are to be used in conjunction with an oral 
explanation. 50 copies of any visual aid material, including paper copies of 
projector slides/overheads, should also be brought to the meeting, for distribut~on 
· just prior to the oral explanation. 
iii) Depending on the issues raised in the reasoned objections, it would normally be 
appropriate for between one and four persons per company to appear on behalf of 
the applicant. However, due to limited space in meeting rooms, a maximum of 8 
persons can be accommodated. 
There are currently no formal rules for the conduct of oral proceedings. The new 
Committees may wish to develop appropriate guidance in due course. 
6. THE COMMITTEE OPINION 
The members of the Committee discuss the application in the light of the recommendation 
of the rapporteur and further evidence/argument presented at the oral explanation. 
An opinion is prepared, which may be favourable or unfavourable. Where a scientific 
consensus cannot be obtained, the majority position is given as the opinion, with divergent 
positions and the reasons for such positions being included at the request of the members 
concerned. 
Within 30 days of its adoption, the Agency shall forward the opinion of the Committee to 
the Commission, the Member States and the applicant together with a report describing the 
assessment of the medicinal product by the Committee and stating the reasons for its 
conclusions. 
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6.1 Favourable opinion 
In the event of an opinion in favour of granting the relevant authorisation to place the 
veterinary medicinal product concerned on the market, the following documents are 
annexed to the opinion: 
i) a draft summary of the product characteristics, as referred to in Article Sa of 
Directive 81/851/EEC~ 
ii) details of any conditions or restrictions which should be imposed on the supply or 
use of the medicinal product concerned~ 
iii) the draft text of the labelling and package insert proposed by the applicant in all 
EC languages~ 
iv) the assessment report. 
Within 15 days of receipt of the opinion, and if the applicant accepts the amendments 
and/or conditions imposed, he may inform the Agency of his decision not to appeal. The 
Agency would thus forward the opinion (and the required annexes) within 30 days of its 
adoption, to the Commission, the Member States and the applicant together with a report 
describing the assessment of the medicinal product by the Committee and stating the 
reasons for its conclusions. 
6.2 Unfavourable opinion 
The Agency immediately informs the applicant when the opinion of the Committee is that: 
i) the application does not satisfy the criteria for authorisation set out in Regulation 
(EEC) No. 2309/93, or 
ii) the summary of the product characteristics proposed by the applicant should be 
amended, or 
iii) the labelling or package insert of the product is not in compliance with Chapter VII 
of Directive 81/8 51/EEC as amended 
iv)the authorisation should be granted subject to the conditions provided for in Article 
35.2 ofDirective 81/851/EEC as amended. 
6.3 Appeal 
Within 15 days of receipt of the opinion, the applicant may provide written notice to the 
Agency that he wishes to appeal. In that case he shall forward the detailed grounds for his 
appeal to the Agency within 60 days of receipt of the opinion. 
Within 60 days of the receipt of the grounds for appeal, the Committee shall consider 
whether its opinion should be revised, and the conclusions reached on the appeal shall be 
annexed to the assessment report. 
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When considering appeals from applicants, the Committee would normally have recourse 
to additional experts who have not participated in the initial consideration of the dossier. 
To maintain the scientific credibility of the fin~ opinion, the choice of these experts would 
be based upon their qualifications and experience, taking into due consideration the issues 
under appeal. 
An oral explanation is not provided for in Regulation (EEC) No. 2309/93. Given that the 
time period is short, the possibility of an oral explanation during an appeal will be reserved 
to those cases where the Committee considers that it would contribute to the discussions, 
and would be at the invitation of the Agency. 
7. VARIATIONS 
Throughout the life of a veterinary medicinal product, the holder of the authorisation is 
responsible for the product which circulates in the marketplace and is also required to take 
into account technical and scientific progress, and to make any amendments that may be 
required to enable the medicinal product to be manufactured and checked by means of 
generally accepted scientific methods. 
Marketing authorisation holders may, in addition, wish to alter/improve the product or to 
introduce an additional safeguard during the period of five years .. 
Such changes or 'variations' may involve administrative and/or more substantial changes, 
, and the procedures for the approval of such changes, without jeopardising public health, 
have been set ou~ in RegUlation (EEC) No. XX/95. 
The term variation is defined in Regulation (EEC) No. XX/95: "variation to the terms of a 
marketing authorisation" as : an amendment to the contents of the clocuments refe"ed to in 
Article 6{1) and (2) or Article 28(1) and (2) of Council Regulation (EEC) No 2309193 
such as they existed at the moment the decision on the marketing authorisation has been 
adopted in accordance with Article 10 or Article 32 of that Regulation or after approval 
of any previous variations, except where a new application for a marketing authorisation 
must be presented pursuant to Annex II of this Regulation. 
The application for the variation is submitted to the Agency, accompanied by the 
appropriate fee and documentation. 
7.1 Urgent Safety Restriction 
An urgent safety restriction is defined in Article 2.2 of Regulation (EEC) No. XX/94 as : 
"An interim change to product information by the marketing authorisation holder 
restricting the indication(s), and/or dosage, and/or target species of the medicinal· 
product;· or adding a contra-indication, and/or warning due to new information having a 
bearing on the safe use of the product". 
The person responsible for placing the veterinary medicinal product on the market must 
immediately inform the Agency, the Commission and the Member States of any new 
information which might influence the evaluation of the benefits and risks of the product. 
In cases of urgency, where there is a risk to public health, marketing authorisation holders 
may make urgent safety restrictions in accordance with Regulation XX/95. These measures 
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must be communicated without delay to the EMEA. If the EMEA has not raised any 
objections within 24 hours, the urgent safety restrictions may be introduced and the 
corresponding application for this variation (type II) shall be submitted without delay to the 
·EMEA, for application ofthe procedures set out in Articles 6 and 7 ofRegulation XX/95. 
7.2 Type I variations 
A "minor variation" (type I} means a variation as defined in Article 2 and listed in Annex I 
to Regulation (EEC) No. XX/95, provided the conditions for such variation laid down in 
the Annex are met. 
The procedure and documentation required for a type I variation are set out in the 
regulation. As an illustrative guide, the following procedure would generally be followed. 
a) initial application acceptable 
Application submitted to the European Agency 
-1-
Variation assessed through a Committee procedure (which may include 
delegation of certain variations to the technical secretariat) 
-1-
DayO 
-1-
-1-
-1-
-1-
Entry into the Community Register of Medicinal Products as appropriate .l-
and notification of the Commission (i.e. approved without the necessity Day 30 
for written confirmation of approval) 
b) initial application not acceptable - marketing authorisation holder does not amend 
Application submitted to the European Agency 
"' Variation assessed through a Committee procedure (which may include 
delegation of certain variations to the technical secretariat) 
-1-
If there are objective grounds against acceptance of the application, the 
marketing authorisation holder is sent a notification with grounds. 
Marketing authorisation has 30 days to amend the application taking into 
account the objective grounds 
-1-
DayO 
-1-
-1-
-1-
-1-
Clock stopped for 
30 days 
-1-
-1-
-1-
If no responce is received, the application ts deemed to have been Day 30 
rejected. 
c) initial application not acceptable - marketing authorisation holder does amend 
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Application submitted to the European Agency 
.1-
varlation assessed through a Committee procedure (which may include 
delegation of certain variations to the technical secretariat) 
.1-
If there are objective grounds against acceptance of the application, the 
marketing authorisation holder is sent a notification with grounds. 
Marketing authorisation has 30 days to amend the application taking into 
account the objective grounds 
.1-
Amendment is submitted to the Agency 
~ ~ 
If the amendment is not acceptable, 
DayO 
-1-
.1-
-1-
.1-
Clock stopped for 
30 days 
-1-
.1-
.1-
Entry into the Community Register 
of Medicinal Products as 
appropriate and notification of the 
Commission (i.e. approved without 
the necessity for written 
confirmation of approval) 
the variation is refused, with .1-
written notification -1-
7.3 Type ll variations 
, -1-
.1-
Day30 
A "major variation" (type II) means a variation which cannot be deemed to be a type I 
variation within the meaning of Article 2 of the Regulation and which does not require a 
new application. 
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Application submitted to the European Agency DayO 
-1. J, 
Variation assessed by the Committee (generally the same rapporteur as J, 
acted for the full application). A single request for supplementary J, 
information may be made and the 'clock' could be stopped for a period of J, 
60 days. These 60 days may be extended by the Committee (on its own J, 
initiative or at the request of the marketing authorisation holder) J, 
-1. 
Assessment report circulated to the Committee 
J, 
Opinion of the Committee 
-1. 
(Appeal procedure may be invoked by the marketing authorisation holder 
- see section 6.3) 
Opinion is sent by the Agency to the Commission for the normal 
decision-making process 
Decision by the Commission 
Refusal in writing Acceptance in writing 
8. COMMISSION DECISION 
Day45 
J, 
Day60 
J, 
J, 
J, 
J, 
Day90 
J, 
J, 
J, 
Day 150 
Within 30 days of receipt ofthe opinion from the Agency, the Commission prepares a draft 
ofthe decision to be taken in respect ofthe application, taking account of Community law. 
In the event of a draft decision which envisages the granting of marketing authorisation, the 
documents referred to in Article 31(3) ofRegulation No. 2309/93 shall be annexed. 
Where, exceptionally, the draft decision is not in accordance with the opinion of the 
Agency, the Commission shall also annex a detailed explanation of the reasons for the 
differences. 
A final decision on the application shall be adopted in accordance with the procedure laid 
down in Article 73 ofRegulation (EEC) No. 2309/93. 
8.1 Status of a Community authorisation 
Medicinal products which have been authorized by the Community in accordance with the 
provisions of the Regulation benefit from the ten-year period referred to in point 1 0 of the 
third paragraph of Article 5 ofDirective 81/851/EEC. 
Without prejudice to Article 34.1 of Regulation (EEC) Nr. 2309/93, a marketing 
authorisation which has been granted in accordance with the procedure laid down in this 
Regulation shall be valid throughout the Community. It confers the same rights and 
obligations in each of the Member States as a marketing authorisation granted by that 
Member State in accordance with Article 3 of Directive 65/65/EEC. The granting of 
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authorisation shall not diminish the general civil and criminal liability in the Member States 
of the manufacturer or, where applicable, of the person responsible for placing the 
veterinary medicinal product on the market. 
The refusal of a Community marketing authorisation shall constitute a prohibition on the 
placing on the market of the veterinary medicinal product concerned throughout the 
Community. 
Decision making procedure 
Standing Committee on 
~eterinary Medicinal Product 
Commission forwards 
draft measures 
COMMISSION 
DECISION 
COUNCIL 
DECISION 
In favour 
or against 
(QUALIFIED MAJORITY) 
3months 
(QUALIFIED 
MAJORITY) 
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No 
Decision 
COMMISSION 
DECISION 
UNLESS 
Council Objects 
(SIMPLE MAJORITY) 
8.2 Publication of the authorisation 
Once a medicinal product has been authorized, it shall be entered in the Community 
Register of Medicinal Products and shall be given a Community marketing authorisation 
number which must appear on the packaging. Appropriate notification of marketing 
authorisation shall be published in the Official Journal of the European Communities. 
8.3 European Public Assessment Report 
In accordance with Article 34.4 of Regulation (EEC) No. 2309/93, and upon request from 
any interested person, the Agency shall make available the assessment report of the 
veterinary medicinal product by the Committee and the reasons for its opinion in favour of 
granting authorisation, after deletion of any information of a commercially confidential 
nature. 
This document (called the European Public Assessment Report or EP AR) is based upon 
the assessment report which accompanied the opinion of the scientific committee. 
Applicants are reminded that the assessment report may include parts of the written 
summaries of the Expert Report. 
8.3.1 Operating approach to the preparation of the EPAR 
In order to prepare its opinion, the Committee will, in the course of developing its 
assessment report, consider the assessment report which will accompany the opinion of the 
Committee. Generally the assessment report will be endorsed by the Committee at the 
same time as the opinion. The task of combining and presenting the EP AR will fall to the 
secretariat of the Agency. 
8.3.2 Commercial confidentiality: 
In accordance with Article 31.3 of the Regulation, the applicant will receive the assessment 
report of the Committee. 
Thus, the applicant should be in a position to identify within a short period of time (for 
example 30 days) those issues which they consider to be commercially confidential. 
Upon receipt of the applicant's response with those issues which the applicant considers to 
be commercial confidentiality, the Agency will prepare a final text of the EP AR, taking into 
account the obligations of the regulation, transparency and confidential considerations. 
The final EP AR would be submitted to the Committee for Veterinary Medicinal Products 
prior to being made available, upon request. 
8.3.3 Availability 
Normally, the EPAR would be available at the same time as the Commission decision on 
the application (and a standard statement to this effect will be included in the O.J. 
publication). 
The EP AR is available upon request - requests would be submitted in writing. At regular 
intervals, a compilation of the requests for the EP AR of a given veterinary medicinal 
product would be made available to the marketing authorisation holder. 
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CHAPTERV 
PHARMACOVIGILANCE OF VETERINARY 
MEDICINAL PRODUCTS 
1. LEGAL BASIS AND PURPOSE 
The legal framework for phannacovigilance of veterinary medicinal products in the 
Community is given in Council Regulation (EEC) No 2309/93 (Title 3, Chapter ill) and 
Council Directive 81/851/EEC as amended by Council Directive 93/40/EEC. 
Pharmacovigilance activities come within the scope of the criteria of quality, safety and 
efficacy, as new information is accumulated on the veterinary medicinal product under normal 
conditions of use in the marketing situation. Pharmacovigilance obligations apply to all 
authorised veterinary medicinal products. 
Council Regulation No 2309/93 (Articles 19 to 22) and Directive . 93/40/EEC (Chapter VI 
Articles 42a to 42d describe the respective obligations of the person responsible for placing 
the medicinal product on the market and of the competent authorities to set up a system for 
pharmacovigilance in order to collect, evaluate and collate information about suspected 
adverse reactions. All relevant information should be shared between the competent 
authorities and the person responsible for placing the veterinary medicinal product on the 
market, in order to allow the partners in phannacovigilance activities to assume their 
obligations and responsibilities. This requires an exchange of information between the Agency, 
the Member States, and the person responsible for placing the medicinal products on the 
market, as well as procedures to avoid duplications, maintain confidentiality and ensQre the 
quality of the systems. 
The person responsible for placing the veterinary medicinal product must ensure that they have 
an appropriate system of pharmacovigilance in place in order to assure responsibility and 
liability for their products on the market and to ~nsure that appropriate action can be taken, 
when necessary. · 
In accordance with Article 46 of the Regulation and Article 42g of the Directive, guidance for 
marketing authorisation holders on the implementation and practical procedures involved iri 
complying with the above legislation, in the interests of protecting public health, have been 
prepared. The following areas are covered: 
1.1 Responsibilities of marketing authorisation holden 
The responsibilities of the qualified person responsible for pharmacovigilance are as follows: 
i) the ~stablishment and maintenance of a system which ensures that information about all 
suspected adverse reactions which are reported to the personnel of the company, 
including to medical representatives, is collected and collated so that it may be accessed 
at a single point within the Community; 
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ii) the preparation for the EMEA and competent authorities of Member States where the 
medicinal product is authorised of the reports referred to in the Regulation and Directive 
and further detailed in this chapter: 
- Adverse reaction reporting 
- Periodic safety update reporting 
- Post-authorisation safety studies 
- Ongoing risk/benefit evaluation during the post-marketing period 
iii) Ensuring that any request from the competent authorities for the provts10n of 
additional information necessary for the evaluation of the benefits and risks afforded by a 
medicinal product is answered fully and promptly, including the provision of information 
about the volume of sales or prescriptions of the medicinal product concerned. 
The person responsible for placing the medicinal product must ensure that they have an 
appropriate system of pharmacovigilance in place in order to assure responsibility and liability 
for their products on the market and to ensure that appropriate action can be taken, when 
necessary. 
1.2 Pharmacovigilance guidelines 
In accordance with Article 46 of Regulation (EEC) Nr. 2309/93 and Article 42g of Directive 
81/851/EEC, guidance for marketing authorisation holders on the implementation and 
practical procedures involved in complying with the above legislation, in the interests of 
protecting public health, have been prepared. The following areas are covered in this chapter: 
Section 2 Adverse reaction reporting 
Section 3 Periodic safety update reporting 
Section 4 Company sponsored post-authorisation safety studies 
Section 5 Ongoing risk/benefit evaluation during the post-marketing period 
2. ADVERSE REACTION REPORTING 
The marketing authorisation holder is responsible for reporting suspected adverse reactions to 
the authorities of the Member States and European Medicines Evaluation Agency (EMEA) for 
their veterinary medicinal products authorised under the centralised procedures and to the 
appropriate authorities of the Member States for their medicinal products authorised through 
the national procedure. 
2.1 Scope 
The scope of veterinary pharmacovigilance is considered to be broader than in 
pharmacovigilance of medicinal products for human use, covering not only clinical safety but 
misuse of a product, epidemio-surveillance of resistances or environmental problems. 
For veterinary medicinal products authorised in the Community (whether through the 
centralised or national procedures): suspected adverse reactions received from veterinarians, 
animal owners or users of the veterinary medicinal product should be reported. These should 
be reported even if the marketing authorisation holder does not agree with the reporter's 
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assessment of a possible causal association. Spontaneously reported suspected adverse 
reactions, suspected adverse reactions from post-marketing surveillance studies and those. 
reported in the world-wide literature are induded. 
Adverse "events" which are not suspected of being product-related by the veterinarian, animal 
owner or other person responsible for the animal should not be reported unless the marketing 
authorisation holder has reason to believe that a causal relationship· is possible. 
If the marketing authorisation holder is aware that a reporter has reported a reaction to one of 
its products directly to the authority of a Member State, the marketing authorisation holder 
should still report the reaction, informing the authority that the report is likely to be a 
duplicate of a previous report. In this situation it is essential for the marketing authorisation 
holder to provide all the available details including any authorisation number provided to the 
reporter by the authority, in order to aid identification of the duplicate. 
Marketing authorisation holders are expected to fully validate and follow-up all serious 
reactions reported by them to the authorities. All available clinical information relevant to the 
evaluation of the reaction should be provided. 
2.1.1 Spontaneous ADR reports and case reports from the world-wide literature 
i) Spontaneous ADR reports occurring in the EC 
The marketing authorisation holder should report all suspected serious adverse reactions 
occurring within the Community and brought to its attention. These should be reported 
immediately and in no case later than 15 calendar days from receipt to Member States in 
whose territory the incident occurred. Any suspected increase in the frequency of serious 
reactions should also be reported. The basis on which the frequency assessment has been 
made should be provided. All other reactions should be reported as line listings on request or 
at 6-monthly intervals for 2 years post-authorisation, yearly for the subsequent 3 years and at 
the 5-yearly renewal. 
ii) Spontaneous ADR reports occurring outside the EC 
The marketing authorisation holder should report all suspected serious and unexpected 
adverse reactions occurring in the territory of a third country and brought to its attention. 
These should be reported to all Member States and the EMEA immediately and in no case 
later than 15 calendar days following receipt. All other suspected adverse reactions should be 
reported as line listings on request or at 6-monthly intervals for 2 years post-authorisation, 
annually for the 3 subsequent years and at the 5-yearly renewal. 
iii) Case reports from published scientific literature 
The marketing authorisation holder is expected to screen the world-wide literature and report 
published suspected adverse reactions in relation to the active substances(s) of its veterinary 
medicinal products, as relevant to the categories identified in (i) and (ii) above. A copy of the 
relevant published Artide should be provided, if necessary, translated into a language 
acceptable to the Member State. 
2.1.2 Reports from post-authorisation studies . 
Compared to human medicine, the tolerance of veterinary drugs is more predictable since it is 
studied in the target species at supra-therapeutic doses, which allows for the evaluation of a 
margin of safety. 
75 
Therefore the need for post-authorisation surveillance studies is certainly not so stringent in 
the veterinary field. Spontaneous reporting schemes provide the complementary information 
concerning adverse drug reactions, especially those which are unexpected. 
However, for specific cases concerning for example the occurrence of pathological events that 
could be drug-related (such as mastitis after intra-mammary infusion) or post-vaccinal 
reactions, post-authorisation studies should be envisaged. 
The methodology for such studies is obviously quite specific to the veterinary field and should 
be considered as an interesting area of investigation in veterinary pharmacovigilance. 
Besides those sponsored by the company, post-authorisation studies might also include those 
reported by veterinary practitioners, centers of veterinary pharmacovigilance and specialists in 
epidemiological and clinical sciences. 
Suspected serious adverse reactions from post-authorisation studies should be reported to all 
Member States. These should be reported immediately and in no case later than 15 calendar 
days from receipt. Non-serious reactions should be reported in summary at the end of each 
study. 
Adverse events not suspected to be due to the study product should not be reported as 
individual cases. 
2.1.3 Minimum requirements for an ADR Report to be recorded by the marketing authorisation 
holder, and reported to the Member State 
A case report will be considered as an adverse reaction report provided that at least the 
following data are available : 
(i) An identifiable source, wherever possible this should include the name and 
address ofthe reporter (e.g. veterinarian, pharmacist, animal owner) 
(ii) animal details : species, gender, age 
(iii) suspect drug 
(iv) suspected reaction 
The reference point for deadlines for submission of reports is the time of receipt of the 
minimum information. It should be stressed that these are minimum requirements and that 
companies should endeavour to provide all the information necessary for a full evaluation. 
2.2 Additional information to be reported within the frame of pharmacovigilance 
2.2.1 Extra-label use (unlicensed use ofproducts)!Misuse/Abuse 
Occasionally reports may be obtained on products used outside the terms of the marketing 
authorisation e.g. use of a product in non-authorised species or use at doses differing from 
those set out in the package insert. 
While this practice is neither endorsed nor recommended, such reports can provide useful 
information on the safety of the product and should be recorded by the person responsible for 
pharmacovigilance and reported to the competent authorities in the normal way. 
The system shall also collate information on frequently observed misuse and serious abuse of 
veterinary medicinal products. 
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2.2.2 Reporting of human reactions to veterinary medicinal products 
Suspected adverse reactions occurring in humans following use of veterinary medicinal 
products should be reported promptly to the competent authorities. 
2.2.J Reporting of lack of efficacy reports 
Directive 81/851/EEC cites the lack of therapeutic effect as a reason for refusal of 
authorisation. It is incumbent therefore for companies to investigate such reports. 
Where the conclusions drawn from the reports differ from those in the dossier on which the 
authorisation was granted and which might normally be expected, the company should inform 
the competent authority. · 
Lack of efficacy in this context means : no therapeutic efficacy of a veterinary medicinal· 
product or no efficacy according to the indications claimed for, leading to the development, 
spreading or deterioration of a disease. 
2.2.4 Medicated premixes 
When medicated premixes which have been incorporated in the finished feed are suspected of 
causing a reaction in consumers, operators or animals, both the premix and the finished feed 
should be investigated without delay. 
Among the factors that have to be examined are the composition of the finished medicated 
feed; the inclusion levels of active ingredients, the operation of the milling process( es) and 
when possible the actual dosage administered to individual target animals. 
2.2.5 Reporting of known side effects 
. Companies are ,required to maintain a record of all adverse reactions reported to them, 
whether or not previously known (i.e. indicated on the package insert or data sheet). 
Where possible, the incidence of such reports should be established in comparison with the 
number of doses sold. Where the incidence is greater than that established in the dossier on 
which the authorisation was granted, the competent authority must be informed. 
2.2. 6 Reporting of insufficient withdrawal periods 
Information on insufficient withdrawal periods is deemed important for pharmacovigilance 
purposes as residues of veterinary medicinal products in food derived from animals can be a 
hazard to human health or a problem to processing of animal products (e.g. milk). 
2.3. Content of suspected serious ADR reports 
It is essential for the marketing authorisation holder to provide as complete as possible details 
for cases of suspected serious ADRs in order to facilitate assessment. The marketing 
authorisation holder is expected to follow-up all reports of serious suspected adverse reactions 
to their products in order to obtain comprehensive information where available. The report of 
a suspected ADR should include the information below. The words used by the reporter . 
should be provided even if they are also classified or coded according to accepted 
terminology. 
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2.3.1 Animal details 
i) Number treated I number showing signs I number dead; 
ii) Characteristics of animals showing signs : 
• species 
•Breed 
• Gender 
•Age 
• Weight 
2.3.2 Company details and original reporter's details 
i) The name of the qualified person responsible for pharmacovigilance employed by the 
marketing authorisation holder. 
ii) Address, telephone and fax number of the qualified person. 
iii) MA number for the suspected product. 
iv) Country of origin of the report, and country of origin of suspect product if different 
from that of the report. 
v) Type ofreport, e.g. spontaneous, post-marketing study, literature. 
vi) Source of report. 
vii)Details of the original reporter - name (if acceptable under national law), address, 
profession and speciality (if available). 
viii)Date of receipt of report by marketing authorisation holder. 
2.3.3 Suspect product details 
i) Product name(s) I brand name(s) 
ii) Approved name(s) (INN) 
iii) Batch number, if appropriate 
iv) Indication( s) for treatment 
v) Dose, frequency and duration of treatment given 
Dose, frequency and duration of treatment recommended 
vi) Route and site of administration used 
Route and site of administration recommended 
vii)Start date I time 
viii)Stop date I time and/or duration of treatment 
ix) Dechallenge information 
x) Re-challenge information 
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2.3.4 Concomitant medication details 
All medicinal treatment over at least a one week period preceding the suspected reaction 
should be provided when available. This should also include non-prescription medicines and 
magistral preparations if appropriate. For each medication: 
i) Medicinal product name( s )/brand name( s) 
ii) Approved name( s) (INN) 
iii) Batch number, if appropriate 
iv) Indication( s) of treatment 
v) Daily dose, frequency and duration of treatment 
vi) Route of administration 
vii)Start date/time 
viii)Stop date/time and or duration of treatment. 
2.3.5 Suspected reaction details 
i) Description ofreactions(s) including site and severity (intensity of the reaction) 
ii) Start date or onset of reaction 
iii) Stop date or duration of reaction 
iv) Outcome- information on recovery and its extent, whether associated with product 
withdrawal and whether specific treatment was required. In a case of fatal outcome, 
the cause of death should be provided and its relationship to the suspected reaction 
commented upon. Post mortem examination findings or laboratory findings, if carried 
out, should be provided. 
It should be noted that death is not an ADR but an outcome. However, when the cause of 
death is unknown the term "sudden unexplained death" may be used to describe a reaction. · 
2.3. 6 Other Information 
Any relevant information available to facilitate assessment of the case should be provided, 
such as previous exposure, disposition to allergy, feed given/changes in feeding habits, 
concomitant use of medicated feedstuffs. 
2.3. 7 Scientific Evaluation (causal assessment) 
Marketing authorisation holders may comment on whether they consider there is a causal 
association between the suspect product(s) and reactions(s) reported and should provide the 
criteria on which they have made the assessment. · 
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The causality assessment should be done using the ABO-system if possible. According to this 
system, four categories of causality can be made: 
category "A": probable 
category "B": possible 
category "0": unclassified (cases where insufficient information was available to draw any 
conclusion) 
category "N": unlikely to be drug related (cases where insufficient information was available 
and where investigation has established this beyond reasonable doubt (document lll/3578/91) 
2.3. 8 Human reactions to veterinary medicinal products 
Information about any reactions in humans as a result of administering veterinary medicinal 
products should be given with at least the following details : 
i) Animal identification, if available 
ii) Gender 
iii) Age or date of birth 
iv)Nature of exposure (e.g. inhalation, injection, ingestion or dermal exposure) 
v) Nature of reaction 
vi) Time between exposure and reaction 
vii)Outcome of reaction (e.g. extent of recovery, specific treatment required) 
viii)Name, address, telephone number of physician or poison center if consulted 
2.4 Reporting forms 
Until a standardised reporting form is agreed, reporting forms acceptable to the Member State 
authorities should be used. An example of a reporting form is attached at Table A. 
Computer-generated forms are acceptable provided they are legible and follow the accepted 
content and layout. 
2.5 Impact of reported ADRs on the overall safety profile and summary of product 
characteristics of a product 
The marketing authorisation holder should indicate when reported ADR(s) impact on the 
established safety profile of the product, in particular when the reported reaction is unexpected 
or when there is a suggestion of a change in the nature, severity or frequency of expected 
ADRs or when new risk factors are identifiable. Information on the frequency of ADRs 
should provide the basis on which the estimate has been made, including data on the total 
number of ADR reports and animal exposures. 
In situations where reported ADRs do impact on the established safety profile, the marketing 
authorisation holder should indicate what action is proposed. 
3. PERIODIC SAFETY UPDATE REPORTS 
A Periodic Safety Update report is intended to provide an update of the world-wide safety 
experience of a veterinary medicinal product to competent authorities at defined times post-
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. authorisation. At these times marketing authorisation holders are expected to provide succinct 
·summary information together with a critical evaluation of the benefit/risk of the product in 
the light of new or changing post-marketing information, in order to ascertain whether further 
investigations need to be carried out and whether changes should be made to the SPC, 
labelling or product promotion. Safety update reports for veterinary medicinal products 
authorised under the centralised procedure should be submitted to all the competent 
authorities of Member States and the EMEA in accordance with Regulation (EEC) No 
2309/93 Articles 43 and 44 and for veterinary medicinal products authorised nationally to the 
competent authorities of the Member States in accordance with Directive 81/851/EEC Articles 
42aand42d. 
3.1 Scope and frequency of reports 
Unless otherwise required by the licensing authority, a periodic safety update summary report, 
in the specified format, should be prepared for all authorised medicines at the following 
intervals: 
6-monthly for the first 2 years after authorisation 
annually for the subsequent 3 years 
thereafter 5-yearly at the time of renewal. 
Each safety update report should cover the period of time since the last update report and 
should be submitted within 60 days of the data lock point. 
Each medicinal product will have an EC birth date, which will be the date on which the 
product was first approved in the EC. The year of the EC birth date determines the start of 
submission of periodic safety updates (6 months, annually and 5 yearly). However, some 
flexibility may be used in order to harmonise periodic safety updates internationally. Thus the 
month for data lock may be+/- six months within the EC birth date, provided that the first 
periodic safety update is submitted not later than 6 months after the EC birth date e.g. 
EC birth date 
May 1995 
J. 
Periodic S~ety Updates 
International Sept. 1993--------------------------------------Sept '95, March '96 etc. 
birth date 
For the purpose of the safety update report the marketing authorisation holder's database 
should be frozen in relation to the product at the time points defined above. These are the 
data lock points {DLPs). Up-to-date safety data, i.e. data that becomes known to the 
marketing authorisation holder after the product's DLP and which may 'influence the 
evaluation should also be included in the report in the final section. Data relating to serious 
adverse reactions must also be reported separately from the safety update report. 
The report should include a cross reference to combination products, where appropriate, with 
reference to the active substance. It will be necessary, in a given report, to separate different 
formulations, routes of administration, and indications, if this information is available. -When 
relevant, the safety update should also differentiate data associated with salient pharmaceutical 
aspects, including the active moiety or moieties, excipients, strength(s) and dosage form(s), 
etc. 
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3.2 Content of Safety Updates 
A Safety Update report should be written in English and fulfil the following format and 
content (for products authorised under a national procedure, the language requirements of the 
member State apply): 
3.2.1 SPC 
The EC SPC must be included for reference in the report. If no SPC is available, the package 
insert should be provided. 
3.2.2 The product's authorisation status world-wide 
Brief information should be provided, usually as a table, on all countries in which a regulatory 
decision about marketing has ever been made (e.g. approved, approved with qualifications, 
rejected, etc.). This should be divided into EC and non-EC countries and presented in order 
of date of regulatory decision. 
Besides listing the dates of approval (or rejection) the date of market introduction (launch 
date) should also be given. The table should also give the 11trade names .. used by the 
marketing authorisation holder or affiliates in the different countries where the product has 
been launched and to which this report refers. Approved indications for use may differ among 
countries, and details should be provided if they are relevant to interpretation of clinical safety 
information. This section (Section III) of the report is the only one that is cumulative. 
3.2.3 Update of regulatory or marketing authorisation holder actions taken for safety reasons 
An update on the significant regulator-initiated or marketing authorisation holder-initiated 
actions taken, or to be taken, for safety reasons during the report period anywhere in the 
world should be presented. This should include: product suspension; restrictions on 
distribution; any curtailment of trial programmes; alterations to label/SPC/Package insert such 
as new contraindications, warnings or addition of important adverse drug reactions, lowering 
of recommended dosage; pharmaceutical changes, e.g. change of excipients, changes in the 
manufacturing process. 
The format should be a brief narrative stating the reasons for significant regulatory or 
marketing authorisation holder action, with documentation appended when appropriate. 
3.2.4 Sales volume 
A safety update must address the relationship of sales volume of a product related to numbers 
of suspected adverse reactions reported. Where a single species can be associated with use of 
pharmaceutical product, then the incidence of reactions and deaths can be calculated in terms 
of the number of single doses of the drug used in animals of x kg. Simple calculations from 
the data sheet (SPC) will give the number of animals treated after a course of treatment with 
the product. Where products are continually administered the calculation of incidence of 
reactions and deaths has to be calculated in an arbitrary manner (medicated premixes). 
In the case of vaccines, sales volume should be expressed as single booster doses for a 
particular species. 
A proportion of veterinary medicines are indicated for more than one species. Where such a 
situation pertains it is clearly not possible to calculate individual species incidence of reactions. 
Theoretical calculations for single species are sometimes of value, but should always be 
treated as arbitrary. A significant number of safety updates will show no reports of suspected 
adverse incidents. In these cases it is not possible to calculate an incidence of reactions. 
82 
3.2.5 Individual case histories 
Each safety update repo.rt should contain the number of doses sold expressed in an appropriate 
form relating to the member state who requested the report. In addition, the report must 
include the incidence of reactions over the period of the report, taking account of doses· sold in 
the member state. 
The minimum information constituting a reportable individual case (line listing) includes : 
1. Licence number 
2. Company case reference number 
3. Date of reaction 
4. Number of animals treated 
5. Species 
6. Age(s) 
7. Number reacting (approximate) 
8. Number dying 
9. Other products, including authorised medicated premixes, used concurrently 
10. Presenting signs 
11. Conclusions, comments and causality assessment 
The appropriate individual case histories defined below should be included only if received 
during the period of review. All should be presented in the line-listing format given in Table 
B. 
a) Spontaneous reports 
All individual case reports sent spontaneously· to the MA holder and attributed to the drug 
which relate to all reactions, including interactions and extra-label use, should be submitted. 
These should include those received from regulatory authorities. 
b) Serious case reports from other sources 
Marketing authorisation holders sometimes receive ADR information on individual incidents 
from other sources, including· regulatory authorities; those from regulatory authorities should 
also be listed, identifying their source. A signal generated on the basis of these case reports 
should be reported in the narrative with sufficient case information. The aim is to be 
comprehensive but to avoid duplication of reporting. 
c) Line listing 
All the required individual case reports should be presented as line listings, in the format as . 
shown in Table B. 
The following information, where available, should be included for each case in addition to the 
minimum information, previously detailed, for each case: 
- Date of treatment I Date of vaccination 
- Was the product used as recommended? 
The line listing should also include all serious reactions that qualified for reporting by MA 
holders as full 15 day reports under the guidelines on adverse reaction reporting by MA 
holders. These cases should be identified (e.g. asterisked) in the conclusions/comments 
section of the line listing. 
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d) Na"ative review of the individual case histories 
The report should include a brief narrative based on the marketing authorisation holder's 
analysis of the cases presented in the line listing. This should include a comment on any 
increase in frequency. 
3. 2. 6 Published ADR reports 
A brief narrative overview with a bibliography of published ADR reports should be attached to 
the copies of the full report. 
3.2. 7 Overall safety evaluation 
The safety update should include a concise critical analysis and opinion on the benefit/risk 
profile of the product written by a person responsible for pharmacovigilance. Any new 
important information on the following should be explicitly included: 
i) evidence of previously unidentified toxicity 
ii) increased frequency of known toxicity 
iii) drug interactions 
iv) overdose and its treatment 
v) extra-label use 
vi) human operator reactions 
For each of these points, lack of significant information should be reported. 
The evaluation should indicate in particular whether the safety data remain in line with the 
cumulative experience to date and the SPC, and should specify any action recommended and 
the reasons why. 
3.2.8/mportant information received after data lock-point 
This section is for reporting any important new information received by the marketing 
authorisation holder since the database was frozen for review. It may include significant new 
cases or follow-up data that affect the interpretation or evaluation of existing reports. The 
impact of this information on the overall safety evaluation should be discussed. 
4. ON-GOING PHARMACOVIGILANCE EVALUATION DURING THE POST-
AUTHORISATION PERIOD 
The granting of a marketing authorisation for a veterinary medicinal product indicates that it is 
considered to have a satisfactory balance of benefits and risks under the conditions defined in 
the Summary of Product Characteristics (SPC), on the basis of the information available at 
that time. 
During the post-marketing period the product will be used in a different setting from clinical 
trials and larger populations are likely to be exposed. Much new information will be generated 
which may impact on the benefit/risk ratio and evaluation of this needs to be an 
on-going process, both within pharmaceutical companies and regulatory authorities. 
The purpose of pharmacovigilance is to protect animal and public health and the environment, 
and new information relating to the safety of marketed veterinary medicinal products may 
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become available at any time. Therefore marketing authorisation holders and competent 
authorities have a responsibility to ensure that the balance of benefits and risks for marketed 
veterinary medicinal products remains favourable, that appropriate action must be taken in 
response to new evidence which impacts on this balance, and that the necessary information in 
relation to these matters must be available to competent authorities and marketing 
authorisation holders, and through product information to prescribers and users of the 
veterinary medicines. 
Thus it is considered useful to: 
i) Define the steps that need to be taken by pharmaceutical companies to ensure that 
veterinary medicinal products marketed within the EC are subjected · to adequate 
ongoing monitoring and benefit/risk evaluation during the post-authorisation period. 
ii) Provide guidance on interactions between pharmaceutical companies and regulatory 
authorities (both the EMEA and national competent authorities) on matters related to 
on-going post-authorisation benefit/risk evaluation. 
iii) Provide the principles on which actions taken to improve the benefit/risk ratio should 
be based. · 
5. OVERALL BENEFIT/RISK EVALUATION 
Benefit/risk evaluation is the process by which the benefits and risks of a veterinary medicinal 
product are assessed and balanced. 
Benefit/risk evaluation of all marketed veterinary medicinal products should be carried out 
using multiple sources of data, principally the following (where available): 
i) Spontaneous ADR reporting data from within the EC 
ii) Spontaneous ADR reporting data from outside the EC 
iii) Post-authorisation safety studies 
iv- World-wide published scientific literature 
v) Product usage 
In the event of any new or changing information becoming available which impacts on, or may 
influence the overall benefit/risk evaluation of a veterinary medicinal product, the marketing 
authorisation holder should immediately inform all the competent authorities in countries in 
which the product is authorised and in addition, for products which are authorised centrally, 
the Commission and the EMEA. A comprehensive report evaluating the issue and the risks in 
the context of the benefits should be submitted at the earliest opportunity and no later than 4 
weeks of being requested, to all competent authorities of the Member States in which the 
medicine has been authorised and in addition, for products which are authorised centrally, the 
Commission and the EMEA. 
Improving the balance of benefits and risks 
The following types of action may be necessary and can be undertaken voluntarily by 
· marketing authorisation holders or compulsorily by competent authorities in accordance with 
their legal powers: 
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i) Variation of the SPC in respect of the indications, dosage recommendations, 
contraindications, warnings or adverse effects and in consequence: 
- modification of the package insert 
- modification of advertising material. 
ii) Direct provision of important safety information to health professionals (e.g. 
through letters and/or bulletins). 
In cases of urgency where there is a risk to animal or public health or the environment, 
marketing authorisation holders may make urgent safety restrictions in accordance with 
Regulation XXX/95. These measures must be communicated without delay to the EMEA and 
Member States, and an application for approval submitted to the relevant authorities within 24 
hours of their introduction. 
When any significant alteration to the safety information in an SPC is made, the appropriate 
health professionals must be informed promptly and circulated with the new SPC either 
directly or by publication of the new SPC in the medical press. The package insert should also 
be updated and made available with the product. The time scales for ensuring that information 
is available to product users should be agreed with the competent authorities of Member 
States and EMEA. 
In the event that the overall benefit/risk ratio is judged to be unacceptable even after the effect 
of any appropriate action is taken into account, the medicine should be withdrawn from the 
market and the appropriate veterinarians, pharmacists and animal owners informed. Such 
action may be taken voluntarily by companies. The appropriate competent authorities must be 
informed and consulted immediately the decision has been taken by the holder of the 
marketing authorisation. 
In the event that the overall benefit/risk ratio is judged to be unacceptable even after the effect 
of any appropriate action is taken into account, the EMEA or any national regulatory authority 
may immediately suspend the marketing authorisation in the following circumstances: 
i) there appears to be an urgent hazard for public or animal health or the environment 
which cannot be prevented by any other means; 
and 
ii) the holder of the Marketing authorisation has been given the opportunity to take such 
action voluntarily and has refused. 
In this event the matter will then be reviewed urgently by the CVMP, in accordance with the 
procedures laid down in Council Regulation (EEC) Nr.2309/93 or Council Directive 
81/851/EEC, as appropriate. 
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DEFINITIONS 
Advene Drug Reaction (ADR) I Advene Reaction 
Adverse drug reaction in this context is considered as synonymous with adverse reaction.· 
Adverse drug reaction means a reaction which is harmful and unintended and which occurs at 
doses normally used in animals for the prophylaxis, diagnosis or treatment of disease or the 
modification of physiological function. 
Advene Event (or experience) 
Any undesirable experience occurring to in animal treated with a pharmaceutical product 
whether or not considered related to the veterinary medicinal product. 
Serious Advene Reaction 
This is an adverse reaction which is fatal, life-threatening, lesion-producing, disabling, 
incapacitating or which results in permanent or prolonged symptoms in the animals treated. 
Unexpected Advene Reaction 
This relates to an adverse reaction which is not mentioned in the EC summary of product 
characteristics (SPC) or for non- EC countries, the national data sheet of the country in which 
the reaction occurred if a SPC does not exist. 
EC Birth Date 
This is the date on which the veterinary medicinal product was first authorised within the 
EC. Safety Updates should normally be prepared at the defined time points after this date. 
Data Lock-Point (cut-off date) 
The date designated as the cut-off date for data to be incorporated into a particular safety 
update. On this date the data available to the author of the safety report is extracted for 
review and stored. 
Abuse 
Persistent or sporadic, intentional excessive use or administration of a veterinary medicinal 
product inconsistent with or unrelated to the recommendations of the summary of product 
characteristics. 
Misuse 
Use of a veterinary medicinal product in a way which is not recommended in the summary 
of product characteristics, with the exception of those cases referred to in Article 4.4 of 
Directive 81/851/EEC. 
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INDIVIDUAL REPORT FORMAT FOR SUBMISSION TO 
COMPETENT AUTHORITIES 
(One form per product used) 
Case reference number : Date of report to company : 
PRODUCT NAME : Composition : 
Authorisation number : 
Manufacturer: 
Batch number : 
Expiry date : 
OTHER PRODUCTS USED <Name and Active Ingredients) 
Date of treatment : Date of onset of unexpected signs : 
Route and site of administration used : 
Route and site recommended : 
Dose frequency and duration of treatment given : 
Dose frequency and duration of treatment recommended : 
Diagnosis/Reason for treatment : 
Authorised indication for use : 
TYPE OF SAR (e.g. extra label. human reaction. lack of efficacy. licensed use): 
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TABLE A 
(TABLE A cont.) 
ANIMAL DETAILS 
No. treated No. showing signs 
Characteristics of animals showing signs : 
Species: Breed: 
Sex: Age: 
Weight: 
NADJRE OF REACTION (describe the sequence of events. all clinical signs and other · 
relevant observations) : 
Time between administration and reaction : 
OUTCOME OF REACTION TO DATE : Date: 
Killed/Dead Under Alive with Recovered Unknown 
Treatment Sequelae 
No. ofanimals 
Had animals had previous exposure to this product ? 
If affinnative. were similar signs seen ? 
. Were the unexpected signs treated? If yes. describe : 
POST MORTEM OR LABORATORY FINDINGS: 
NATURE OF COMPANY INVESTIGATION: 
SUMMARY OF PRODUCT SAMPLE INVESTIGATION : 
Product source : Type of analysis : Result: 
CONCLUSIONS/ACTION TAKEN: 
CAUSALITY ASSESSMENT : 
Name and signature of company investigator : 
Date: 
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CHAPTER VI 
VETERINARY MEDICINAL PRODUCTS CONSISTING OF 
OR CONTAINING GENETICALLY MODIFIED 
ORGANISMS 
This chapter contains three separate guidance documents relating to the environmental 
risk assessment which must accompany applications for marketing authori~tion of 
veterinary medicinal products which consist of or contain genetically modified organisms 
(GM0s)1• 
Guidelines for the environmental risk assessments of non-GMO containing veterinary 
medicinal products are under development and should be completed by the end of 1995. 
Guideline on the presentation of particulars concerning the environmental risk 
assessment for veterinary medicinal products which contain, or consist of, 
genetically modified organisms. 
1. INTRODUCTION 
This text provides detailed guidance on the form in which the particulars relevant to the 
environmental risk assessment are to be presented by the applicant as part of his/her 
application for authorisation to market a medicinal product for veterinary use which 
contains, or consists of, a genetically modified organism (GMO) It is important to 
distinguish carefully between products which contain substances simply derived from 
genetically modified organisms, and those products which contain, or consist of, such 
organisms. while advanced methods of genetic modification such as recombinant DNA 
technology have been applied in several instances to micro-organisms for the purpose of 
producing drug substances from them, micro-organisms which have been genetically 
modified by such means, and retain a capacity for replication, have only rarely themselves 
been developed for administration to animals for therapeutic or diagnostic purposes. As 
1 Note: This guidance does not apply to products which are made using genetically modified organisms· 
but which, by virtue of the manufacturing method and with appropriate validation, do not contain or 
consist of GMOs 
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applications are foreseen in the field of veterinary vaccinology (including vaccines 
formulated as bait and intended for dissemination in an open environment) it is assumed 
that any affected products will be Immunological Veterinary Medicinal Products, as 
defined by Directive 90/677/EEC. 
Council Directive 901220/EEC on the deliberate release into the environment of 
genetically modified organisms requires that applicants wishing to place on the market a 
product which contains, or consists of, a Genetically Modified Organism (GMO) shall 
submit a notification for evaluation to an appropriate competent authority designated for 
carrying out the Directive's requirements. These provisions do not, however, apply to 
products containing, or consisting of, GMOs covered by other Community legislation 
which provides for a specific environmental risk assessment similar to that laid down in 
the Directive. Where a notification is required by the Directive, it must include at least the 
following: 
- specified information relating to the product and the release (Annex IIA of the 
Directive), including any relevant data arising from previous releases involving research 
and development, and an environmental risk assessment, and 
- details of any proposed conditions for placing on the market of the product (Annex III 
of the Directive), including conditions related to use, handling, labelling and packaging 
where relevant. 
The notification is evaluated according to defined procedures. Deliberate release may 
proceed only if the applicant receives a formal consent, and is subject to any conditions 
specified in the consent. 
However, where it is the case that the GMO constitutes, or more likely is contained in, a 
medicinal product, then, following from provisions appearing in Article 28 of Council 
Regulation (EEC) No. 2309193laying down Community procedures for the authorisation 
and supervision of medicinal products for human and veterinary use and establishing a 
European Agency for the Evaluation of Medicinal Products: 
- the above particulars shall accompany the application for authorisation to market a 
medicinal product; 
- these particulars shall include in addition a copy of any previously obtained written 
consent or consents for deliberate release for research and development purposes; 
- as these requirements provide for a specific environmental risk assessment similar to 
that laid down in Directive 90/220/EEC, the provisions of the Directive relating to 
placing a medicinal product on the market no longer apply; (it should be noted that the 
provisions of the Directive relating to research and development or any purpose other 
than placing a medicinal product on the market continue to apply where relevant); and 
- during the process of evaluating applications for marketing authorisations for such 
products, necessary consultations will be held by the rapporteur with those bo~ies set up 
by the Community or the Member States in accordance with Directive 90/220/EEC. 
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2. DEFINmONS 
The definitions which appear in European Community law apply. The following extracts 
from these are intended for the purpose of introduction only. 
Medicinal Product: any substance or combination of substances presented for preventing 
or treating disease in human beings or animals. 
Immunq/ogical Veterinary Medicinal Product: a veterinary , medicinal product 
administered to animals in order to produce active or passive immunity, or to diagnose the 
state of immunity. 
Organism: any biological entity capable of replication or of transferring genetic material. 
Genetically Modified Organism (GMO): an organism in which the genetic material has 
been altered in a way that does not occur naturally by mating and/or natural 
recombination. 
Deliberate Release; any intentional introduction into the environment of a GMO or a 
combination of GMOs without provision for containment such as physical barriers or a 
combination of physical barriers together with chemical and/or biological barriers used to 
limit their contact with the general population and the environment. 
Environmental Risk Assessment: the evaluation of the risk to human health and the 
environment (which includes plants and animals) connected with the release of GMOs or 
products containing GMOs. 
3. GENERAL CONSIDERATIONS 
3.1 It is essential that the approach to the environmental risk asse~sment presented by 
the applicant is similar to that laid down in Directive 90/220/EEC, including the relevant 
parts of Annexes IIA and III of the Directive. Headings in Annex IIA of the Directive 
have been omitted in this Note for Guidance in the cases in which it is considered that they 
are normally not applicable to medicinal products for veterinary use or to their placing on 
the market. 
3.2 The particulars presented in accordance with this Note for Guidance will be in 
addition to the documentation already required in support of the claimed quality, safety 
and efficacy of the product. In the case of overlapping requirements, the information 
should be repeated in full as necessary, though the data provided will in many cases be 
identical to data appearing in the remainder of the dossier. The applicant will obviously 
need to take care to ensure consistency in the presentation of data. The various 
requirements affecting tests, trials, documentation etc. stated in the Rules Governing 
Medicinal Products in the European Community, as with the rest of the dossier, apply 
where relevant. 
3.3 The particulars submitted in accordance with this Note for Guidance should form 
part of the dossier submitted in support of the application for marketing authorisation, 
and should therefore be bound, paginated and indexed as such. 
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3.4 Binding, pagination and indexation should be logical and thorough as stated 
elsewhere in the Notices to Applicants. 
3.5 The particulars outlined in this Note for Guidance should be presented in a 
separate volume, which physically could stand alone and which could be handled 
separately from the remainder of the dossier if necessary. 
3.6 The applicant should indicate any information in Section 11-H which he wishes to 
be treated as confidential, where this is allowed by Community law. The respective 
confidential and non-confidential parts should be appropriately marked, ideally on each 
page, and should be bound separately. 
4. PRESENTATION OF DATA IN mE MAIN DOSSIER 
The information presented in accordance with this Note for Guidance will form Part 11-H 
of the dossier. The entries should be presented in six sections, Part 11-H 1 to 6, as 
follows. 
Part D-B: DATA RELATED TO mE ENVIRONMENTAL RISK ASSESSMENT 
FOR PRODUCTS CONTAINING, OR CONSISTING OF. GENETICALLY 
MODIFIED ORGANISMS CGMOs) 
Part D-H-1. Introduction. 
This should include a brief product profile and a description of, and justification for, the 
proposed release. 
Part D-H-2. A copy of any written consent or consents of the competent 
authorities to the deliberate release into the environment of the genetically modified 
organisms for research and development purposes where provided for by Part B of 
Directive 90/220/EEC. 
Any written consent(s) to release obtained within the Community must be submitted. It 
would also be useful to submit any written consent(s) to release obtained outside the 
Community. 
Part D-H-3. The complete technical dossier supplying the information requested in 
Annex llA of Directive 90/220/EEC. including the results of any investigations 
performed for the purposes of research and development. 
The following points, which are extracts of Annex IIA ofDirective 90/220/EEC, are those 
which are normally relevant to placing a veterinary medicinal product on the market. 
Headings in Annex IIA of the Directive which are considered to be normally not 
applicable to placing on the market, or not applicable to veterinary medicinal products, are 
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omitted. The notes in italics indicate where overlap is likely or not likely to occur with 
entries already required in other sections of the dossier submitted in support of a 
marketing authorisation, the Part numbers referring to those of the Notice to Applicants 
for Veterinary Medicinal Products (where Part I is equivalent to Part V of Directive 
81/852/EEC, as amended by Directive 92/18/EEC, Part II is equivalent to Part 6, Part III 
to Part 7 (and 9) and Part IV to Part 8). 
The applicant should add to the particulars listed below any additional items which are 
required by the nature or use of the GMO or the proposed release. 
Similarly, not all the points included will apply in every case. It is to be expected, 
therefore, that individual applications will address only the particular subset of 
considerations which are appropriate to individual situations. 
The level of detail required in response to each subset of considerations is also likely to 
vary according to the nature and scale of the proposed release. 
I. General Information. 
A. Name and address of the notifier. 
The name and address of the applicant should be stated, in the form in which it 
already appears in Part I of the dossier. 
II. Information Relating to the GMO. 
A. Characteristic the recipient or (where appropriate) parental organism. 
The entries should address each organism (recipient and/or parental organism) 
as appropriate. 
1. Scientific name; 
Part//C 2.1.. 
2. taxonomy; 
Part 1/C 2.1. 
3. other names (usual name, strain name, etc.);. 
Part 1/C 2. 1. 
4. phenotypic and genotypic markers; 
Part 1/C 2.1. 
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5. degree of relatedness between donor and recipient or between parental 
organisms~ 
This information. is required specifically to fulfil the requirements of the 
environmental risk assessment and may not necessarily appear elsewhere in the 
dossier. 
6. description of identification and detection techniques. 
Part II C, but applicants should also note this requirement for the environment-
specific entries which are not covered elsewhere i~ the dossier. 
7. sensitivity, reliability (in quantitative terms) and specificity of detection and 
identification techniques: 
Already required for Partl/C, but applicants should also note this requirement 
for the environment-specific entries which are not covered elsewhere in the 
dossier. 
8. description of the geographic distribution and of the natural habitat of the 
organism including information on symbionts and hosts; 
This information is required specifically to fulfil the requirements of the 
environmental risk assessment and may not necessarily appear elsewhere in the 
dossier 
9. potential for genetic transfer and exchange with other organisms; 
This information is required specifically to fulfil the requirements of the 
environmental risk assessment and may not necessarily appear elsewhere in the 
dossier. 
10. verification of the genetic stability of the organisms and factors affecting it; 
This information is required (for the recipient/parental organism) specifically to 
fulfil the requirements of the environmental risk assessment and may not 
necessarily appear elsewhere in the dossier. 
11. pathological, ecological and physiological traits: 
(a) classification of hazard according to existing Community rules concerning the 
protection of human health and the environment; 
This information is required specifically to fulfil the requirements of the 
environmental risk assessment and may not necessarily appear elsewhere 
in the dossier. 
(b) generation time in natural ecosystems, reproductive cycle; 
This information is required specifically to fulfil the requirements of the 
environmental risk assessment and may not necessarily appear elsewhere 
in the dossier. 
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(c) infonnation on. survival, including seasonability and the ability to form 
survival structures, eg. spores. · 
This information is required specifically to fulfil the requirements of the 
environmental risk assessment and may not necessarily appear elsewhere 
in the dossier. 
(d) pathogenicity: infectivity, toxigenicity, virulence, allergenicity~ carrier 
· (vector) of pathogen, possible vectors, host range including non-target 
. organism. Possible activation oflatent viruses (proviruses). Ability to 
(:()Ionise other organisms. 
This information is required specifically to fulfil the requirements of the 
environmental risk assessment and may not necessarily appear elsewhere 
in the dossier. 
(e) antibiotic resistance, and potential use of these antibiotics in humans 
and domestic organisms for prophylaxis and therapy. 
This information is required specifically to fulfil the requirements of the 
environmental risk assessment and may not necessarily appear elsewhere 
in the dossier. 
(f) involvement in environmental processes: primary production, nutrient 
turnover, decomposition of organic matter, respiration etc. 
This information is required specifically to fulfil the requirements of the 
environmental risk assessment and may not necessarily appear elsewhere 
in the dossier. 
12. Nature of indigeJ.10US vectors: 
(a) sequence; 
Part 1/C 2.1. 
(b) frequency of mobilisation; 
Part IJC 2.1. 
(c) specificity; 
Part IIC 2.1. · 
(d) presence of genes which confer resistance. 
This information is required 8pecifica/ly to fulfil the requirements of the 
environmental risk assessment and may not necessarily appear elsewhere 
in the dossier. 
13. History of previous genetic modifications. 
Part IIC 2. 1. 
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B. Characteristics of the vector: 
1. Nature and source of the vector; 
PartliC 2.1. 
2. Sequence of transposons, vectors and other non-coding genetic segments used 
to construct the GMO and to make the introduced vector and insert function in the 
GMO; 
Part 1/C 2.1. 
3. frequency of mobilisation of inserted vector and/or genetic transfer capabilities 
and methods of determination; 
Part TIC 2.1. 
4. information on the degree to which the vector is limited to the DNA required to 
perform the intended function. 
Part IIC 2.1. 
C. Characteristics of the modified organism: 
1. Information related to the genetic modification: 
(a) methods used for the modification; 
Part 1/C 2.1. 
(b) methods used to construct and introduce the insert(s) into the recipient 
or to delete a sequence; 
Part l/C 2.1. 
(c) description of the insert and/or vector construction; 
Part IIC 2. 1. 
(d) purity of the insert from any unknown sequence and information on the 
degree to which the inserted sequence is limited to the DNA required to 
perform the intended function; 
Part IIC 2. 1. 
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(e) sequence, functional identity and location of the altered/inserted/deleted 
nucleic acid segments in question with particular reference to any known 
bannful sequence. 
Part 1/C 2.1. 
2. Information on the final GMO: 
(a) description of genetic trait(s) or phenotypic characteristics and in 
particUlar any new traits and characteristics which may be expressed or no 
longer expressed; 
Part 1/C 2.1, but more data and detail may be required in so far as the 
data relate to the environmental risk assessment. 
(b) structure and amount of any vector and/or donor nucleic acid remaining 
in the final construction of the modified organism; · 
Part IIC 2. 1. 
. (c) stability of the organism in terms of genetic traits; 
Part 1/C 2.1. 
(d) rate and level of expression ofthe new genetic material. Method and 
sensitivity of measurement; 
Also Part 1/C 2. 1. 
(e) activity of the expressed proteins; 
Part IIC 2.1. 
(f) description of identification and detection techniques including 
techniques for the identification and detection of the inserted sequence and 
the vector; 
Part!IC2.1 
(g) sensitivity, reliability (in quantitative terms) and specificity of detection 
and identification techniques; 
Part iiC 2.1. 
(h) history of previous releases or uses of the GMO; 
This information is required specifically to fulfil the requirements of the 
environmental risk assessment and may not necessarily appear elsewhere, 
in the dossier. See also Part //-H-2. 
(i) health considerations: 
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(i) toxic or allergenic effects of the non-viable GMOs and/or their 
metabolic products; 
Part III, especially Part II/E. 
(ii) product hazards~ 
Part Ill. especially Part /1/C 8 and II/E. 
(iii) comparison of the modified organism to the donor, recipient or 
(where appropriate) parental organism regarding pathogenicity; 
1his information is required specifically to fulfil the requirements 
of the environmental risk assessment and may not necessarily 
appear elsewhere in the dossier. 
(iv) capacity for colonisation; 
1his information is required specifically to fulfil the requirements 
of the environmental risk assessment and may not necessarily 
appear elsewhere in the dossier. 
(v) if the organism is pathogenic to humans who are 
immunocompetent 
- diseases caused and mechanism of pathogenicity including 
invasiveness and virulence; 
- communicability; 
- infective dose; 
• host range, possibility of alteration; 
- possibility of survival outside of human host; 
- presence of vectors or means of dissemination; 
• biological stability; 
- antibiotic-resistance patterns; 
- allergenicity; 
- availability of appropriate therapies. 
1he information specified under (v) is required specifically to 
fulfil the requirements of the environmental risk assessment and 
may not appear in Part Ill of the dossier in the detail which is 
required for the purposes of an environmental risk assessment. 
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Til. Information Relating to the Conditions of Release and the Receiving Environment. 
A. Information on the release. 
1. Description of the proposed deliberate release, including its. purpose. 
This is equivalent to the indications for use of the product, and the information 
provided should be consistent with that stated In Parts lA. JB and WA.l of the 
dossier. in the Summary of Product Characteristics and on· the labelling. 
2. method(s) to be used for the releaSe. 
This is equivalent to the method of administration of the product, and the 
information provided should be consistent with that stated in Parts I and IV of 
the dOssier, in the Summtuy of Product Characteristics and on the labelling. . 
3. Information on, and results ot: previous releases of the GMOs, especially at 
different scales and in different ecosystems. 
Possibly addresSed in Part IUD, but this information is largely is required 
specifically to fulftl the requirements of the environmental risk assessment and 
may not necessarily appear elsewhere in the dossier. For example, the results oj 
the release should include the consequences of any shedding of the. virus. 
4. Quantities ofGMOs to be released. 
Part II A. The quantities of GMO to be administered per dose should be stated 
IV. Information Relating to the Interactions Between the GMOs and the Environment. 
A. Characteristics affecting survival, multiplication and dis~emination. 
1. biological. features which affect survival, multiplication and dispersal; 
Parts OIA, /1/C 6.1, IIIC 6.2,ll/E. 
2. known or predicted environmental conditions which may affect survival, 
multiplication and dissemination (wind, water, soi~ temperature, pH etc.); 
I 
This information is required specifically to fulftl the requirements of the 
environmental risk assessment and may not necessarily appear elseWhere in the 
dossier. 
3. sensitivity to specific agents. 
This information is required specifically to fulftl the requirements of the 
environmental risk assessment and may not necessarily appear elsewhere in the 
dossier. 
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B. Interactions with the environment: 
l. predicted habitat of the GMOs; 
Partll!E. 
2. studies of the behaviour and characteristics ofthe GMOs and their ecological 
impact carried out in simulated natural environments, such as microcosms, growth 
rooms, greenhouses; animal houses etc may also be of relevance to medicinal 
products 
This information is required specifically to fulfil the requirements of the 
environmental risk assessment and may not necessarily appear elsewhere in the 
dossier. 
3. genetic transfer capability: 
(a) post-release transfer of genetic material from GMOs into organisms in 
affected ecosystems; 
Partly covered in Part IIIC 6.2 but this information is largely required 
specifically to fulfil the requirements of the environmental risk assessment 
and may not necessarily appear in detail elsewhere in the dossier. 
(b) post-release transfer of genetic material from indigenous organisms to 
theGMOs; 
Partly covered in Part IIIC 6.2 but this information is largely required 
specifically to fulfil the requirements of the environmental risk 
assessment and may not necessarily appear in detail elsewhere in the 
dossier. 
4. likelihood of post-release selection leading to the expression of unexpected 
and/or undesirable traits in the modified organism; 
This information is required specifically to fulfil the requirements of the 
environmental risk assessment and may not necessarily appear elsewhere in the 
dossier. 
5. measures employed to ensure and to verify genetic stability. Description of 
genetic traits which may prevent or minimise dispersal of genetic material. 
Methods to verify genetic stability. 
This entry should include detailed information specifically relevant to the 
environmental risk assessment and should if necessary be more extensive than 
that presented in Part IIC 2 of the dossier. 
6. routes of biological dispersal, known or potential modes ofinteraction with the 
disseminating agent, including inhalation, ingestion, surface contact etc. 
Part IliA 1, IIIC 6.1, IIIC 6.2, lifE. 
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7. description of ecosystems to which the GMOs could be disseminated. 
Parts!IIA. II/E. 
C. Potential environmental impact: 
1 , potential for ~cessive population increase in the environment. 
Part //IE. 
2. competitive advantage of the GMOs in relation to the unmodified recipient or 
parental organism( s ); 
Part II/E. 
3. identification and description of the target organisms; 
Parts lilA 1, 11/C 6.1, II/E. 
4. anticipated mechanism and result of interaction between the released GMOs and 
the target organism; · 
Partl//E 
5. identification and description of non-target organisms which may be affected 
unwittingly; 
Parts IliA I, /1/C 6.1 and II/E. 
6. likelihood of post-release shifts in biological interactions or in host range; 
Part II/E. 
7. known or predicted effects on non-target organisms in the environment, impact 
on population levels of competitors, hosts, symbionts and pathogens; · 
Part /1/E. 
8. known or predicted involvement in biogeochemical processes; 
Part II/E. 
9. other potentially significant interactions with the environment. 
PartllJE. 
V. Information on Monitoring. Control. Waste Treatment and Emergency Response 
Plans 
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A. Monitoring Techniques. 
1. Methods for tracing the GMOs, and for monitoring their effects~ 
This information is required specifically to fulfil the requirements of the 
environmental risk assessment and may not necessarily appear elsewhere in the 
dossier. 
2. specificity (to identify the GMOs, and to distinguish them from the donor, 
recipient or, where appropriate, the parental organisms), sensitivity and reliability 
of the monitoring techniques; 
This information is required specifically to fulfil the requirements of the 
environmental risk assessment and may not necessarily appear elsewhere in the 
dossier. 
3. techniques for detecting transfer of the donated genetic material to other 
organisms. 
This information is required specifically to fulfil the requirements of the 
environmental risk assessment and may not necessarily appear elsewhere in the 
dossier. 
B. Control of the Release 
1. Methods and procedures to avoid and/or minimise the spread of the GMOs 
beyond the site of the release or the designated areas of use. 
1his information is required specifically to fulfil the requirements of the 
environmental risk assessment and may not necessarily appear elsewhere in the 
dossier, and is likely to be relevant in the case of vaccines disseminated as a 
baited formulation in an open environment. 
C. Waste treatment: 
1. Type of waste generated~ 
Parts 11/AJ, 1/1C6.2, 11/C6.3. 
2. expected amount of waste~ 
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This information is required specifically to fulfil the requirements of the 
·environmental risk assessment and may not necessarily appear elsewhere in the 
~sier. · 
3. possible risks; 
Part1IIE. 
4: description of treatment envisaged. 
Pari IB, but this information is largely required specifically to fulfil the 
requirements of the environmental risk assessment and may not necessarily 
appear elsewhere in the dossier. · 
D. . Emergency response plans: 
l. Methods and procedures for controlling the GMOs in case of unexpected 
spread; 
This informdtion is ·required specifically to fulfil the requirements of the 
environmental risk assessment and may not necessarily appear elsewhere in the 
dossier, and is likely to be relevant in the case ofvaccines disseminated as a 
baited formulation in an open environment .. 
2. Methods for decontamination of the areas, eg. eradication ofthe GMOs. 
This information is required specifically to fulfil the requirements of the 
enVironm~ntal risk assessment and may not necessarily appear elsewhere in the 
dossier. and is likely to be relevant in the case of vaccines disseminated as a 
baited formulation in an open environment. 
3. plans for protecting human health and the environment in case of the occurrence 
'or an undesirable effect. · 
This information is required specifically to fulfil the requirements of the 
environmental risk assessment and may not necessarily appear elsewhere in the 
dossie~ · 
Part D-H-4. The complete technical dossier supplying the information requested in 
Annex m of Directive 90/220/EEC. including the results of any investigations 
performed for the purooses of research and development. 
A. The following information shall be provided: 
1. Name ofthe product and names of the GMOs contained therein; 
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The information should be consistent with that provided in Part I of the dossier. 
2. name of the manufacturer or distributor and his address in the Community~ 
1he information should be consistent with that provided in Part I of the dossier. 
3. specificity of the product, exact conditions of use including, when appropriate, 
the type of environment and/or the geographical area(s) of the Community for 
which the product is suited; 
4. type of expected use: industry, skilled trades, consumer use by public at large 
etc. 
In the case of medicinal products for veterinary use, any veterinary or animal 
care personnel, institutions etc. specified for handling the product should be 
stated 
B. The following information shall be provided where relevant. 
1. Measures to take in case of unintended release or misuse; 
Proposed measures should also appear elsewhere in the dossier as appropriate, 
including the Summary of Product Characteristics, the labelling and the package 
insert. 
2. specific instructions or recommendations for storage and handling; 
Proposed measures should also appear elsewhere in the dossier as appropriate 
including the Summary of Product Characteristics, the labelling and the 
package insert. 
3. estimated production in and/or imports to the Community; 
This information is required specifically to fulfil the requirements of the 
environmental risk assessment and may not necessarily appear elsewhere in the 
dossier. 
4. proposed packaging. This must be appropriate so as to avoid unintended 
release of the GMOs during storage, or at a later stage; 
The information should be consistent with that provided in Part I and II of the 
dossier. 
5. proposed labelling. This must include, at least in summarised form, the 
information referred to in A 1, A.2, A.3, B. I and B.2, above. 
Proposed labelling and package insert particulars related to the environmental 
risk should appear also elsewhere in the dossier (ie., Part I) as appropriate, 
should be consistent with the Summary of Product Characteristics and should 
comply with the requirements of Council Directive 811852/EEC. 
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Part D-B -5. The environmental risk assessment resulting from the information 
provided under points D-B .. t to ll-B-4 above. 
The assessment of environmental risk should follow logically from the data presented in 
ll-H-1 to ll-H-4. Risks to human health, non-target animals, soil, water, air, individual 
ecosystems etc. should be addressed as appropriate. This section should be compiled in 
accordance with the Note for Guidance lll/5573/94 on Environmental Risk Assessments 
for Veterinary Medicinal Products Containing or Consisting of GMOs. 
Part D-B-6. Conclusion. 
The applicant should present his overall conclusions. 
5. PRESENTATION OF PARTICULARS IN THE EXPERT REPORTS 
Part 11-H of the main documentation should be addressed in the Analytical (Chemical, 
Pharmaceutical and Biological or Microbiological) Expert Report and should include a 
critical evaluation, the opinion of the expert as to whether sufficient guarantees have been 
provided as to the suitability of the product for its proposed use, and an appendix 
containing a summary of all the important data. 
The entries should be compiled by the Expe~ in accordance with the general requirements 
for Expert Reports outlined in the Notice to Applicants. In particular, the expert should 
be appropriately qualified. 
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Guideline for the conduct of the environmental risk assessment for veterinary 
medicinal products which contain or consist of genetically modified organisms 
1. BACKGROUND AND INTRODUCTION 
This guidance concerns the environmental risk assessment needed to comply with the 
requirements of Article 28(2) of Council Regulation 2309/93 on the licensing of 
veterinary medicinal products which contain or consist of genetically modified organisms 
(GMOs) . The Regulation makes provision for an environmental risk assessment similar 
to that in Directive 90/220/EEC on the Deliberate Release into the Environment of 
Genetically Modified Organisms (GMOs). In both this Directive and in the Regulation, 
the environmental risk assessment is derived from the technical dossier containing the 
information required under Annex II and III of the Directive. Under Council Regulation 
2309/93 therefore, the environmental risk assessment should be a reasoned statement of 
the overall risk of damage to human health and to the environment from the proposed 
marketing of a veterinary medicinal product containing or consisting of a GMO. 
There are no hard and fast rules for risk assessments. The following guidance outlines the 
generally accepted terminology for a risk assessment and includes some practical steps 
and a workable format to aid applicants. 
The level of detail to be considered in a risk assessment will depend on circumstances. It 
will be lower, for example, where it is immediately obvious that the hazards and hence the 
consequent risks are low or that the proposed control measures are clearly adequate to 
limit the contact of the product with humans and the environment. 
2. SCOPE OF THE REGULATION (Types ofproducts) 
This guidance has been based largely on the considerations appropriate to what will 
probably be the most likely type of veterinary medicinal products containing or consisting 
of GMOs capable of replication or of transferring genetic material, namely, live viral, 
bacterial or parasitic vaccines including vector vaccines. 
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3. ENVIRONMENTAL RISK ASSESSMENT 
3.1 General considerations 
For veterinary medicinal products it may be. appropriate fint to consider the risks 
to human health and to address whether it is necessary to take certain measures to 
control the risks arising from the administration and use of the product. The 
potential risks to the environment should then be . assessed on the basis that those 
control measures are in place. 
The main considerations for the risks to human health will be determined by whether or 
not the GMO is a zoonotic agent, or likely to be a zoonotic agent taking into account the 
characteristics of the parental organism, any organisms used as donors and the possibility 
of changes in host range, pathogenicity or tropism as a result of the genetic modifications. 
The classification system for pathogenicity of micro-organisms as set out in Council 
Directive 90/679/EEC, as amended, may provide a useful reference· for these 
considerations. 
To all intents and purposes, the human health part of the environmental risk assessment 
considers the risk to human health as if humans were a sub-set of the wider environment, 
or another non-target species. The human risk assessment must include consideration of 
the risk to those who handle or administer the product and or treated animals, risks to 
relatives and other contacts of these operators and risk to the general public. It will be 
necessary to consider the possible effects on healthy humans as well as to more vulnerable 
individuals (the young or old, immunocompromised or otherwise· susceptible). For 
example, the increasing incidence of people who are receiving immunosuppressants, or 
have recently undergone chemotherapy, or who have developed AIDS may mean that 
there is a section of the population who are at greater risk and this needs to be taken into 
account at each stage of the risk assessment. 
3.2 Sources of information 
The risk assessment is intended to be an overall statement reflecting all the information 
contained in the dossier. 
Although wherever possible the risk assessment should be based on quantifiable 
outcomes, it is recognised that many of the judgements must necessarily be qualitative. 
But any statements or assertions in the assessment should be supported by some evidence, 
quantitative where possible. 
How much information is needed on any particular point will depend on its importance in 
the assessment and the extent to which it is generally accepted material. There is no need 
to spell out in great detail what is elsewhere in the dossier or in text books or literature. 
But the logic of the argument should be clear and enough ju~tification should be included 
on any unusual or particularly important points for the assessment to be testable. Note 
that it is always permissible to assume the worst and act accordingly, if the cost of 
gathering the information (by experimentation or review) for a more precise assessment is 
disproportionate. 
. 109 
4. FRAMEWORK FOR RISK ASSESSMENT 
The aim of the risk assessment is to identify hazards, to estimate the likelihood that the 
hazards will lead to actual harm and to take decisions regarding the appropriate control 
measures. The main elements of a risk assessment are therefore: 
i. hazard identification; 
ii. assessment of the likelihood that the hazard will occur; 
111. assessment of exposure to the hazard and the consequences of that exposure; 
iv. assessment of the level of risk (by consideration of the severity of any adverse 
consequences and the likelihood that they will occur); 
v. selection and assignment of appropriate control measures (risk management). 
4.1 Assessment of risk to humans 
4.1.1. Hazard identification 
In the context of this guidance, hazards are defined as those features of the GMO which 
have the potential to cause harm, either directly (such as infection) or through some form 
of possible event (such as the transfer of hazardous genes to and from other organisms). 
It is important to be exhaustive in the identification of possible hazards and not to 
discount at this stage any of the hazards given below on the basis that they are unlikely to 
occur. The assessment of possible exposure and likelihood are separate stages of the 
assessment process. 
The stage of the assessment should aim to identify all possible adverse effects on humans 
and should include the following: 
4.J.J.a. Pathogenicity or other adverse effects 
With respect to humans and animals, details of the pathogenicity of the parental organism 
and the GMO itself, will have been considered during the safety studies on the product. 
When determining the hazards associated with the GMO, consideration should be given 
to the pathogenicity and virulence, any changes to the host range or tissue tropism and, if 
it is still potentially pathogenic, whether the GMO is susceptible to available therapies or 
is expected to exhibit altered interactions with host defence mechanisms. As well as the 
possibility of infection in healthy individuals, the possibility of infection m 
immunocompromised or other especially susceptible individuals should be identified. 
4.1.J.b. Genetic instability (especially attenuating mutations) 
Consider whether the GMO is stable over repeated generations, and in particular, whether 
any genetic instability could affect attenuating mutations or alter the behaviour of the 
GMO, particularly if it could result in a reversion to virulence. The type of attenuating 
mutation (point mutation or deletion) will be an important consideration in assessing the 
likelihood of the hazard ocurring. Attention should be paid to those bacterial GMOs if 
110 
potentially transferable vectors based on plasmids, bacteriophages or transposons have 
been used. 
4.J.J.c. Gene transfer . 
Gene transfer may be considered a hazard under some circumstances, for example if it 
could result in the spread of genes to other organisms with potentially undesirable 
consequences. In some senses it can be considered as a subset of genetic stability. 
4.J.J.d Survival I dissemination 
The ability of the GMO to survive for long periods in the environment (for example in the 
litter of the poultry house or grazing pastures) may constitute a hazard under some 
circumstances, for example if it could mean that there is a greater likelihood of contact 
with individuals. This may be further compounded if survival offers an increased 
possibility of wide spread dissemination by water or other routes or by any arthropod or 
animal vectors. 
4.1.2. Assessment of the degree of exposure and the likelihood of the hazard 
occurring 
In order to determine the risk posed by the GMO it will be necessary to determine the 
likelihood of any of the above hazards occurring i.e. whether people will be exposed to 
the hazard associated with-a GMO and, if so, whether they would suffer an adverse effect. 
· 4.1.2.a. Potentia/for exposure to the GMO in the product 
At this stage, it will also be necessary to consider whether everyone exposed to the GMO 
would suffer an adverse effect or whether any adverse effect would occur only in a small 
proportion of exposed individuals. Infrequent adverse effects may be either due to a low 
probability of an effect occurring in any given individual or because a small proportion of 
the population is susceptible. The latter may include immunocompromised individuals or 
those with a particular vaccination status or on an antibiotic regimen. 
One important component of this factor is whether the wider environment (including other 
humans) comes into contact with the GMO in the product under normal circumstances 
(i.e. are exposed to the GMO). The degree of exposure of operators will have a bearing 
on the likelihood of a hazard occurring. When considering the degree of exposure of 
operators and their relatives and contacts and the general public to the product, the 
following matters should be taken into account. 
4.1.2.a (i) Type of packaging and procedures before and after administration 
Most, if not all, veterinary medicinal products containing GMOs will be securely packaged 
on receipt and the packaging should allow any initial preparatory steps (e.g. reconstituting 
freeze-dried preparations) to be undertaken in a safe and aseptic manner. However, the 
proposed method of preparation and administration will have a bearing on the degree of 
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~posure of operators to the GMOs and need to be considered. For example, single dose 
preparations for administration to a companion animal in the surgery is likely to result in 
less exposure than mass medication of farm animals. It may be appropriate to consider 
who is likely to administer the product (veterinary surgeon or farmer) and the likelihood 
of any necessary instructions for safe use of products being achievable. It will also be 
necessary to consider whether or not unused product can be readily disposed of in a 
reliably safe manner. 
4.1.2.a (ii) Route of administration (parenteral vs. oral vs. oculonasal vs. spray) 
It may be expected that there is more opportunity for exposure of the operator to the 
product organisms when the product is administered by spray, orally or oculonasally than 
by injection but the risks of self injection must be borne in mind. 
4.1.2.a.(iii) Shedding oflive product organisms (route, numbers, duration) 
The extent to which the product organisms multiply in the host, can be excreted and 
spread will have been studied as part of the safety studies. Many products may well 
consist of attenuated or replication defective organisms and the likelihood of exposure will 
be less than that associated with the wild type, parental strain. 
The overall degree of exposure of humans such as animal attendants should be indicated. 
It should be noted that high exposure does not necessarily mean high risk and conversely 
that even 'low' exposure, but with severe consequences, may lead to an unacceptable risk. 
It is recommended that the possibility of exposure and likelihood of hazards occurring is 
qualitatively judged as either 'negligible', 'low', 'moderate' or 'high'. 
4.1.3. Assessment of level of risk 
Having identified any hazards and assessed the degree and likelihood of exposure and the 
consequences of that exposure it is necessary to evaluate the risk associated with each 
hazard. Risk is generally held to be the product of exposure/likelihood and consequence. 
It is inevitably always going to be difficult to 'multiply' qualitative statements such as 'high' 
and 'low', but table 1 should help this process. The risk matrix is not definitive and there 
will always be some scope for flexible, case by case evaluation. In many cases, it will be 
necessary to decide between one of two outcomes and as in the earlier parts of the 
process, some justification for the choice should be provided. In addition, a range of risks 
may be apparent if more than one hazard is being evaluated. There will therefore be a 
need to make an overall assessment of the risk taking all factors into consideration. 
Once an overall assessment of the risk associated with each hazard has been produced it 
will be necessary to evaluate the significance of the risk. 
It is generally considered that any risk other than 'effectively zero' or 'low' is unacceptable 
without some consideration of measures and proposals to control the risks to human 
health. 
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4.1.4. Consequences tJ/ a hazard occurring 
This stage.ofthe assessment should consider, for each identified hazard, what is the result 
of the hazard occurring i.e. what effect it may have on an exposed individual or 
population. It is anticipated that the range of consequences will fall between those that 
are negligible and self-limiting and those that would be severe, either having an immediate 
and serious effect or possibly leading to long term, harmful consequences. 
It is suggested that the consequences of each hazard is indicated qualitatively as 
'negligible', 'low', 'medium' or 'severe'. 
An adverse effect may be either immediate or delayed. Immediate and relatively trivial 
effects such as seroconversion in casual contacts may be extremely easy to identify but 
may not be particularly important. However, longer term and less obvious effects, such as 
oncogenicity or toxicity will clearly be difficult to assess but extremely important. 
The assessment of the consequences of a hazard occurring will need to consider the 
effects on individuals as well as the overall community. For each hazard it may be 
necessary to split the considerations into the 'worst case' and the 'normal case'. During the 
overall assessment of the level of risk, such differences should then be weighed up in 
arriving at the final risk assessment. For example, the consequences to rare individuals 
may be judged to be 'serious'. However, because such individuals do not form a large part 
of the community (and therefore the likelihood of the hazard occurring is low), the risk 
associated with the particular hazard may be acceptable. 
4.1.5. Control of risk 
This stage of the risk assessment will require some consideration of the particular aspect 
of the assessment. which lead to an unacceptable level of risk. For example, if it were 
caused by a lack of detailed knowledge on a particular hazard then it might be necessary 
to acquire further information, either by experimentation or from published literature. 
Alternatively, it could be that changes to the instructions for use or to any recommended 
precautions would reduce the level of exposure to staff or other people. In any case, 
personnel, such as those administering the product and those handling the animals at the 
time, will be subject to worker protection legislation such as the Biological Agents 
Directive (90/679/EEC as amended by 93/88/EEC), requiring among other things, risk 
assessment and appropriate control measures. 
4.2 Assessment of the risks to the environment 
Having decided on the controls (if any) that are appropriate in order to minimise the risks 
to humans, it is necessary to evaluate whether there could be any adverse effect on the 
environment resulting from the use of the product. The characteristics of the GMO need 
to be considered, particularly its.host range and pathogenicity. Account must be taken of 
the characteristics of the parental orgarusm, any organisms used as donors and the 
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possibility of changes to host range, pathogenicity or tropism as a result of the genetic 
modifications. 
The objective of the environmental part of the risk assessment is to determine the 
probability of adverse consequences, or 'harm', to the environment. Harm results if 
hazards are realised. The steps are in principle as for the human health part of the risk 
assessment, but the particular considerations are of course different. 
4.2.1. Hazard identification 
The starting point for risk assessment is to identify the characteristics of the GMO which 
are a hazard because they have the potential to cause harm in the receiving environment. 
Appropriate information about the recipient or parental organism and the donors as well 
as information about the GMO itself, should be considered. 
4.2.J.a. Capacity to transmit to non-target species 
The specificity of the host range is very important for veterinary products. Any likely 
changes as a result of the genetic modification should be taken into account. 
4.2.l.b. Shedding of live product organisms (route, numbers, duration) 
The extent to which the product organisms multiply in the host, can be excreted and 
spread will have been studied as part of the safety studies. Many products may well 
consist ;f attenuated or replication defective organisms and the likelihood of exposure will 
be less than that associated with the wild type, parental strain. However, the potential for 
organisms passaged from animal to animal to become less attenuated must be taken into 
consideration. 
4.2.l.c. Capacity to survive, establish and disseminate 
This is also a key consideration: if an organism is not capable of surviving, say, because of 
multiple disablement, then other hazards are likely to be minimised. The risk assessment 
could be completed at this stage if the risks to the environment are low or effectively zero. 
However, if it is likely that the organism could survive for a sufficiently long period for it 
to cause harm, and possibly establish and disseminate in the environment, then not only 
this hazard but also other hazardous characteristics need to be considered. 
4.2.J.d Potentia/for gene transfer 
Although most organisms have the ability to transfer genes, some do not. Consider, in 
particular, the extent to which the method of modification might increase the potential for 
transfer, as, for example, in the case of non-integrating viral vectors. 
4. 2. 1. e. Products of expression of inserted sequences 
Identify all products of gene expression that could cause harm, bearing in mind that an 
inserted gene might code for a product that is toxic, or otherwise detrimental, to other 
organisms. Consider the extent to which those products could have an effect on other 
organisms. 
4.2.J.f Phenotypic and genotypic stability 
Consider whether genes inserted into the GMO on extrachromosomal elements might be 
transferred more readily and the extent to which genotypic instability might lead to 
phenotypic instability. 
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4.2.l.g. Pathogenicity to other organisms 
The pathogenic properties of many org~sms used as recipient or parental organisms are· 
well documented; these should be identified, if appropriate. Consider whether a change in 
host range could occur as a result of the genetic modification which has been undertaken. 
4.2.l.h. Potentia/for other effects 
Consider whether the GMO might have the potential to exert other effects such as the 
transmission and r~plication of viruses in other organisms as a result of transcapsidation, 
and the effects of recombination. 
4.2.2. Assessment of likelihood 
The next step is to estimate the likelihood (probability and frequency) of hazard(s) being 
manifested. A key factor in determining this is the potential receiving environment. This 
includes the wider as well as the local environment in which the product is intended or 
likely to be used. 
Particular characteristics of the local environment that could contribute to manifestation of 
the hazard should be identified and assessed. Climatic, geographical and soil conditions, 
demographic considerations, the types of flora and fauna in the potential receiving 
environment are some of the important ones. 
Consideration should be given to any potential exposure of the living and non-living 
environment to the GMOs and the magnitude and duration of such exposure. 
When estimating probabilities and frequencies, consideration should include the number of 
organisms that might reach the environment since the probability that a hazard will be 
realised will often be influenced by the number of viable organisms in the environment 
due, for example, to excretion. For the hazard 'survival capacity', therefore, it is 
appropriate to assess the proportion of the GMOs that are likely to survive. In the case of 
the likelihood of gene transfer, the probable number of such events or the extent to which 
transfer will occur should be considered. If the GMO has pathogenic characteristics, 
assess the proportion of target organisms in the environment likely to be affected, 
including taking into consideration, the likelihood of the GMO to spread to or reach these 
organisms. 
The mode of administration might have an impact on the likelihood that hazard(s) will be 
manifested. For example, spray or other forms of mass administration are more likely to 
lead to the introduction of the GMO into the environment than if given by injection. 
Likelihood shoul<;l be expressed as 'high', 'medium', 'low' or negligible'. 
4.2.3. Assessment of level of risk 
Having judged the magnitude of harm if the hazard were to be realised, and the likelihood 
or frequency of such harm being caused, the level of risk is assessed by considering the 
combined effect of these two components. 
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This should be carried out for each of the hazards identified. The matrix in Annex 1 used 
for the human health part of the risk assessment can be used again to come to an 
evaluation ofthe environmental risk for each environmental hazard. 
4.2.4. Assessment of the consequence 
For each hazard of the GMO identified, whenever it is possible or probable that the GMO 
in the product will reach the environment, it must be considered whether that environment 
would cause or allow the hazard to be realised. Thus, again, the characteristics of the 
potential receiving environment need to be considered. 
An assessment of the magnitude of harm is based on the assumption that the hazard will 
be realised. Inevitably there will be a degree of judgement in making the assessment, but 
the consequences should be described as 'severe', 'medium', 'low', or 'negligible'. A 'severe' 
consequence might be a major change in the numbers of one or more species leading to 
negative effects on the functioning of the ecosystem and/or other connected ecosystems. 
It is unlikely that the changes would be reversible. A 'low' consequence might be if any 
change in population densities is such that it has no negative effects on ecosystem function 
and no impact on endangered or beneficial species. 
The above illustrations reflect the potential effect of the GMO on populations. In some 
cases, however, it may be more appropriate to consider the likely effects on individual 
organisms, for example endangered mammals. In most cases it should be possible to use 
the guidelines to assess in qualitative terms the degree of harm which a particular GMO 
might cause. 
4.2.5. Selection and assignment of appropriate control measures (risk management) 
If the environmental risks are not as low as reasonably practicable, the process of risk 
assessment in relation to that hazard should be repeated to ascertain whether the 
application of additional management techniques could reduce the level . of risk. 
Consideration might be given, for example, to limiting the proposed routes of 
administration to those likely to lead to a lower level of risk. 
5. SUGGESTED FORMAT FOR PRESENTATION OF CONCLUSIONS OF 
RISK ASSESSMENT 
Applicants may find the following structure useful to record their risk assessment. 
1. Summary 
Summary of the overall risk of damage to the environment (including human health) from 
the proposed marketing of the GMOs forming the subject of the application. 
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l. Agusment of risk to humaps 
2.1. Hazard identification: Hazardous characteristics of the GMO that could, in certain 
circumstaliCes, lead to hann in humans : 
a. Pathogenicity or other adverse effects 
b. Genetic instability (esj>ecially attenUating mutations) 
c. Gene transfer 
d. Survival I dissemination 
.2.2. Assessment of the degree of exposure and the likelihood of each hazard occurring 
2.3. Assessment of level of risk 
2.4. Consequences of a hazard occurring 
2.5. Assessment of the overalt"risk of harm to humans (the total risk after consideration 
of the risk of each of the hazards occurring): High, medium, low, effectively zero. 
3. Assessment of the risks to the environment 
3.1. Hazard identification Hazardous characteristics of the GMO that co,uld, in certain 
circumstances, lead to harm to the environment 
a. Capacity to transmit to non-target species 
b. Shedding of live product organisms (route, numbers, duration) 
c. Capacity to survive, establish and disseminate 
d. Potential /or gene transfer 
e. Products of expression of inserted sequences 
f. Phenotypic and genotypic stability 
g. Pathogenicity to other organisms 
h. Potentiat for other effects 
3.2. Assessment oflikelihood 
3.3. Assessment oflevel of risk 
3 .4. Assessment of the consequence 
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3.5. Assessment of the overall risk to the environment (the total risk after consideration 
ofthe risk of each of the hazards occurring): High, medium, low, effectively zero. 
4. Assessment of the overall risk 
Assessment of the overall risk to humans and the environment (from Points 2.5 and 3.5 
above). 
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Table I 
ESTIMATION OF RISK 
I 
Consequence Likelihood of Hazard 
of Hazard 
I 
High Moderate Low Negligible 
Severe High High Medium Effectively Zero 
Medium High High Medium/Low Effectively Zero 
Low Medium/Low Low Low Effectively Zero 
Negligible Effectively Zero Effectively Zero Effectively Zero Effectively Zero 
This matrix is not intended to be definitive, but illustrative of the way in which an estimate 
of risk might be obtained from the consequence and likelihood that a hazard will be 
realised. Different components may be differently weighted, however, depending on the 
knowledge and experience of the GMO and operation involved. 
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Guidance on the integration of the evaluation of the environmental risk assessment 
with the evaluation of the rest of the application for marketing authorisation for a 
medicinal product consisting of or containing live genetically modified organisms 
1. INTRODUCTION 
From 1 January 1995, applications for marketing authorisations for medicinal products 
which contain or consist oflive genetically modified organisms will fall within the scope of 
Council Regulation 2309/93. The particulars and documents required in support of an 
app!ication for marketing authorisation for such a medicinal product will include an 
environmental risk assessment and related information, in accordance with Articles 6.2 or 
28.2 of the Regulation (depending on whether it is for human or veterinary use). 
The authorisation procedure, which is laid down in the Regulation, will be mandatory for 
such medicinal products containing live GMOs, since they fall within the scope of the 
annex, part A. The evaluation of the entire dossier, which must take place according to a 
strict time-table, will be coordinated by a rapporteur appointed by the CPMP/CVMP. 
The key principles in the evaluation procedure of a medicinal product containing a live 
GMO are as follows: 
2. APPLICATION DOSSIER 
A single application dossier will be submitted to the European Medicines Evaluation 
Agency (EMEA). (The number of copies and languages will be set out in the Notice to 
Applicants). 
In the case of a medicinal product consisting of or containing a live GMO, the dossier will 
include (Articles 6.2 and 28.2 of the Regulation): 
• a copy of written consents issued by the competent authorities to the deliberate release 
of GMOs for research and development purposes, 
• the results of any investigations performed for the purposes of research and 
development 
• the complete technical dossier supplying the information as set out in Annexes IIA and 
III of 90/220/EEC, 
• the environmental risk assessment resulting from this information 
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3. PRESUBMISSION 
An applicant may seek advice from ~he Agency within its Committees on the conduct of 
the various tests and trials necessary to demonstrate the quality, safety and efficacy of 
medicinal products. Usually the Committee concerned will appoint one of its members to 
coordinate the advice to be given. Advice may also be sought on the fulfillment of the 
requirements of Article 6.2 or 28.2 of Regulation N° (EEC) 2309/93. Applicants niay 
seek advice on applications prior to submission. See appropriate section in the Notice to 
Applicants on advising applicants on the conduct of various tests and trials necessary to 
demonstrate the quality, safety and efficacy of medicinal products. (Article 51 of the 
Regulation) 
4. AUTHORISATION PROCEDURE 
In accordance with Article 53 of the Regulation at the start of the procedure, the 
CPMP/CVMP shall appoint a rapporteur to coordinate the evaluation 
During the evaluation the rapporteur shall in a timely manner hold the necessary 
consultations with the bodies set up in accordance with 90/220/EEC. In the first instance, 
it is recommended that the rapporteur contact one of the Competent Authorities for 
90/220/EEC which will then coordinate the views of the other Competent Authorities. 
The conclusions and results of any consultations will be included in the assessment report, 
including requests for clarification or further information. 
The CPMP/CVMP will give its opinion within 210 days of the receipt of a valid 
application. The opinion shall respect the environmental safety requirements resulting 
from the risk assessment on the basis of Directive 90/220/EEC to ensure that appropriate 
measures are taken to avoid the adverse effects on human health and the environment 
which might arise from the deliberate release or placing on the market of a medicinal 
product containing live GMOs. 
121 
Scientific Evaluation Timing 
Committee receives the valid application, a rapporteur (taking into consideration any 
proposal from the applicant for the choice of a rapporteur) and as appropriate a co-
rapporteur, is nominated along with the experts in the evaluation team; necessary 
consultations with the bodies set up in accordance with 90/220/EEC to take place 
during this period. Requests for further information/ clarification which relate to the Day 1 
environmental risk assessment, to be proposed during this time. 
The secretariat liaises with the applicant, informing them of the rapporteur (and co-
rapporteur) and timetable which has been prepared. 
Rapporteur (and co-rapporteur, as appropriate) circulate their preliminary assessment Day90 
reports to the Committee. This will include the evaluation of the information presented 
in accordance with article 6.2 or 28.2 ofRegulation N°2309/93 and the conclusions and 
results of consultations with the bodies set up m accordance with Directive 
90/220/EEC. Only one assessment report of the ERA would be prepared for this 
evaluation. 
Committee considers preliminary assessment report(s) and establishes those 1ssues Day 120 
which the applicant is invited to clarify and the clock is stopped 
Applicant submits a written response to the Agency Day 120 
Clock restarts when a response to all parts of the dossier is received 
Rapporteur(/co-rapporteur) prepares a report with conclusions on the written response Day 150 
ofthe applicant and circulates to members and the applicant 
The need for an oral explanation with the Committee is discussed with the rapporteur, Day 180 
which is then arranged by the secretariat if necessary (clock may be stopped to allow the 
applicant to prepare the oral explanation) 
The Committee members conclude the evaluation and adopt the opinion Day 210 
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CHAPTER VII 
ADDITIONAL INFORMATION 
STANDARD FORMAT FOR APPLICATIONS FOR AUTBORISA TION FOR 
NON-IMMUNOLOGICAL VETERINARY MEDICINAL PRODUCTS 
(NATIONAL AND COMMUNITY PROCEDURES) 1 
PART I 
PART II 
SUMMARY OF THE DOSSIER 
I.A Administrative data 
I.B Summary of product characteristics 
I.C Expert reports on: 
chemical, phannaceutical and biological documentation 
safety documentation 
residues documentation (if necessary) 
pre-clinical and clinical documentation 
CHEMICAL PHARMACEUTICAL AND BIOLOGICAL 
DOCUMENTATION 
II.A Composition 
II.B Method of preparation 
II. C Control of starting materials 
II.D Control tests on intermediate products 
' 
II.E Control tests on the finished product 
II.F Stability 
II. Q Other information 
Each application must contain a detailed index, with volume and page number of the 
file clearly indicated for each item 
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PART II Bis CHEMICAL. PHARMACEUTICAL AND BIOLOGICAL 
DOCUMENTATION FOR VETERINARY MEDICINAL PRODUCTS 
DERIVED FROM BIOTECHNOLOGY 
PART III 
PART IV 
II Bis A 
II Bis B 
II Bis C 
II Bis D 
II Bis E 
II Bis F 
II Bis Q 
Composition 
Method of preparation 
Production and control of starting materials 
Control tests on intermediate products 
Control tests on the finished product 
Stability 
Other information 
SAFETY AND RESIDUES DOCUMENTATION 
III. A Safety Documentation 
A. 1 Precise identification of the substance concerned by the 
application 
A.2 Relevant pharmacological studies 
A.3 Toxicological studies 
A.4 Studies of other effects 
A. 5 Ecotoxicity 
Conclusions 
III.B Residue Documentation 
B.l Precise identification ofthe product concerned by the 
application 
B.2 Residue studies 
B.3 Routine analytical method for the detection of residues 
Conclusions 
PRE-CLINICAL AND CLINICAL DOCUMENTATION 
IV. I Pre-clinical documentation 
l.A Pharmacology 
l.B Tolerance in the target species 
1. C Resistance 
IV.2 Clinical documentation 
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STANDARD FORMAT FOR APPLICATIONS FOR AUTHORISATION FOR 
IMMMUNOLOGICAL VETERINARY MEDICINAL PRODUCTS 
(NATIONAL AND COMMUNITY PROCEDURES) 
PART I 
PART IT 
PART III 
PART IV 
PARTV 
SUMMARY OF THE DOSSIER 
I. A · Administrative data 
I.B Summary of product characteristics 
I.C Expert reports on: 
analytical (physico-chemical, biological and microbiological 
documentation) 
safety documentation 
efficacy documentation 
CHEMICAL. PHARMACEUTICAL AND BIOLOGICAL 
DOCUMENTATION 
II.A Qualitative and quantitative composition of the constituents 
II.B Description of the method of preparation of the finished product 
II.C Production and control of starting materials 
II.D Control tests during production 
II.E Control tests on the finished product 
II.F Stability 
II. Q Other information 
SAFETY DOCUMENTATION 
EFFICACY DOCUMENTATION 
GENERAL CONCLUSIONS 
BffiLIOGRAPIDCAL REFERENCES 
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EC APPLICATION FORMAT (Part lA) 
This is not intended to be a ''formu/aire ", or for completion as an "application form". It is 
a list of headings, in sequence, to facilitate examination of dossiers and ensure all 
relevant data is included Where insufficient space is provided on the form, full details 
should be provided separately, following the same order as in the form. 
Part lA - Administrative data 
Part lA: 
Fees, declaration and signature 
It is hereby confirmed that fees are going to be paid/have been paid according to the 
national rules. 
(If fees have been paid, please attach proof of payment) 
It is hereby confirmed that all existing data which are relevant to the benefit/risk assessment 
of this veterinary medicinal product have been supplied in the dossier Parts II, III and IV. 
Place, date 
(Function and signature(s) ofthe applicant) 
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Part lA: 
Type of Application 
Processing number .......................................................................... . 
(for competent authority use only) ................................................. . 
1. This application concerns: 
0 A national application (if available, number: ............... ) 
0 An application according to Art. 17 ofDirective 81/851/EEC as amended (mutual 
recognition procedure) 
Reference Member State: .............. . 
date of authorisation: .................. . 
marketing authorisation number: ................... . 
EC Member States involved in the mutual recognition procedure: 
EC Member States where additional national applications are pending: ........... . 
Non EC/EEA States where additional national applications are pending: ........... . 
If there are differences between the pending national application and the 
decentralised procedure, elaborate: 
D different indications 
D different dossier Part II 
D different dossier Part III 
D different dossier Part IV 
0 An EC-application according to Council Regulation EEC No. 2309/93 (centralised 
procedure) 
rapporteur: ....... :........... co-rapporteur: ................ . 
0 Part A 0 Part B 
date of acceptance as a Part B veterinary medicinal product by the CVMP: 
0 A resubmission (previous national application number): .................. . 
0 A renewal (i.e. updated Part lA) of a marketing authorisation granted under 
Directive 87/22/EEC (concertation no ........ ) 
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2. The application is in accordance with the following legal base: 
0 A full application (a full dossier) 
0 An abridged application 
0 according to Directive 81/851/EEC Article 5.10a)i) 
(A letter of consent from the holder of the authorisation of the original 
veterinary medicinal product should be included.) 
0 according to Directive 81/851/EEC Article 5.1 Oa)ii) 
0 according to Directive 81/851/EEC Article 5.1 Oa)iii) 
(Proof should be provided that an essentially similar product has been 
authorised within the Community, in accordance with Community 
provisions in force, for not less than six/ten years and is marketed in the 
Member State for which the application is made.) 
0 Other abridged application (extension): 
0 quantitative change in declared active substance/different strength 
0 qualitative changes in declared active substance(s) including addition or 
deletion 
0 addition of an indication to a different therapeutic area 
0 change of an indication to a different therapeutic area 
0 different route of administration 
0 different pharmaceutical form 
0 change ofbioavailability 
0 change of pharmacokinetics 
0 addition or change of target animal species 
0 shortening of the withdrawal period for a veterinary medicinal product used 
in food-producing animals 
0 Biological substances or products of biotechnology: 
0 replacement with one of a different molecular structure 
0 modification of vector including master cell bank from different source 
0 Other abridged applications not listed above, please specify 
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3. This is an application for: 
1 [] An "essentially similar" product 
[] A veterinary medicinal product containing a new active substance 
[] A veterinary medicinal product contairting an excipient not previously 
authorised in a veterinary medicinal product 
[] A veterinary medicinal product containing a new combination of known 
active substances 
[] A veterinary medicinal product with a new proposed indication 
[] A new strength of an authorised veterinary medicinal product 
[] A new pharmaceutical form of an authorised veterinary medicinal product 
When a veterinary medicinal product is intended for use in food-producing 
animals 
[] Maximum Residue Limits according to Council Regulation 
2377/90/EEC are published in the Official Journal of the European 
Communities 
Substance: Date of publication: Species: 
[] Maximum Residue Limits according to Council Regulation 
2377/90/EEC are applied for: 
Substance: Date of submission: Species: 
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1. Proposed brand name of the veterinary medicinal product in the Community/concerned 
Member State: 
If different brand names2 in different Member States are proposed in a mutual 
recognition procedure, these should be listed: 
Country: Name: 
1.1 Name ofthe active ingredient(s) 
(INN, Ph. Eur., National Pharmacopoeia, trivial name and chemical description): 
1.2 Pharmacotherapeutic classification (use ATC vet classification): 
1.3 Target species 
2. Pharmaceutical form and strength (Please use CVMP List of Allowed Terms): 
2.1 Route of administration (Please use CVMP List of Allowed Terms): 
2.2 Container, closure and administration devices (Please use CVMP List of Allowed 
Terms): 
2 A justification for different brand names should be appended in an Annex (see 
Chapter I and item 7.2 of this format). 
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2.2.1 Package sizes 
2.2.2 Shelflife 
2.2.3 Shelf life (after first opening of container) 
2.2.4 Shelf life (after reconstitution) 
2.2.5 Storage conditions 
2.3 Dispensing/classification proposed by the applicant: 
Veterinary medicinal products 
0 subject to prescription 
0 subject to other controls (specify) 
0 not subject to other controls 
2.4.1 For veterinary medicinal products subject to prescription3: 
0 Veterinary medicinal products on prescription which may be renewed 
0 Veterinary medicinal products on prescription which may not be renewed 
0 Veterinary medicinal products on special prescription 
0 Veterinary medicinal products on restricted prescription 
2.4.2 For veterinary medicinal products not subject to prescription: 
0 Promotion to health care professionals only 
0 Promotion to the general public 
2.4.3 (Only applications submitted to Germany, Ireland, the Netherlands, Sweden & the 
U.K): 
3 
0 Supply through pharmacies only 
0 Supply through non-pharmacy outlets 
Applications submitted to the UK only: 
0 Pharmacy 
0 Pharmacy merchant list 
0 General sale list 
Not all the listed options are applicable in each Member State. Applicants are 
invited to indicate which categories they are requesting, however, the Member States 
reserve the right to apply only those categories provided for in their national 
legislation. 
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3. Applicant (= future marketing authorization holder/future person responsible for 
placing the veterinary medicinal product on the market): 
Name: 
Address: 
Country: 
Telephone: 
Telefax: 
3.1 Person responsible for the technical data of the dossier (Spain & Portugal): 
Name: 
Address: 
Country: 
Telephone: 
Telefax: 
3.2 The following person is authorised for communication on behalf of the applicant 
during the procedure: 
Person of contact: 
Address: 
Country: 
Telephone: 
Telefax: 
3.3 Address for regulatory communication between the marketing authorisation holder and 
competent authorities after authorisation, if different from 3.2: 
Name: 
Address: 
Country: 
Telephone: 
Telefax: 
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3.4 Manufacturer(s) of the finished veterinary medicinal product and sites of manufacture 
(including a description of the steps they perform and the location of qualified person) 
Name: 
Address: 
Country: 
Telephone: 
Telefax: 
3.5 ·The manufacturer/importer responsible for batch control in the EEA: 
Name: 
Address: 
Country: 
Telephone: 
Telefax: 
3.5.1 Site where batch control takes place: 
Name: 
Address: 
Country: 
Telephone: 
Telefax: 
3.6 Manufacturer(s) ofthe active substance(s): · 
Name: 
Address: 
Country: 
Telephone: 
Telefax: 
Drug Master File reference/E.P. certificate of suitability reference number_, if 
applicable: Date of submission: 
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3. 7 Contract companies used for bioavailability or bioequivalence trials: 
For each contract company, give: 
Name: 
Address: 
Country: 
Telephone: 
Telefax: 
Task performed according to contract: 
4. Qualitative and quantitative composition in terms of the active substance(s) and the 
excipient(s): 
A note should be given to which quantity the composition refers to 
(e.g. 1 capsule) 
List the active substance(s) separately from the constituents of the excipients 
4.1 Non-immunological medicinal product 
Name of the Quantity Unit Reference 
standards 
- active substances: 
1. 
2. 
3. etc. 
- excipients:-
1. 
2. 
3. etc. 
Details of any overages: - these should not be included in the Fonnulation Columns 
but stated in this section. 
-active substance(s) 
- excipient(s) 
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4.2 Immunological veterinary medicinal product 
Names of ingredients4 Quantity5 
/dose or /ml 
Active 
ingredients 
Constituents of 
the adjuvant 
Constituents of 
the excipients6 
Constituents of 
the diluent 
Constituents of the 
pharmaceutical form 
4 
s 
See Part 6, A.2 of the Annex.to the Directive. 
See Part 6, A.3 of the Annex to the Directive. 
Function Reference to 
standards 
6 For the purposes of this section, excipients mean products other than the active 
ingredient and the adjuvant, blended to prepare the finished product. 
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Marketing Authorisation particulan 
5. Marketing applications for this veterinary medicinal product in the EEA (i.e. from the 
same company or a related company, i.e. "daughter", "sister" or "mother" company of 
the same corporation/holding company or licensee, containing the same active 
substances for a comparable indication) 
Authorised: country: 
Pending: 
Rejected: 
Withdrawn: 
(by applicant 
before authorisation) 
Withdrawn: 
(by applicant 
after authorisation) 
Suspended/revoked/ 
withdrawn 
(by competent authority) 
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date of authorisation: 
authorization number: 
trade name: 
country: 
date of submission: 
application number 
country 
date of rejection 
application number 
country 
date of withdrawal 
application number 
trade name 
reason for withdrawal 
country 
date of withdrawal 
application number 
trade name 
reason for withdrawal 
country 
date of suspension: 
authorization number: 
reason for withdrawal: 
trade name 
6. For new active substances, marketing authorisations outside the EEA (i.e. from the . 
same company or atelated company, i.e. "Ciaughter", "sister" or "mother" company of 
the same corporation/holding company or licensee, containing the same active 
substances for a comparable indication) 
Authorised: country: 
Pending: 
Re.iected: 
Withdrawn: 
(by applicant 
before authorisation) 
Withdrawn: 
(by applicant 
after authorisation) 
Suspended/revoked/ 
withdrawn 
(by competent authority) 
Appended Documents 
date of authorisation: 
authorisation number: 
trade name: 
country: 
date of submission: 
application number 
country 
date of rejection 
application number 
country 
date of withdrawal 
application number 
trade name 
reason for withdrawal 
country 
date of withdrawal 
application number 
trade name 
reason for withdrawal 
country 
date of suspension: 
authorization number: 
reason for withdrawal: 
trade name 
7. 
7J, Manufacturer's Authorisations required under 81 /851/EEC Article 24 (or equivalent, 
if outside the EEA) 
7.2 
7.3 
Justification o~ use of one or more trade name in the Member Stat~s. if appropriate 
List of samples sent with the application 
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Instructions for completion of Section 4 of the application format: 
• Enter the constituent(s) as the actual substances included in the formulation (e.g. as 
salt or hydrate) and then as the active entity equivalent where appropriate. 
• A specification should always refer to the latest published official monograph. 
Where an ingredient has no official monograph please enter company standard. 
Official abbreviations should be used for pharmacopoeias. 
• Expression of quantity of active substance: 
a) For pharmaceutical forms that comprise a defined dosage unit, the quantity 
should be expressed per unit (ampoules, capsules, coated tablets, prefilled 
syringes, suppositories, single-use vials etc.). 
b) For pharmaceutical forms that do not comprise a defined dosage unit, the 
quantity should be expressed by weight, by volume or by unit. 
• Recommended abbreviations for quantities: 
a) Quantities expressed as mass: 
g - gram; mg -milligram; ~g - microgram; ng - nanogram 
b) Quantities expressed as volumes: 
m1 - millilitre; ~1 - microlitre ; nl - nanolitre 
c) Quantities expressed as amount of substance e.g. for inorganic salts in large 
volume parenterals: 
mol - mole; mmol - millimole; ~mol - micromole 
d) Quantities expressed as Units: 
U - Units; kU - kiloUnits; MU - MegaUnits 
e) Quantities expressed as units of radiation: 
MBq - Megabecquerels; GBq - Gigabecquerels 
f) Adjustable quantities: 
Insert upper and lower limit 
• Trailing zeros following the decimal point may be omitted e.g. 10.02 mg will 
suffice. 
• Include head-space gases used in ampoules etc. and propellants used in aerosols. 
• Leave a line between different components of the dosage form, e.g. for capsule shell 
components, coating components. 
• Complete "quantity" column as follows where appropriate: Insert ND for 
substances not detectable in the final formulation, e.g. solvents. Insert upper and 
lower limit if quantity not fixed e.g. for substance used to adjust pH. 
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NOTE FOR GUIDANCE ON THE PREPARATION OF SUMMARIES OF 
PRODUCT CHARACTERISTICS FOR NON-IMMUNOLOGICAL VETERINARY 
MEDICINAL PRODUCTS 
1. INTRODUCTION 
In accordance with Article Sa of directive 81/851/EEC as amended and Article 28 of 
Council Regulation (EEC) 2309/93. Any application for marketing authorisation submitted 
after 1 January 1992 must be accompagnied by the summary of product characteristics 
which is proposed by the applicant. Once they have completed the evaluation of the 
dossier, the Agency with its Committees or the competent authorities of the Member States 
approve the summary of product characteristics, if necessary, after suggesting certain 
amendments to the applicant to take account of the evaluation of the product. 
In the case of veterinary medicinal products which were first authorised before I January 
1992, the person responsible for marketing will be required to propose summaries of 
product characteristics for the products concerned during the five yearly renewal of 
marketing authorizations required by Directive 81/851/EEC. 
The fundamental purpose of the summary of product characteristics is to provide a clear 
and unambiguous description of the approved conditions ofuse of a veterinary medicinal 
product in the European Community or Member State(s) concerned, presented in 
accordance with a single standardised layout. As such, the summary of product 
characteristics forms part of the marketing authorisation which is granted by the competent 
authorities of the Member States. It may be amended only with the express approval of the 
competent authority concerned. 
The summary of product characteristics is intended to fulfil several objectives. The 
labelling, package insert and any data sheet must comply with the approved conditions of 
use set out in the summary of product characteristics. The SPC also provides an 
instrument for the control by the Agency with its Committtees or'competent authorities of 
promotional material provided by the authorisation holder. 
At the .community level, the SPC provides a basis for comparing the approved conditions 
of use of a particular veterinary medicinal product in the different Member States. When 
using the Community "decentralised" or "centralised" procedures, applicants must propose 
an identical SPC for all Member States. In the case of the decentralised procedure this SPC 
must also be identical with that approved by the Member State on whose authorisation the 
application is based. At the conclusion of the Community procedures, the Committee for 
Veterinary Medicinal Products always reviews the SPC in order to reach agreement on a 
single SPC for the product concerned which will apply throughout the Community. The 
CVMP will agree the summary of product characteristics as part of its opinion (with the 
exception of the information under points 6.5 and 7 which may differ from Member State 
to Member State. 
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The SPC is also used as a means of providing information to third countries about the 
conditions of use of a veterinary medicinal product within the Member States of the 
Community. In accordance with Article 24a of Directive 84/851/EEC, the competent 
authorities of a Member State will, upon request, provide the authorities of a third country 
with a copy of the SPC for the product concerned. Thus the regulatory authorities of third 
countries can easily obtain information about the officially authorised conditions of use of a 
product in the Community or a Member State. 
The order of presentation of the SPC is specified in Article Sa of the Directive, and should 
always be followed. This order of presentation is set out on the following page. 
2. SUMMARY OF PRODUCT CHARACTERISTICS 
1. NAME ofthe veterinary medicinal product 
2. QUALITATIVEANDQUANTITATIVECOMPOSITION in terms ofthe active ingredients 
and constituents, knowledge of which is necessary for the proper administration of 
the medicinal product~ the international non-proprietary names recommended by the 
World Health Organisation shall be used, or failing this, the usual non-proprietary 
name or chemical description 
3. PHARMACEUTICALFORM 
4. PHARMACOLOGICAL PROPERTIES, and in so far as this information is useful for 
therapeutic purposes, pharmacokinetic particulars 
5. CLINICAL PARTICULARS: 
5.0. Target species 
5.1 Inidcations for use, specifying the target species 
5.2 Contra-indications 
5.3 Undesirable effects (frequency and seriousness) 
5.4 Special precautions for use 
5.5 Use during pregnancy and lactation 
5. 6 Interaction with other medicaments and other forms of interaction 
5. 7 Posology and method of administration 
5.8 Overdose (symptoms, emergency procedures, antidotes) (if necessary) 
5.9 Special warnings for each target species 
5.10 Withdrawal periods 
5.11 Special precautions to be taken by the person administering the product to animals 
6. PHARMACEUTICAL PARTICULARS 
6.1 Incompatibilities (major) 
6.2 Shelf-life, if necessary after reconstitution ofthe product, or when the container is 
opened for the first time 
6.3 Special precautions for storage 
6.4 Nature and contents of container 
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6.5 Name or style and permanent address or registered place ofbusiness of the holder 
of the authorization to place the product on the market 
6.6 Special precautions for the disposal of unused product or waste material, if any 
3. GENERAL CONSIDJ:RATIONS FOR THE PREPARATION OF THE SPC 
When preparing an SPC, it should be noted that the SPC is intended to provide a detailed 
objective summary of the conditions of authorisation of a veterinary medicinal product. 
The SPC is not a promotional document, nor is it intended to constitute a summary of the 
evaluation of the medicinal product by the competent authorities. 
It follows that all the statements contained in the SPC must be justified by the contents of 
the application dossier which is submitted to the competent authority. Statements of a 
promotional nature such as "x is the treatment of choice for y" are not acceptable. 
Moreover, extraneous information such as the results of toxicity studies should not be 
included unless necessary to enable the practitioner to assess the benefits and risks of the 
use of the product in a particular case. 
Particular care should be taken in ensuring that clear and unambiguous language is used 
throughout the SPC. Attention should be given to the clear definition of the scope of the 
inidications, contra-indications, precautions for use and warning statements to ensure that 
these clearly identifY the groups or sub-groups of animals concerned. 
The SPC must always be presented in the national language or languages of the Member 
State concerned by the application. Where the SPC has been translated from another 
language, particular care should be taken to ensure the accuracy of the translation and to 
ensure that appropriate terminology has been used in the different languages concerned. A 
copy ofthe originall~nguage version of the SPC should always be included in the 
authorisation file. 
4. SPECIFIC CONSIDERATIONS FOR THE PREPARATION OF THE SPC 
1. NAME of the veterinaty medicinal product 
The name of the veterinary medicinal product may be a brand name or a generic 
name 
When selecting brand names, care should be taken to avoid the use of words or 
abbreviations which may give rise to confusion. 
Where generic names are used, the generic name of the active ingredient should . 
always be followed by the name of the authorisation holder, the manufacturer or the 
distributor, as appropriate. 
Where a single brand or generic name is used to cover a range of veterinary 
medicinal products, the name of each product within the range should be completed 
by reference to: 
the concentration in terms of active ingredients; 
the pharmaceutical form, if necessary; 
the target species, if necessary. 
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2. Qualitative and quantitative composition 
Full details of the qualitative and quantitative composition in tenns of active 
ingredients should be provided. 
In describing the qualitative composition of the product, the following principles 
should be followed: 
Where a substance is the subject of a monograph in the European 
Phannacopoeia, or failing this, one of the phannacopoeia of the Member 
States, the main title at the head of the monograph in question should be 
used to describe the substance concerned, with a reference to the 
monograph. 
In other cases, the international non-proprietary name (I.N.N.) 
recommended by the World Health Organisation should be used. 
In the absence of an I.N.N., the exact scientific designation should be given. 
Substances not having an I.N.N. or an exact scientific designation should be 
described by a statement of how and from what they were prepared. 
Where the active ingredient is present in the fonn of the parent molecule, the 
standard terminology should be used (e.g. dexamethasone, levamisole). 
Where the active ingredient is present as a salt or hydrate, this should be clearly 
stated e.g.: 
dexamethasone (as acetate); 
levamisol (as chlorhydrate). 
Where the active ingredient is of a particular quality standard, for example in the 
case of active ingredients used in premixes for the manufacture of medicated 
feeding-stuffs, this should also be indicated, e.g.: 
neomycin (as sulphate) for the premixes for medicated feeding-stuffs. 
For the description of the quantitative composition: 
Where the active ingredient is present in the fonn of a salt, derivative (e.g. 
ester) or hydrate, the quantitative composition must always be expressed in 
tenns of the mass (or biological activity in International (or other) Units 
where appropriate) ofthe active moeity of the molecule which is present in 
the molecule (e.g. x mg levamisol in the fonn oflevamisol sulfate). 
However, in the case of older compounds which have traditionally been 
expressed in the fonn of a salt, derivative or hydrate, it may in some case be 
appropriate to indicate the quantitative composition in tenns ofboth the salt 
or derivative and the parent molecule (e.g. x mg levamisol sulfate, 
equivalent to y mg levamisol). 
In the case ofunit dose preparations, the quantitative composition should 
also be stated per unit dose (e.g. x mg per mg or per ml; y mg per vial). 
In the case of solid or liquid preparation, the quantitative composition 
should be stated in tenns of mg per g or per ml. 
In addition to the qualitative and quantitative composition in tenns of active 
principles, the qualitative and quantitative composition of the EXCIPIENT should be 
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stated, where knowledge of this is essential for the safe administration of the 
medicinal product. 
The following examples, which are not exhaustive, are intended to illustrate the 
operation of this requirement:· 
Colouring matters should always be mentioned, and the "E" numbers 
allocated to them should be included. 
Preservatives should always be mentioned, and any "E" numbers allocated 
should be indicated. 
In the case of premixes for medicated feeding-stuffs, information should be 
provided about the vehicle of the premix. 
3. PHARMACEUTICAL FORM 
If the .product is not presented in the final pharmaceutical form intended for 
administration to animals, the final pharmaceutical form should be stated. 
4. PfiAR,MACOLOOICAI.PRQPERTIES, and in so far as this information is useful for 
therapeutic purposes, pharmacokinetic particulars; 
Whenever possible, this section should be presented in accordance with the 
following sequence: 
Summary presentation of the active ingredient(s); 
Pharmacodynamic properties; 
Pharmacokinetic properties. 
SUMMARY PRESENTATION OF THE ACTIVE INGREDIENT 
The following information should be given: 
The active ingredient; 
The therapeutic group; 
The pharmacological action, with the mechanism of action, if 
known; 
The group of substances to which it belongs; 
The mechanism of action, if known. 
For example: "X is a bactericidal antibiotic belonging to the xx group which 
acts by inhibition of protein synthesis." 
~CODYN~CPROPERTIES 
The pharmacodynamic activity of the active ingredient(s) should be 
specified, together with the mechanism of the action, on the basis of the 
information contained in the application dossier. 
P~co~CPROPERTIES 
Relevant information may be provided on the absorption, distribution, 
biotransformation and elimination of the product in each of the target 
species, for example: 
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Absorption: 
Percentage of the dose absorbed by the oral route; 
Time necessary to obtain the maximum concentration (T max); 
The maximum concentration (C max); 
Influence of feeding regime for absorption by the oral route; 
Quantity absorbed after topical administration. 
Distribution: 
Existence of possible linearity between the concentrations obtained 
and the dose administered; 
Level of protein binding; 
Tissue distribution. 
Biotransformation 
Information relating to metabolism. 
Elimination 
Half life; 
Principal routes of excretion, including secondary routes which 
may be relevant from an environmental point of view. 
5. CLINICAL PARTICULARS 
5.0 Target species 
The target species, and/or any sub-category should be indicated. 
5.1 Indications for use. specifying the target species 
The indications should be defined as precisely as possible and should be fully 
substantiated by the contents ofthe application dossier. In each case, indicate 
whether the treatment is for prophylactic, therapeutic or diagnostic purposes. 
5.2 Contra-indications 
Contra-indications result from a set of circumstances which make it undesirable to 
use a product. In particular, contra-indications may be linked with a target species, 
a group of animals or an individual animal, the administration of the product by a 
particular route or administration in conjunction with other products. 
A contra-indication may be absolute or relative. 
Absolute contra-indications must be clearly and unambiguously worded. They 
should also cover the possibility of the extra label use of the product in non-target 
species, where this is clearly contra-indicated by the results of the stuides or the 
scientific literature. 
In certain circumstances, it may be necessary to state relative contra-indications to 
aid the prescriber to balance the potential benefits and risks of the use of the 
product in a specific situation. 
5.3 Undesirable effects. frequency and seriousness 
As appropriate, the following information should be provided for each undesirable 
effect; the nature ofthe effect, duration, itensity, frequency, reversibilty, effect on 
the general state of health of the animal and possible treatments. In addition, it 
should be indicated whether certain species or breeds or types of individual are 
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·more susceptible to the undesirable effect concerned, or whether it is more frequent 
under certain types of husbandry conditions. ' 
In the case of products intended for use in food-producing animals, any adverse 
effects on the quantity or quality of food-stuffs of animal origin should also be 
mentioned. 
5.4 Special precautions for use 
The purpose of this section is to warn prescribers and suppli~rs of the possibility of 
class or drug-related modifications of the safety or efficacy profile of the product 
which may arise in particular situations such as renal, hepatic or cardiac failure, or 
in very old or veri young animals and to describe the conditions under which the 
medicinal product may be recommended for use in such groups provided the special 
precautions are followed. 
5. 5 Use during pregnancy and lactation 
In order to ensure the safe use of the product, the practitioner must be informed of 
the information necessary and recommendations for the use of the product in 
pregnant animals and lactating animals. Obviously, this section has no relevance in 
the case of products intended exclusively for very young animals or for males. In 
other cases, information about use during pregnancy or lactation may have been 
provided in the sections dealing with contra-indications or special precautions for 
use. In such cases, a cross reference to the relevant section will be sufficient. 
Examples of the type of additional information which might usefully be included in 
this section are: 
"Laboratory studies in the rat and the rabiit have not produced any evidence of a 
teratogenic effect." 
"When administered to lactating fem~es, residues of x are present. in the maternal 
milk. Since no studies have been reported of the effects on the development of new 
born young of the ingestion of this milk, it would be prudent not to feed very young 
animals with milk obtained from the mother." 
Information about the consequences of residues for the use of milk for human 
consumption should be given in section 5.10, withdrawal periods. 
5.6 Interaction with other medicaments and other forms of interaction 
The concomitant use of two or more veterinary medicinal products may give rise to 
interactions of a pharmacokinetic or a pharmacodynamic nature which may result in 
additonal or increased adverse effects, or which may result in the failure of efficacy 
of the product conc.erned. 
In certain cases, the nature or risk of interactions will be such that the use of a 
particular product Will be contra-indicated in absolute or relative terms while 
another substance or product' is administered to animals. In such cases, the relevant 
information should be given in the section dealing with contra-indications, and a 
cross-reference should be included in this section. 
In other cases, information should be provided in this section about the nature, 
mechanism and effects of interactions, with details of any corrective action which 
may need to be taken. 
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In addition to interactions between medicinal products, consideration should be 
given to other interactions with elements in the animals' diet and additives, for 
example. 
5.7 Posology (dosage) and mehtod of administration 
Where necessary, the posoux;r must be indicated for each target species and each 
therapeutic indication. Where the posology is expressed in active princ,ple it should 
be given in terms of mg per kg of live bodyweight. 
Where the posology is expressed in terms of a veterinary medicinal product, (for 
example by unit doses or by a volume of injectable solution), it should be given both 
in terms of the amount to be administered to the animal and the equivalent in terms 
ofmg per kg ofbodyweight, for example: 
120 mg tablet, equivalent to 5 mg/kg; 
10 mglkg orally, as 20 mill drinking water. 
The frequency of treatment should be stated in hours or days for each target species 
and the total duration of treatment should be stated. 
The description of the method of administration should include all the information 
necessary to enable the user to administer the product successfully to the target 
species, including the method of administration, the site of administration and any 
special equipment which is necessary. Where necessary, information should be 
provided on the timing of administration in relation to feeding, milking, exercise etc. 
In addition, any necessary guidance should be given on the adjustment of the 
dosage to take account of the disease status of the animal, and of the possibility of a 
reduced intake of feed or water by sick animals. 
5. 8 Overdose 
If necessary, the following information should be provided: 
Symptoms, nature, evolution, seriousness, duration; 
A vail able symptomatic treatments; 
Emergency procedures; 
Antidotes, if no antidote is available, this should be clearly stated. 
5.9 Special warnings for each target species 
The purpose of this section is to provide for the detailed, clear and precise 
statement of any physico-chemical, pharmacological, toxicological or clinical 
information, knowledge of which is necessary in order to ensure the safe and 
effective use of the medicinal product. 
Where appropriate, information may also be provided about possible risks resulting 
from the extra-label use ofthe product. 
5.10 Withdrawal periods 
In Community legislation, the withdrawal period is defined as the period between 
the last administration of the veterinary medicinal product to animals and the 
production of food-stuffs from such animals. 
If necessary, different withdrawal periods should be stated for meat and offal, milk, 
eggs and honey. Withdrawal periods should be indicated in days, using arabic 
numerals. A zero withdrawal period should be expressed as "0". 
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However, for fishmeat, the withdrawal period should be stated in degree days. The 
number of degree days is divided by the average water temperature, in °C, to give 
the withdrawal period in days. 
In the case of bolus and other sustained release preparations, the withdrawal period 
should be calculated from the date of the physical administration of the product to 
the animal. 
In certain instances, the use of a veterinary medicinal product will be formally 
contra-indicated for use in animals during the phase in which they .produce food for 
human consumption. For example, the product may be authorised for use in dairy 
cattle only during the dry period, or authorised .only for use in broilers and not in 
laying birds. Alternatively, a product may be indicated only for animals which are 
not used for food production. Although such restrictions on use will already have 
been indicated in the sections describing the target species, the indications and 
contra-indications, they should be repeated in this section, for example: 
"Withdrawal period: meat and offal: n days 
milk: x is not permitted for use in lactating dairy cattle. 
In the event of premature lactation, discard the milk 
obtained during the first n days." 
5.11 Special precautions to be taken by the person administering the product to animals 
Mention should be made of any risks resulting from the nature of the product, its 
preparation and use and of any risks resulting from the particular characteristics of 
the user. Any recommendations for the use of protective clothing during the 
preparation or administration of the product to animals should be clearly and 
unambiguously stated. Similarly, clear guidance should be provided on·any 
remedial action to be taken following accidental contact with the product, either 
through spillage or accidental self-injection. In some cases recommendations for 
appropriate action will be linked with particular characteristics of the user, such as a 
susceptibility to allergies or to asthma. 
6. PHARMACEUTICAL PARTICULARS 
6.1 Incompatibilities (major) 
In this section information should be given about physical or chemical 
incompatibilities of the product with others with which it is likely to be mixed or co-
administered. This may be particularly important for products to be diluted before 
parenteral administration. Significant problems of sorption of product to syringes, 
large volume parenteral containers etc. should be stated. Similarly, in the case of 
premixes for medicated feeding-stuffs, any restriction on the range of feeds which 
may be used for the preparation of the final feed should be indicated. 
6.2 Shelf-life 
The shelf-life should be expressed in arabic numerals as a number of years or 
months. If the storage temperature required is less than 25°C, the storage 
temperature should also be indicated. 
In the case of multi-dose preparations presented in sealed containers, or where 
reconstitution of the product is required before administration to animals, the shelf-
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life ofthe broached or opened container/reconstituted product should also be 
stated. Similarly, in the case of premixes for medicated feeding-stuffs, the shelf-life 
should be indicated for the premix, and for the medicated feed. 
6.3 Special precautions for storage 
Temperature, light and humidity may all effect the storage of a veterinary medicinal 
product. This section will contain the information necessary for the correct storage 
of the product, e.g.: 
11 Do not store at temperatures above/below n°C 11 ; 
11 Store out of direct sunlight"; 
" Store in a dry place". 
6.4 Nature and contents of container 
A summary but complete description of the contents of the final sales presentation 
should be provided. Where a single SPC covers a range of products, this 
information should be provided for each product in the range. 
6.5 Name or style and permanent address or registered place ofbusiness of the holder 
of the authorisation to place the product on the market 
Where different, the name and address ofthe manufacturer should also be given. 
6.6 Special precautions for the disposal of unused product or waste materials. if any 
This section should include information necessary for the safe disposal of unused 
product, and the equipment used for the administration of the product to animals. 
In addition, reference should be made to any restrictions on the disposal of waste 
products from treated animals. 
7. Final information 
At the end of the SPC, the following information should be provided: 
The marketing authorisation number of the product(s) concerned, if 
known; 
The date of the approval/last revision of the SPC, as relevant; 
The conditions of supply of the veterinary medicinal product to animal 
owners. 
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DOSSIER CHECK-IN PROCEDURE-
National application number: 
Date of entry 
Conclusion r.le accepted 0 
Yes 
Part I 
Application forms 0 
Summary of product characteristics 0 
Expert Report 
Quality 0 
Pharmacologyffoxicology 0 
Residues 0 
Clinical 0 
Proof that fees have been paid 0 
All pages present and legible 0 
Draft packaging 0 
Draft package insert in nationallanguageO 
Draft SPC in national language 0 
Manufacturers' authorisation 
of finished product 0 
Marketing authorisation(s) 0 
Sample(s) 0 
Part I acceptable 0 
Date of decision 
not accepted 0 
No Language 
0 [ ----] 
0 [-----] 
0 [-----] 
0 [-----] 
0 [-----] 
0 [-----] 
0 
0 
0 [-----] 
0 
0 
0 [-----] 
0 [----~] 
0 
0 
Not acceptable for reasons ................................................... 
Part 11/ll bis 
Chemical, Pharmaceutical 
and Biological documentation 0 0 [-----] 
Drug Master File 0 0 [-----] 
All volumes present 0 0 
All pages present and legible 0 0 
Part DID bis acceptable 0 0 
Not acceptable for reasons .................................................. . 
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Partm 
Pharmaco-Toxicological Documentation 0 0 
All volumes present 0 0 
All pages present and legible 0 0 
Residues Documentation 0 0 
All volumes present 0 0 
All pages present and legible 0 0 
Part ill acceptable 0 0 
Not acceptable for reasons .................................................. . 
Part IV 
Clinical Documentation 
All volumes present 
All pages present and legible 
Part IV acceptable 
0 
0 
0 
0 
0 
0 
Not acceptable for reasons .................................................. . 
Abridged application 
[-----] 
[-----] 
[-----] 
Yes No 
Application according to Directive 81/851/EEC Article 5 point 1 O(a)i 
Letter of consent from the holder of the authorisation of the 
original proprietary medicinal product for reference to 
Part III 
Part IV 
0 
0 
0 
0 
Application according to Directive 81/851/EEC Article 5 point 1 O(a)iii 
Evidence that an essentially similar product has been 
authorised within the Community in accordance with 
Community provision in force for not less than six/ten yearsO 0 
Evidence that an essentially similar product is marketed in the Member State 
for which an application is made 0 0 
For immunological veterinary medicinal products 
Part V acceptable 0 0 
Not acceptable for reasons ..................................... . 
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LIST OF OFFICIAL JOURNALS 
In accordance with Article 40 of Directive 8 1/851/EEC, all decisions to grant marketing 
authorization must· be published. The name and address of the Official Journal in each 
Member State is given below. 
Austria 
Belgium 
Denmark 
(to be entered when available) 
Belgisch Staatsblad/Moniteur Beige 
Leuvensestraat 40-42/Rue de Louvain 40-42, 
BRUSSELS 
Statstidende 
Otto Mcjmsteds Gade 3, 
DK-1571, K0BENHAVN V 
Finland Virallinen Lehti, Officiella tidningen 
P.O. Box23 
SF - 00431 HELSINKI 
France · Journal Officiel de Ia Republique Fran~aise 
· rue Desaix, F-75727 PARIS 
Germany Bundesanzeiger Verlags-GmbH 
Postfach 10 05 34, D-50445 KOLN 
Greece Ephimeris Kyvernisseos Ellenikis Dimokratias 
(Official Journal, Government Publications) 
Kapodistriou 34, ATHENS 
Ireland Iris Oifiguil, Stationery Office 
Bishop Street, DUBLIN 8 
Italy Gazzetta Ufficiale della Reppublica Italians 
lstituto Poligrafico e Zecca dello Stato 
Piazza G. Verdi 10, 1-00198 ROMA 
Luxemburg Memorial Service Central de Legislation 
boulevarde F D Roosevelt, 
L - 2450 LUXEMBURG 
Netherlands Nederlandse Staatscourant 
Postbus 20014, NL-2500 EA DEN HAAG 
Portugal Diario da Republica Casa da Moeda EP 
Rua D. Francisco Manuel de Melo 5 1092 LISBOA Codex 
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Spain 
Sweden 
United 
Kingdom 
European 
Union 
Boletin Oficial de Estado 
Trafalgar 27 28010 MADRID 
Post-och Inrikes Tidningar 
Bamangsgatan 21 
P.O. Box 4731 
S - 116 92 STOCKHOLM 
London Gazette 
HMSO Publications Centre 
51 Nine Elms Lane 
LONDON SW8 2DR 
Edinburgh Gazette 
55 Lothian road 
EDINBURGH 
EH3 9AZ 
Official Journal of the European Communities 
Belfast Gazette 
Chichester House 
Chichester Street 
BELFAST BTl 3JY 
Office for Official Publications of the European Communities 
2 rue Mercier 
L - 2985 LUXEMBURG 
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ADDRESSES FOR DELIVERY OF THE DOSSIER AND SUBSEQUENT 
CORRESPONDENCE 
VETERINARY MEDICINAL PRODUCTS 
OTHER THAN IMMUNOLOGICAL VETERINARY MEDICINAL PRODUCTS 
N.B. Unless otherwise indicated, infonnation about the national fees payable for the evaluation of 
an application may be obtained from the first address indicated below. 
Austria 
Bundesministerium fiir Gesundheit und Konsumentenschutz 
Pharmazeutische Angelegenheiten 
Radetzkystrasse 2 
A-1031 WIEN 
Tel 43 1 71 172 46 55 
Fax 43 1 71492 22 
Belgium 
Ministry of Public Health and the Environment 
Pharmaceutical Inspectorate 
Secretariat of the Medicines Commission 
Quartier Vesale 
B- 1010 BRUXELLES 
Tel 32 2 210 48 96 
Fax 32 2 210 48 80 
Denmark 
Sundhedsstyrelsen 
Lzgemiddelafdelingen 
378 Frederikssundsvej 
DK- 2700 BRONSHOJ 
Tel 45 44 94 36 77 
Fax 45 44 94 02 37 
Telex 35333 IPHARM DK 
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France 
Ministere de l'Agriculture et de Ia Foret 
CNEVA (Centre National d'Etudes Vererinaires et Alimentaires) 
Laboratoire des Medicaments V ererinaires 
Javene 
F - 35133 FOUGERES 
Tel 33 99 94 78 72 
Fax 33 99 94 78 99 
Gennany 
Bundesinstitut fur gesundheitlichen 
Verbraucherschutz und Veterinannedizin 
Fachbereich 6 
Diedersdorfer Weg 1 
D - 12277 Berlin 
Tel 49 30 7236 2364 
Fax 49 30 7236 2955 
Greece 
National Drug Organisation (EO<I>) 
284 Mesogion A venue 
GR- 15562 ATHENS 
Tel 30 1 654 51 94 
Fax 30 1 654 55 35 
Ireland 
National Drugs Advisory Board 
Charles Lucas House 
63/64 Adelaide Road 
IRL - Dublin 2 
Tel 353 16 76 49 71-7 
Fax 353 16 76 78 36 
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Italy 
Ministero della Sanita 
Direzione Generale dei Servizi Veterinari-Divisione IX 
Ministero della Sanita 
Piazzale Marconi 25 
IT- 00144 ROME 
Tel 39 6 599 436 76 
Fax 39 6 599 43 584 
Luxembourg 
Direction de Ia Sante 
· Division de Ia Pharmacie et des Medicaments 
10 rue C M Spoo 
L- 2546 LUXEMBOURG 
Tel 352 478 55 92 
Fax 352 22 44 58 
Netherlands 
Bureau Registratie Diergeneesmiddelen 
· Postbus 289 
NL -6700 AG Wageningen 
Tel 31 8370 75491 
Fax 31 8370 23193 
Portugal 
IPPAA-Centro Nacional de Protec~ e Controlo Zoo-Sanitario 
Lg da Academia Naciorial de Belas Artes 2 
P - 1294 LISBOA CODEX 
Tel 351 1 346 51 65 
Fax 351 1 346 35 18 
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Spain 
Ministerio de Agricultura 
Subdireccion General de Sanidad Animal 
Direccion General de Sanidad de Ia Produccion Agraria 
C/ Velzquez, 2a planta 
E - 28002 Madrid 
Tel 34 1 347 83 04 
Fax 34 1 347 82 99 
A copy of the application should also be sent to: 
Subdireccion General de Evaluacion de Medicarnentos 
Ministerio de Sanidad y Consumo 
Paseo de Prado 18-20 
E - 28014 Madrid 
Tel 34 1 596 40 40 
Fax 34 1 596 40 69 
United Kingdom 
Veterinary Medicines Directorate 
Woodham Lane 
New Haw, Addlestone 
GB - SURREY KT15 3NB 
Tel 44 1932 33 69 11 
Fax 44 1932 33 66 18 
Finland 
National Agency for Medicines 
Marketing Authorisation 
Mannerheimintie 166 
PO Box 55 
Fin-00301 
Helsinki 
Tel: 358 0 47 441 
Fax: 358 0 47 445 25 
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Sweden 
Medical Products Agency 
Husargatan 8 
P.O. Box26 
S-75103 UPPSALA 
Tel 46 18 17 46 00 
Fax 46 18 54 85 66 
European Agency for the Evaluation of Medicinal Products CEMEA) 
Westfeny Circus 
Canary Wharf 
GB-LONDON E14 4HB 
Tel: 44 171 418 84 00 
Fax: 44 171 418 84 16 
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IMMUNOLOGICAL VETERINARY MEDICINAL PRODUCTS 
N.B. Unless otherwise indicated, information about the national fees payable for the evaluation of 
an application may be obtained from the first address indicated below. 
Austria 
Bundesministerium fiir Gesundheit und Konsumentenschutz 
Pharmazeutische Angelegenheiten 
Radetzkystrasse 2 
A-1031 WIEN 
Tel 43 1 71 172 46 55 
Fax 43 1 71 492 22 
Belgium 
Ministry ofPublic Health and the Environment 
Pharmaceutical Inspectorate 
Secretariat of the Medicines Commission 
Quartier v esale 
B -1010 BRUXELLES 
Tel 32 2 210 48 96 
Fax 32 2 210 48 80 
Denmark 
Sundhedsstyrelsen 
Lregemiddelafdelingen 
378 Frederikssundsvej 
DK - 2700 BRONSHOJ 
Tel 45 44 94 36 77 
Fax 45 44 94 02 37 
France 
Ministere de !'Agriculture et de Ia Foret 
CNEVA (Centre National d'Etudes Veterinaires et Alimentaires) 
Laboratoire des Medicaments V eterinaires 
Javene 
F - 35133 FOUGERES 
Tel 33 99 94 78 72 
Fax 33 99 94 78 99 
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Germany 
Paul Ehrlich Institut 
\ 
Bundesarnt fiir Sera und Impstoffe 
Paul-Ehrlich Strasse 51-59 
D - 6070 Langen 1 
Tel 49 06103 77 0 
Fax 49 06103 77 1234 
For vaccines for foot and mouth disease, hog cholera and exotic diseases a copy of the dossier 
should be sent to : 
BFA Tiibingen 
P.O. Box 1149 
D- 7400 Tiibingen 
Tel 49 07071 6031 
Fax 49 07071 603201 
Greece 
National Drug Organisation (EO<l>) 
284 Mesogion Avenue 
GR- 15562 ATHENS 
Tel 30 1 654 51 94 
Fax 30 1 654 55 35 
Ireland 
Department of Agriculture, Food and Forestry 
Agricu,lture House 
Kildare Street 
IRL - Dublin 2 
Tel 353 1 678 90. 11 
Fax 353 I 661 62 63 
.. 
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Italy 
Direttore Generale 
Direzione Servizi Veterinari 
Ministero della Sanitil 
Piazzale Marconi 25 
IT- 00144 ROME 
Tel 39 6 592 67 80 
Fax 39 6 592 58 57 
One further copy of the application should be submitted to: 
Direttore 
Laboratorio di Medic ina V eterinaria 
Istituto Superiore di Sanita 
Viale Regina Elena 299 
I- 00161 Rorna 
Tel 39 6 444 00 77 
Fax 39 6 444 00 77 
Luxembourg 
Direction de Ia Sante 
Division de Ia Pharmacie et des Medicaments 
10 rue C M Spoo 
L - 2546 LUXEMBOURG 
Tel 352 478 55 92 
Fax 352 22 44 58 
Netherlands 
Bureau Registratie Diergeneesmiddelen 
Postbus 289 
NL- 6700 AG Wageningen 
Tel 31837075491 
Fax 31 8370 23 193 
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Portugal 
IPP AA-Centro Nacional de Pro~ e Controlo Zoo-Sanitario 
Lg da Academia Nacional de Belas Artes 2 
P - 1294 LISBOA CODEX 
Tel 351 I 346 51 65 
Fax 351 I 346 35 18 
Spain 
Ministerio de Agricultura 
Subdireccion General de Sanidad Animal 
Direccion General de Sanidad de Ia Produccion Agraria 
C/ Velazquez n° I47, 2a planta 
E - 28002 Madrid 
Tel 34 I 347 83 04 
Fax 34 I 347 82 99 
A copy of the application should also be sent to : 
Subdireccion General de Evaluacion de Medicarnentos 
Ministerio de Sanidad y Consumo 
Paseo de Prado 18-20 
E - 28014 Madrid 
Tel 34 1 596 40 40 
Fax 34 1 596 40 69 
United Kingdom 
Veterinary Medicines Directorate 
Woodham Lane 
New Haw, Addlestone 
GB- Surrey KT15 3NB 
Tel 44 1932 33 69 1 i 
Fax 44 1932 33 66 18 
I67 
Finland 
The application should be sent to: 
Ministry of Agriculture and Forestry 
Veterinary and Food Department 
POBox232 
FIN-00 171 Helsinki 
Tel 358 0 1601 
Fax 358 0 160 33 38 
The full dossier, the additional copies and samp!es: 
Veterinary Officer DVM U. Rikula 
Ministry of Agriculture and Forestry 
c/o National Veterinary and Food Research Institute 
PO Box 368 
FIN-00231 Helsinki 
Tel 3580 393 101 
Fax 3580 393 18 64 
Sweden 
Medical Products Agency 
Husargatan 8 
P.O. Box26 
S-75103 UPPSALA 
Tel 46 18 17 46 00 
Fax 46 18 54 85 66 
European Agency for the Evaluation of Medicinal Products (EMEA) 
Westferry Circus 
Canary Wharf 
GB-LONDON E14 4HB 
Tel: 44 171 418 84 00 
Fax: 44 171 418 84 16 
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GLOSSARY 
Applicant: A (legal) person or company making an application for marketing for a national 
or centralised authorisation. If successful, an applicant becomes a marketing authorisation 
holder. 
Arbitration rapporteur (mutual recognition): Member of the CPMP appointed to 
prepare a report after notification by the originating and concerned· Member States that 
there are serious public health issues which remain in relation to the product at the end of 
the 90 day clarification and dialogue phase of the procedure. 
ATC: Anatomical Therapeutic Chemical. 
ATC classification: The 'Guidelines for ATC Classification' are published jointly by: 
The WHO Collaborating Centre for 
Drug Statistics Methodology 
PO Box 100 VEITVET 
N-0518 Oslo 5 
and'. 
Catalogue references : ISBN 0802-8753 
ISBN 82-90312-12-1 
The Nordic Council for Medicines 
P0Box607 
S-751 25 Uppsala 
Check-in 'pplication: Administrative confirmation by a competent authority (Member 
State or EMEA as appropriate) that: 
• the application is made according to the requirements of Articles 1 & 2 of Directive 
75/319/EEC (i.e. that it contains Expert Reports), 
• that fees have been paid where this is required before evaluation commences, 
• that the physical completeness of the dossier is verified (Parts 1 to IV), and 
• that the documentation is translated into national languages as required 
Co-rapporteur (centralised): A second member of the Committee contributing to the 
assessment of a centralised application. The need for and specific role of the co-rapporteur 
is defined on a case-by-case basis by the Committee. 
Committee for Veterinary Medicinal Products: A scientific committee set up to 
facilitate the adoption of common decisions by the Member States on the authorisation of 
veterinary medicinal products on the basis of scientific criteria of safety, quality and 
efficacy. The Committee is part of the EMEA. 
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Competent authority: An authority in a Member State responsible for the authorisation 
and supervision of medicinal products. 
Concerned Member State (mutual recognition): Member State which is included in an 
application for mutual recognition. 
European Agency for the Evaluation of Medicinal Products (EMEA): Agency 
established under Council Regulation 2309/93 responsible for coordinating the scientific 
resources put at its disposal by the competent authority of the Member States for the 
evaluation and supervision of medicinal products. It comprises the CPMP, CVMP, the 
Secretariat, the Executive Director and the Management Board. 
Evaluation team (centralised): Experts nominated by the rapporteur/co-rapporteur from 
the lists of experts transmitted by the competent authorities in accordance with Article 51 
of Regulation 2309/93 with proven experience in the assessment of medicinal products. 
Expert Report: Report drawn up according to Directive 75/319/EEC on Quality, Safety or 
Efficacy by an expert, on behalf of the applicant including a tabulation, a written summary 
(optional) and a critical discussion of the properties of the product. 
GMO medicinal product: Product containing or consisting of a Genetically Modified 
Organism (an organism in which the genetic material has been altered in a way that does 
not occur naturally by mating and/or natural recombination). 
Parallel national application: Applications made in the transition period 1 January 1995 
to 1 January 1998 at the same time to two or more competent national authorities in the 
EC. 
Rapporteur (centralised): Member of the CPMP appointed to coordinate the evaluation 
of an evaluation of an application, taking into account any proposal from the applicant for 
choice of rapporteur. 
Reference Member State: The Member State whose Assessment Report is used as the 
basis for mutual recognition Type II variations in other concerned Member State(s). Also 
used as a synonym for 'Originating Member State' in mutual recognition marketing 
authorisation applications (q.v.). 
Scientific committees of the European Medicines Evaluation Agency: The Committee 
for Proprietary Medicinal Products (CPMP) and the Committee for Veterinary Medicinal 
Products (CVMP). 
Summary of Product Characteristics: Text prepared according to Article 4(a) of 
Directive 65/65/EEC describing the properties of the product as authorised. 
Tests, Studies and Trials: Investigations done to demonstrate quality, preclinical and 
clinical safety, ecotoxicity and efficacy of a medicinal product. 
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Trials: See tests. 
Type I variation: a minor variation defined in Article 2 of the Variations Regulation 
(XX/95) and listed in Annex I of those Regulations provided that the conditions for such a 
variation laid down in the Annex are met. 
Type ll variation: A major variation which cannot be deemed to be a Type 1 variation and 
which is not a change leading to a new application as stated in Annex 2 of the Regulation 
(XX/95). 
Urgent safety restriction: An interim change to product information by the marketing 
authorisation holder restricting the indication(s) and/or dosage, [and/or target species] of 
the medicinal products and/or warning due to new information having a bearing on the safe 
use of the product. 
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